此应用程序的某些内容目前无法使用。
如果这种情况持续存在,请联系我们反馈与联系
1. (WO2018145620) SULPHAMOYLARYL DERIVATIVES AND USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF LIVER FIBROSIS
Document

Description

Title of Invention 0001   0002   0003   0004   0005   0006   0007   0008   0009   0010   0011   0012   0013   0014   0015   0016   0017   0018   0019   0020   0021   0022   0023   0024   0025   0026   0027   0028   0029   0030   0031   0032   0033   0034   0035   0036   0037   0038   0039   0040   0041   0042   0043   0044   0045   0046   0047   0048   0049   0050   0051   0052   0053   0054   0055   0056   0057   0058   0059   0060   0061   0062   0063   0064   0065   0066   0067   0068   0069   0070   0071   0072   0073   0074   0075   0076   0077   0078   0079   0080   0081   0082   0083   0084   0085   0086   0087   0088   0089   0090   0091   0092   0093   0094   0095   0096   0097   0098   0099   0100   0101   0102   0103   0104   0105   0106   0107   0108   0109   0110   0111   0112   0113   0114   0115   0116   0117   0118   0119   0120   0121   0122   0123   0124   0125   0126   0127   0128   0129   0130   0131   0132   0133   0134   0135   0136   0137   0138   0139   0140   0141   0142   0143   0144   0145   0146   0147   0148   0149   0150   0151   0152   0153   0154   0155   0156   0157   0158   0159   0160   0161   0162   0163   0164   0165   0166   0167   0168   0169   0170   0171   0172   0173   0174   0175   0176   0177   0178   0179   0180   0181   0182   0183   0184   0185   0186   0187   0188   0189   0190   0191   0192   0193   0194   0195   0196   0197   0198   0199   0200   0201   0202   0203   0204   0205   0206   0207   0208   0209   0210   0211   0212   0213   0214   0215   0216   0217   0218   0219   0220   0221   0222   0223   0224   0225   0226   0227   0228   0229   0230   0231   0232   0233   0234   0235   0236   0237   0238   0239   0240   0241   0242   0243   0244   0245   0246   0247   0248   0249   0250   0251   0252   0253   0254   0255   0256   0257   0258   0259   0260   0261   0262   0263   0264   0265   0266   0267   0268   0269   0270   0271   0272   0273   0274   0275   0276   0277   0278   0279   0280   0281   0282   0283   0284   0285   0286   0287   0288   0289   0290   0291   0292   0293   0294   0295   0296   0297   0298   0299   0300   0301   0302   0303   0304   0305   0306   0307   0308   0309   0310   0311   0312   0313   0314   0315   0316   0317   0318   0319   0320   0321   0322   0323   0324   0325   0326   0327   0328   0329   0330   0331   0332   0333   0334   0335   0336   0337   0338   0339   0340   0341   0342   0343   0344   0345   0346   0347   0348   0349   0350   0351   0352   0353   0354   0355   0356   0357   0358   0359   0360   0361   0362   0363   0364   0365   0366   0367   0368   0369   0370   0371   0372   0373   0374   0375   0376   0377   0378   0379   0380   0381   0382   0383   0384   0385   0386   0387   0388   0389   0390   0391   0392   0393   0394   0395   0396   0397   0398   0399   0400   0401   0402   0403   0404   0405   0406   0407   0408   0409   0410   0411   0412   0413   0414   0415   0416   0417   0418   0419   0420   0421   0422   0423   0424   0425   0426   0427   0428   0429   0430   0431   0432   0433   0434   0435   0436   0437   0438   0439   0440   0441   0442   0443   0444   0445   0446   0447   0448   0449   0450   0451   0452   0453   0454   0455   0456   0457   0458   0459   0460   0461   0462   0463   0464   0465   0466   0467   0468   0469   0470   0471   0472   0473   0474   0475   0476   0477   0478   0479   0480   0481   0482   0483   0484   0485   0486   0487   0488   0489   0490   0491   0492   0493   0494   0495   0496   0497   0498   0499   0500   0501   0502   0503   0504   0505   0506   0507   0508   0509   0510   0511   0512   0513   0514   0515   0516   0517   0518   0519   0520   0521   0522   0523   0524   0525   0526   0527   0528   0529   0530   0531   0532   0533   0534   0535   0536   0537   0538   0539   0540   0541   0542   0543   0544   0545   0546   0547   0548   0549   0550   0551   0552   0553   0554   0555   0556   0557   0558   0559   0560   0561   0562   0563   0564   0565   0566   0567   0568   0569   0570   0571   0572   0573   0574   0575   0576   0577   0578   0579   0580   0581   0582   0583   0584   0585   0586   0587   0588   0589   0590   0591   0592   0593   0594   0595   0596   0597   0598   0599   0600   0601   0602   0603   0604   0605   0606   0607   0608   0609   0610   0611   0612   0613   0614   0615   0616   0617   0618   0619   0620   0621   0622   0623   0624   0625   0626   0627   0628   0629   0630   0631   0632   0633   0634   0635   0636   0637   0638   0639   0640   0641   0642   0643   0644   0645   0646   0647   0648   0649   0650   0651   0652   0653   0654   0655   0656   0657   0658   0659   0660   0661   0662   0663   0664   0665   0666   0667   0668   0669   0670   0671   0672   0673   0674   0675   0676   0677   0678   0679   0680   0681   0682   0683   0684   0685   0686   0687   0688   0689   0690   0691   0692   0693   0694   0695   0696   0697   0698   0699   0700   0701   0702   0703   0704   0705   0706   0707   0708   0709   0710   0711   0712   0713   0714   0715   0716   0717   0718   0719   0720   0721   0722   0723   0724   0725   0726   0727   0728   0729   0730   0731   0732   0733   0734   0735   0736   0737   0738   0739   0740   0741   0742   0743   0744   0745   0746   0747   0748   0749   0750   0751   0752   0753   0754   0755   0756   0757   0758   0759   0760   0761   0762   0763   0764   0765   0766   0767   0768   0769   0770   0771   0772   0773   0774   0775   0776   0777   0778   0779   0780   0781   0782   0783   0784   0785   0786   0787   0788   0789   0790   0791   0792   0793   0794   0795   0796   0797   0798   0799   0800   0801   0802   0803   0804   0805   0806   0807  

Claims

1   2   3   4   5   6   7   8   9   10   11   12  

Description

Title of Invention : SULPHAMOYLARYL DERIVATIVES AND USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF LIVER FIBROSIS

[0001]
Background Art
[0002]
Liver fibrosis is a chronic disease in which the damaged parenchymal tissue fails to regenerate. This damage causes liver stellate cells to be over active and triggers the extra cellular matrix (ECM) synthesis to increase. Advanced liver fibrosis can result in cirrhosis and life-threatening live failure. Cirrhosis is a disease of the liver with as a pathological hallmark the development of scar tissue that replaces normal parenchyma. Damage to these hepatic parenchyma (due to inflammation) leads to activation of the stellate cell, which increases fibrosis through production of myofibroblasts. This process might result in the generation of fibrous tissue bands (septa) , which eventually replace the entire liver architecture ending in the obstruction of blood flow.
[0003]
Recently, it has become clear that 5-HT2B might play a role in the progression of liver fibrosis and/or cirrhosis. M. Ebrahimkhani et al have shown that selective antagonism of 5-HT2B enhanced hepatocyte growth in models of acute and chronic liver injury (Nature Medicine 17, 1668–1673 (2011) ) .
[0004]
5-Hydroxytryptamine receptor 2B (5-HT2B) also known as serotonin receptor 2B is a protein that in humans is encoded by the HTR2B gene. 5-HT2B is a member of the 5-HT2 receptor family that binds the neurotransmitter serotonin (5-hydroxytryptamine, 5-HT) .
[0005]
There is a need for selective and potent 5-HT2B antagonist chemical classes, useful in the treatment or prevention of fibrosis and/or cirrhosis.
[0006]
Amongst the problems which 5-HT2B antagonists may encounter are toxicity, mutagenicity, lack of selectivity, poor efficacy, poor bioavailability, low solubility and difficulty of synthesis. There is a need for drugs to treat liver fibrosis and/or cirrhosis, more specifically 5-HT2B antagonists that may overcome at least one of these disadvantages or that have additional advantages such as increased potency or an increased safety window.
[0007]
WO2013/006394, published on January 10, 2013, relates to a subclass of sulphamoyl-arylamides active against Hepatitis B Virus (HBV) . WO2013/096744, published on June 26, 2013 also relates to sulphamoyl-arylamides active against HBV.
[0008]
Description of the Invention
[0009]
Surprisingly it was found that certain sulphamoyl-arylamides are potent 5-HT2B antagonist.
[0010]
The present invention relates to a compound of Formula (I)
[0011]
[0012]
or a stereoisomer or tautomeric form thereof, wherein:
[0013]
Ar represents a monocyclic or bicyclic aromatic ring, optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such aromatic ring optionally being substituted with one or more substituents each independently selected from the group consisting of halogen, -CN, -OR 6, C 1-C 3 alkyl, C 3-C 7 cycloalkyl, CHF 2, CH 2F and CF 3;
[0014]
R 1 represents a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such 3-7 membered saturated ring optionally being substituted with one or more substituents each independently selected from the group consisting of fluor, -OH, oxo and C 1-C 3 alkyl optionally substituted with one or more fluor and/or OH;
[0015]
R 6 represents hydrogen, C 1-C 3 alkyl optionally substituted with one or more fluor, or -C 1-C 3 alkyl-O (R 5) ;
[0016]
R 5 represents hydrogen or C 1-C 3 alkyl;
[0017]
or a pharmaceutically acceptable salt or a solvate thereof.
[0018]
The present invention also relates to use of a compound of Formula (A)
[0019]
[0020]
or a stereoisomer or tautomeric form, and/or a salt or solvate thereof, in the manufacture of a medicament for the prevention or treatment of fibrosis and/or cirrhosis in a mammal, wherein
[0021]
Ar represents a monocyclic or bicyclic aromatic ring, optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such aromatic ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halogen, -CN, -OH, C 1-C 3 alkyl, C 3-C 7 cycloalkyl, -O (R 6) , CHF 2, CH 2F and CF 3;
[0022]
R 1 represents hydrogen, a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, or C 1-C 6 alkyl, such 3-7 membered saturated ring or C 1-C 6 alkyl optionally being substituted with one or more substituents each independently selected from the group consisting of C 1-C 3 alkyl, halogen, CHF 2, CH 2F and CF 3, -CN, -C (=O) R 5, oxo-C (=O) N (R 6) 2, -N (R 6) 2 and -OR 6;
[0023]
R 2 represents hydrogen, or C 1-C 3 alkyl;
[0024]
R 3 represents fluor or -OC 1-C 3 alkyl optionally substituted with one or more fluor;
[0025]
R 4 represents hydrogen, fluor or -OC 1-C 3 alkyl;
[0026]
R 6 represents hydrogen, C 1-C 3 alkyl optionally substituted with one or more fluor, or -C 1-C 3 alkyl-O (R 5) ;
[0027]
R 5 represents hydrogen or C 1-C 3 alkyl.
[0028]
The invention further relates to the compound of Formula (I) for use as a medicament, preferably for use in the prevention or treatment of fibrosis and/or cirrhosis in a mammal.
[0029]
The invention also relates to the compound of Formula (A) for use as a medicament, preferably for use in the prevention or treatment of fibrosis and/or cirrhosis in a mammal.
[0030]
The invention further relates to a method for preventing or treating fibrosis and/or cirrhosis in a mammal, comprising administering the compound of Formula (I) to the subject in need thereof.
[0031]
The invention also relates to a method for preventing or treating fibrosis and/or cirrhosis in a mammal, comprising administering the compound of Formula (A) to the subject in need thereof.
[0032]
The invention further relates to use of the compound of Formula (I) in the manufacture of a medicament for the treatment or the prevention of liver fibrosis and/or cirrhosis.
[0033]
The invention further relates to a pharmaceutical composition comprising compounds of Formula (I) , and a pharmaceutically acceptable carrier.
[0034]
The invention also relates to a pharmaceutical composition comprising compounds of Formula (I) and Formula (A) , and a pharmaceutically acceptable carrier.
[0035]
In a further aspect, the invention relates to a combination of compounds of Formula (I) and Formula (A) , and another fibrosis and/or cirrhosis inhibitor.
[0036]
The invention also relates to a product containing (a) a compound of Formula (I) , and (b) another fibrosis and/or cirrhosis inhibitor, as a combined preparation for simultaneous, separate or sequential use in the treatment of fibrosis and/or cirrhosis.
[0037]
The invention further relates to a product containing (a) compounds of Formula (I) and Formula (A) , and (b) another fibrosis and/or cirrhosis inhibitor, as a combined preparation for simultaneous, separate or sequential use in the treatment of fibrosis and/or cirrhosis.
[0038]
Definitions
[0039]
The term “optional” or “optionally” means the event described subsequent thereto may or may not happen. This term encompasses the cases that the event may or may not happen.
[0040]
The term “one or more” means one, two, three, four, five, six, seven, eight, nine or more.
[0041]
The term "aryl" means a monocyclic-or polycyclic aromatic ring comprising carbon atoms, and hydrogen atoms. If indicated, such aromatic ring may include one or more heteroatoms, preferably, 1 to 3 heteroatoms, independently selected from nitrogen, oxygen, and sulfur, preferably nitrogen (heteroaryl) . As is well known to those skilled in the art, heteroaryl rings have less aromatic character than their all-carbon counter parts. Thus, for the purposes of the present invention, a heteroaryl group need only have some degree of aromatic character. Illustrative examples of aryl groups are optionally substituted phenyl and naphtyl. Illustrative examples of heteroaryl groups according to the invention include optionally substituted, pyridine, pyrimidine, thiazole, indazole.
[0042]
The terms "C 1-x alkyl" and C 1-C x alkyl can be used interchangeably.
[0043]
The term "C 1-3 alkyl" as a group or part of a group refers to a hydrocarbyl radical of Formula C nH 2n+1 wherein n is a number ranging from 1 to 3. In case C 1-3 alkyl is coupled to a further radical, it refers to a Formula C nH 2n. . C 1-3 alkyl groups comprise from 1 to 3 carbon atoms, more preferably 1 to 2 carbon atoms. C 1-3 alkyl includes all linear, or branched alkyl groups with between 1 and 3 carbon atoms, and thus includes such as for example methyl, ethyl, n-propyl, and i-propyl. C 1-4 alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 4 carbon atoms such as the group defined for C 1-3alkyl and butyl and the like. C 1-6 alkyl and C 2-6 alkyl as a group or part of a group defines straight or branched chain saturated hydrocarbon radicals having from 1 to 6 carbon atoms, or from 2 to 6 carbon atoms such as the groups defined for C 1-4alkyl and pentyl, hexyl, 2-methylbutyl and the like.
[0044]
The term “C 1-3 alkyloxy” as a group or part of a group refers to a radical having the Formula --OR c wherein R c is C 1-3 alkyl. Non-limiting examples of suitable C 1-3 alkyloxy include methyloxy (also methoxy) , ethyloxy (also ethoxy) , propyloxy and isopropyloxy.
[0045]
The term oxo, C (=O) , or carbonyl refers to a group composed of a carbon atom double bonded to an oxygen atom.
[0046]
As used herein, the term “3-7 membered saturated ring” means saturated cyclic hydrocarbon (cycloalkyl ) with 3, 4, 5, 6 or 7 carbon atoms and is generic to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
[0047]
Such saturated ring optionally contains one or more heteroatoms, such that at least one carbon atom is replaced by a heteroatom selected from N, O and S, in particular from N and O. Examples include oxetane, tetrahydro-2H-pyranyl, piperidinyl, tetrahydrofuranyl, morpholinyl, thiolane 1, 1-dioxide and pyrrolidinyl. Preferred are saturated cyclic hydrocarbons with 3 or 4 carbon atoms and 1 oxygen atom. Examples include oxetane, and tetrahydrofuranyl.
[0048]
It should be noted that different isomers of the various heterocycles may exist within the definitions as used throughout the specification. For example, pyrrolyl may be 1H-pyrrolyl or 2H-pyrrolyl.
[0049]
The term halo and halogen are generic to fluoro, chloro, bromo or iodo. Preferred halogens are bromo, fluoro and chloro.
[0050]
It should also be noted that the radical positions on any molecular moiety used in the definitions may be anywhere on such moiety as long as it is chemically stable. For instance pyridyl includes 2-pyridyl, 3-pyridyl and 4-pyridyl; pentyl includes 1-pentyl, 2-pentyl and 3-pentyl.
[0051]
Lines drawn from substituents into ring systems indicate that the bond may be attached to any of the suitable ring atoms.
[0052]
When any variable (e.g. halogen or C 1-4 alkyl) occurs more than one time in any constituent, each definition is independent.
[0053]
Combinations of substituents and/or variables are permissible only if such combinations result in chemically stable compounds. "Stable compound" is meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into a therapeutic agent.
[0054]
For therapeutic use, the salts of the compounds of Formula (I) are those wherein the counter ion is pharmaceutically or physiologically acceptable. However, salts having a pharmaceutically unacceptable counter ion may also find use, for example, in the preparation or purification of a pharmaceutically acceptable compound of Formula (I) . All salts, whether pharmaceutically acceptable or not are included within the ambit of the present invention.
[0055]
The pharmaceutically acceptable or physiologically tolerable addition salt forms which the compounds of the present invention are able to form can conveniently be prepared using the appropriate acids, such as, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid; sulfuric; hemisulphuric, nitric; phosphoric and the like acids; or organic acids such as, for example, acetic, aspartic, dodecylsulphuric, heptanoic, hexanoic, nicotinic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclamic, salicylic, p-aminosalicylic, pamoic and the like acids.
[0056]
Conversely said acid addition salt forms can be converted by treatment with an appropriate base into the free base form.
[0057]
The term “salts” also comprises the hydrates and the solvent addition forms that the compounds of the present invention are able to form. Examples of such forms are e.g. hydrates, alcoholates and the like.
[0058]
The present compounds may also exist in their tautomeric forms. For example, tautomeric forms of amide (-C (=O) -NH-) groups are iminoalcohols (-C (OH) =N-) . Tautomeric forms, although not explicitly indicated in the structural formulae represented herein, are intended to be included within the scope of the present invention.
[0059]
The term stereochemically isomeric forms of compounds of the present invention, as used hereinbefore, defines all possible compounds made up of the same atoms bonded by the same sequence of bonds but having different three-dimensional structures which are not interchangeable, which the compounds of the present invention may possess. Unless otherwise mentioned or indicated, the chemical designation of a compound encompasses the mixture of all possible stereochemically isomeric forms which said compound may possess. Said mixture may contain all diastereomers and/or enantiomers of the basic molecular structure of said compound. All stereochemically isomeric forms of the compounds of the present invention both in pure form or in admixture with each other are intended to be embraced within the scope of the present invention.
[0060]
Pure stereoisomeric forms of the compounds and intermediates as mentioned herein are defined as isomers substantially free of other enantiomeric or diastereomeric forms of the same basic molecular structure of said compounds or intermediates. In particular, the term 'stereoisomerically pure' concerns compounds or intermediates having a stereoisomeric excess of at least 80% (i.e. minimum 90%of one isomer and maximum 10%of the other possible isomers) up to a stereoisomeric excess of 100% (i.e. 100%of one isomer and none of the other) , more in particular, compounds or intermediates having a stereoisomeric excess of 90%up to 100%, even more in particular having a stereoisomeric excess of 94%up to 100%and most in particular having a stereoisomeric excess of 97%up to 100%. The terms 'enantiomerically pure' and 'diastereomerically pure' should be understood in a similar way, but then having regard to the enantiomeric excess, respectively the diastereomeric excess of the mixture in question.
[0061]
Pure stereoisomeric forms of the compounds and intermediates of this invention may be obtained by the application of art-known procedures. For instance, enantiomers may be separated from each other by the selective crystallization of their diastereomeric salts with optically active acids or bases. Examples thereof are tartaric acid, dibenzoyltartaric acid, ditoluoyltartaric acid and camphosulfonic acid. Alternatively, enantiomers may be separated by chromatographic techniques using chiral stationary phases. Said pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically. Preferably, if a specific stereoisomer is desired, said compound will be synthesized by stereospecific methods of preparation. These methods will advantageously employ enantiomerically pure starting materials.
[0062]
The stereomeric forms of Formula (I) can be obtained separately by conventional methods. Appropriate physical separation methods that may advantageously be employed are, for example, selective crystallization and chromatography, e.g. column chromatography.
[0063]
The present invention is also intended to include all isotopes of atoms occurring on the present compounds. Isotopes include those atoms having the same atomic number but different mass numbers. By way of general example and without limitation, isotopes of Hydrogen include tritium and deuterium. Isotopes of carbon include C-13 and C-14.

Detailed description of the invention

[0064]
Whenever used hereinafter, the term “the compounds of the present invention” or “the present compounds” or similar term is meant to include all compounds of general Formula (I) and Formula (A) , and compounds listed in table 1, salts, stereoisomeric forms and racemic mixtures and any subgroups thereof.
[0065]
In a first aspect, the present invention provides compounds of Formula (I)
[0066]
[0067]
or a stereoisomer or tautomeric form thereof, wherein:
[0068]
Ar represents a monocyclic or bicyclic aromatic ring, optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such aromatic ring optionally being substituted with one or more substituents each independently selected from the group consisting of halogen, -CN, -OR 6, C 1-C 3 alkyl, C 3-C 7cycloalkyl, CHF 2, CH 2F and CF 3;
[0069]
R 1 represents a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such 3-7 membered saturated ring optionally being substituted with one or more substituents each independently selected from the group consisting of fluor, -OH, oxo and C 1-C 3 alkyl optionally substituted with one or more fluor and/or OH;
[0070]
R 6 represents hydrogen, C 1-C 3 alkyl optionally substituted with one or more fluor, or -C 1-C 3 alkyl-O (R 5) ;
[0071]
R 5 represents hydrogen or C 1-C 3 alkyl;
[0072]
or a pharmaceutically acceptable salt or a solvate thereof.
[0073]
In one embodiment of the present invention, Ar is phenyl, pyridine or benzimidazole optionally substituted with one or more substituents each independently selected from the group consisting of -CN, halogen, C 1-C 3 alkyl, C 1-C 3cycloalkyl, CHF 2, CH 2F and CF 3.
[0074]
In yet another embodiment, Ar is phenyl or pyridine, optionally substituted with one or more substituents each independently selected from halogen, -OH, C 1-C 3 alkyl, C 1-C 3cycloalkyl, CHF 2, CH 2F and CF 3.
[0075]
In a further embodiment, R 1 represents a 4-7 membered saturated ring containing carbon atoms and optionally one oxygen atom, such 4-7 membered saturated ring optionally substituted with one or more C 1-C 3 alkyl and/or OH.
[0076]
In another embodiment, R 1 represents a 5 membered saturated ring containing carbon atoms and one oxygen atom, optionally substituted with one or more C 1-C 3 alkyl and/or OH. In a preferred embodiment, R 1 represents a 5 membered saturated ring containing carbon atoms and one oxygen atom.
[0077]
In another aspect, the present invention provides use of compounds of Formula (A)
[0078]
[0079]
or a stereoisomer or tautomeric form, and/or a salt or solvate thereof, in the manufacture of a medicament for the prevention or treatment of fibrosis and/or cirrhosis in a mammal,
[0080]
wherein
[0081]
Ar represents a monocyclic or bicyclic aromatic ring, optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such aromatic ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halogen, -CN, -OH, C 1-C 3 alkyl, C 3-C 7cycloalkyl, -O (R 6) , CHF 2, CH 2F and CF 3;
[0082]
R 1 represents hydrogen, a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, or C 1-C 6 alkyl, such 3-7 membered saturated ring or C 1-C 6 alkyl optionally being substituted with one or more substituents each independently selected from the group consisting of C 1-C 3 alkyl, halogen, CHF 2, CH 2F and CF 3, -CN, -C (=O) R 5, oxo, -C (=O) N (R 6) 2, -N (R 6) 2 and -OR 6;
[0083]
R 2 represents hydrogen, or C 1-C 3 alkyl;
[0084]
R 3 represents fluor or -OC 1-C 3 alkyl optionally substituted with one or more fluor;
[0085]
R 4 represents hydrogen, fluor or -OC 1-C 3 alkyl;
[0086]
R 6 represents hydrogen, C 1-C 3 alkyl optionally substituted with one or more fluor, or -C 1-C 3 alkyl-O (R 5) ;
[0087]
R 5 represents hydrogen or C 1-C 3 alkyl.
[0088]
In one embodiment of the present invention, R 3 represents fluor or -OC 1-C 3 alkyl and R 2 and R 4 represent hydrogen.
[0089]
In a further embodiment, Ar is phenyl, pyridine or benzimidazole optionally substituted with one or more substituents each independently selected from the group consisting of halogen, C 1-C 3 alkyl, C 1-C 3cycloalkyl, CHF 2, CH 2F and CF 3.
[0090]
In another embodiment, R 1 represents a 5 membered saturated ring containing carbon atoms and one oxygen atom, optionally substituted with one or more C 1-C 3 alkyl and/or OH. In a preferred embodiment, R 1 represents a 5 membered saturated ring containing carbon atoms and one oxygen atom.
[0091]
In yet another embodiment, Ar is phenyl optionally substituted with one or more substituents each independently selected from -CN, C 1-C 3 alkyl, C 1-C 3cycloalkyl, CHF 2, CH 2F and CF 3.
[0092]
Further combinations of any of the embodiments as described for both Formula (I) and Formula (A) are also envisioned to be in the scope of the present invention.
[0093]
Preferred compounds according to the invention are compound or a stereoisomer or tautomeric form thereof with a Formula as represented in the synthesis of compounds section and of which the activity is displayed in Table 1.
[0094]
In a further aspect, the present invention concerns a pharmaceutical composition comprising a therapeutically or prophylactically effective amount of a compound of Formula (I) or Formula (A) as specified herein, and a pharmaceutically acceptable carrier. In still a further aspect, this invention relates to a process of preparing a pharmaceutical composition as specified herein, which comprises intimately mixing a pharmaceutically acceptable carrier with a therapeutically or prophylactically effective amount of a compound of Formula (I) , as specified herein.
[0095]
Therefore, the compounds of the present invention or any subgroup thereof may be formulated into various pharmaceutical forms for administration purposes. As appropriate compositions there may be cited all compositions usually employed for systemically administering drugs. To prepare the pharmaceutical compositions of this invention, an effective amount of the particular compound, optionally in addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirable in unitary dosage form suitable, particularly, for administration orally, rectally, percutaneously, or by parenteral injection. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs, emulsions and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules, and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit forms, in which case solid pharmaceutical carriers are employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. Also included are solid form preparations intended to be converted, shortly before use, to liquid form preparations. In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant deleterious effect on the skin. The compounds of the present invention may also be administered via oral inhalation or insufflation in the form of a solution, a suspension or a dry powder using any art-known delivery system.
[0096]
It is especially advantageous to formulate the aforementioned pharmaceutical compositions in unit dosage form for ease of administration and uniformity of dosage. Unit dosage form as used herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such unit dosage forms are tablets (including scored or coated tablets) , capsules, pills, suppositories, powder packets, wafers, injectable solutions or suspensions and the like, and segregated multiples thereof.
[0097]
The compounds of Formula (I) are potent 5-HT2B antagonist.
[0098]
The compounds of the present invention are potent antognists of 5-Hydroxytryptamine receptor 2B (5-HT2B) . Due to their 5-HT2B antagonist properties, the compounds of Formula (I) and Formula (A) or any subgroup thereof, are useful in the inhibition of 5-HT2B enhanced hepatocyte growth, in particular in the treatment of liver fibrosis and/or cirrhosis in warm-blooded animals, in particular humans, , and for the prophylaxis of liver fibrosis and/or cirrhosis. The present invention furthermore relates to a method of treating liver fibrosis and/or cirrhosis in a warm-blooded animal, in particular human, or being at risk of infection by HBV, said method comprising the administration of a therapeutically effective amount of compounds of Formula (I) and Formula (A) .
[0099]
The compounds of Formula (I) and Formula (A) , as specified herein, may therefore be used as a medicine, in particular as medicine to treat or prevent liver fibrosis and/or cirrhosis. Said use as a medicine or method of treatment comprises the systemic administration to subjects with liver fibrosis and/or cirrhosis or to subjects susceptible to liver fibrosis and/or cirrhosis of an amount effective to combat the conditions associated with liver fibrosis and/or cirrhosis or an amount effective to prevent liver fibrosis and/or cirrhosis.
[0100]
The present invention also relates to use of the present compounds in the manufacture of a medicament for the treatment or the prevention of liver fibrosis and/or cirrhosis.
[0101]
In general it is contemplated that an anti-fibrosis and/or cirrhosis effective daily amount would be from about 10 to about 200 mg/kg. It may be appropriate to administer the required dose as two, three, four or more sub-doses at appropriate intervals throughout the day. Said sub-doses may be formulated as unit dosage forms, for example, containing about 1 to about 500 mg, or about 1 to about 300 mg, or about 1 to about 100 mg, or about 2 to about 50 mg of active ingredient per unit dosage form.
[0102]
The present invention also concerns combinations of compounds of Formula (I) and Formula (A) or any subgroup thereof, as specified herein with other agents for treating liver fibrosis and/or cirrhosis. The term “combination” may relate to a product or kit containing (a) compounds of Formula (I) and Formula (A) , as specified above, and (b) at least one other compound capable of treating liver fibrosis and/or cirrhosis, as a combined preparation for simultaneous, separate or sequential use in treatment of liver fibrosis and/or cirrhosis. In an embodiment, the invention concerns combination of compounds of Formula (I) and Formula (A) or any subgroup thereof with at least one other agent for treating liver fibrosis and/or cirrhosis. In a particular embodiment, the invention concerns combination of compounds of Formula (I) and Formula (A) or any subgroup thereof with at least two other agents for treating liver fibrosis and/or cirrhosis. In a particular embodiment, the invention concerns combination of compounds of Formula (I) and Formula (A) or any subgroup thereof with at least three other agents for treating liver fibrosis and/or cirrhosis. In a particular embodiment, the invention concerns combination of compounds of Formula (I) and Formula (A) or any subgroup thereof with at least four agents for treating liver fibrosis and/or cirrhosis.
[0103]
The term agent for treating liver fibrosis and/or cirrhosis also includes compounds that are therapeutic nucleic acids, antibodies or proteins either in their natural form or chemically modified and or stabilized. The term therapeutic nucleic acid includes but is not limited to nucleotides and nucleosides, oligonucleotides polynucleotides of which non limiting examples are antisense oligonucleotides, miRNA, siRNA, shRNA, therapeutic vectors and DNA/RNA editing components.
[0104]
The combination of previously known agents for treating liver fibrosis and/or cirrhosis, and compounds of Formula (I) and Formula (A) or any subgroup thereof can be used as a medicine in a combination therapy.
[0105]
Generic synthesis:
[0106]
The substituents (R1 and Ar) represented in this general synthesis section are meant to include any substituent or reactive aromatic amine which is suitable for transformation into any substituent according to the present invention without undue burden for the person skilled in the art.
[0107]
The general synthesis of compound of Formula (IV) is described in scheme 1 and scheme 2 in four different methods (method A-D) . As described in scheme 1, an 2-methoxybenzoic acid of general Formula (I) is reacted with sulfurochloridic acid to form a chlorosulfonyl methoxybenzoic acid of general formula (II) , which was followed by benzoyl chloride formation and reacts with aromatic amine to transform a amide of general Formula (III) . The final product was synthesized reacting with an amine to provide sulfonyl amide with general formula (IV) . The detailed synthetic procedure was shown with an example of synthesis of compound 1.
[0108]
Scheme 1 (method A)
[0109]
[0110]
Method A (compound 1 as example)
[0111]
Intermediate 1.2: 5- (Chlorosulfonyl) -2-methoxybenzoic acid
[0112]
[0113]
2-Methoxybenzoic acid (30.0 g, 197 mmol) was dissolved in chlorosulfonic acid (115 g, 986 mmol) at 0 ℃. The resultant reaction mixture was heated at 50 ℃ for 1 hour. After cooling to room temperature, the mixture was poured into ice water and precipitation formed. The precipitation was collected and dried to give the title compound (6.00 g, 25%yield) .
[0114]
1H NMR (400MHz, DMSO-d6) δ 7.85 (d, J = 2.2 Hz, 1H) , 7.67 (dd, J = 2.3, 8.7 Hz, 1H) , 7.05 (d, J = 8.8 Hz, 1H) , 3.79 (s, 3H) .
[0115]
Intermediate 1.3: 3- ( (4-Fluoro-3-methylphenyl) carbamoyl) -4-methoxybenzene-1-sulfonyl chloride
[0116]
[0117]
5- (Chlorosulfonyl) -2-methoxybenzoic acid (6.00 g, 22.7 mmol, purity 95%) was dissolved in a mixture of DMF (0.5 mL) and DCM (60 mL) followed by the addition of oxalyl dichloride (14.4 g, 114 mmol) at 0 ℃. The mixture was stirred at 20 ℃ for 12 hours before concentrating it to dryness. The residue was dissolved in anhydrous toluene (100 mL) and then 4-fluoro-3-methylaniline (2.79 g, 22.3 mmol) were added. The reaction was heated to reflux for 1 h and concentrated under reduced pressure. The residue was purified by column chromatography over silica gel (petroleum ether : ethyl acetate=1: 1) to give the crude product which was recrystallized from ethyl acetate (20 mL) to give the title compound (4.50 g, 55%yield, purity 98%) .
[0118]
LCMS (ESI) : R T = 0.81 min, mass calcd. for C 15H 13ClFNO 4S 357.02, m/z found 357.8 [M+H] +. 1H NMR (400 MHz, DMSO-d 6) δ 10.11 (s, 1H) , 7.83 (d, J = 2.0 Hz, 1H) , 7.69 (dd, J = 2.4, 8.7 Hz, 1H) , 7.65 (dd, J = 2.5, 7.0 Hz, 1H) , 7.58 -7.52 (m, 1H) , 7.14 -7.06 (m, 2H) , 3.89 (s, 3H) , 2.23 (d, J = 1.8 Hz, 3H) .
[0119]
Compound 1: 5- (N- (3, 3-Difluorocyclobutyl) sulfamoyl) -N- (4-fluoro-3-methylphenyl) -2- methoxybenzamide
[0120]
[0121]
3- ( (4-Fluoro-3-methylphenyl) carbamoyl) -4-methoxybenzene-1-sulfonyl chloride (200 mg, 0.559 mmol) was dissolved in DCM (10 mL) followed by the addition of 3, 3-difluorocyclobutanamine (65.9 mg, 0.615 mmol) and triethylamine (170 mg, 1.68 mmol) at 0 ℃. The mixture was stirred for 1h at 20 ℃ and then concentrated to dryness under reduce pressure. The residue was purified by prep. HPLC (column: Agela DuraShell C18 150 mm x 25 mm, 5 μm; mobile phase: CH 3CN in water (0.05%base water) from 43%to 73%, flow rate: 30 mL/min) . The pure fractions were collected and the volatiles were removed under vacuum. The residue was suspended in water (5 mL) . The aqueous layer was lyophilized to dryness to give the title compound as a white solid (67.9 mg, 28%yield, and purity 97.7%) .
[0122]
LC-MS (ESI) : R T = 5.17 min, mass calcd. for C 19H 19F 3N 2O 4S 428.10, m/z found 429.1 [M+H] +. 1H NMR (400 MHz, DMSO-d 6) δ 10.21 (br. s., 1H) , 8.14 (br. s., 1H) , 7.97 (d, J = 2.4 Hz, 1H) , 7.91 (dd, J = 2.4, 8.8 Hz, 1H) , 7.65 -7.60 (m, 1H) , 7.58 -7.52 (m, 1H) , 7.37 (d, J = 8.8 Hz, 1H) , 7.13 (t, J = 9.2 Hz, 1H) , 3.97 (s, 3H) , 3.61 -3.49 (m, 1H) , 2.78 -2.68 (m, 2H) , 2.43 -2.33 (m, 2H) , 2.24 (s, 3H) .
[0123]
The other three possible routes to compound of general Formula (IV) are described in scheme 2. The chlorosulfonylmethoxybenzoate was reacted with amine to give sulfonyl amide of general Formula (V) . This sulfonyl aminde benzoate was used as a reagent for the final product formation or converted to the other reagents benzoic acid and benzoic chloride by hydrolysis and chloride formation in sequence. The final compounds of general Formula (IV) were formed through methed B, C and D by an amide formation with reagent V, VI, VII respectively. The detailed synthetic procedure was shown with an example of synthesis of compound 2, 3, 4.
[0124]
Scheme 2 (method B, C, D)
[0125]
[0126]
[0127]
Method B (Compound 2 as example)
[0128]
Intermediate 2.2: (S) -Methyl 2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzoate
[0129]
[0130]
To a solution consisting of (S) -3-aminotetrahydrofuran hydrochloride (3.74 g, 30.2 mmol, Shanghai Nuohey Chemical Technology CO., LTD. ) , TEA (12.6 mL, 90.7 mmol) and DCM (100 mL) was added methyl 5- (chlorosulfonyl) -2-methoxybenzoate (8.00 g, 30.2 mmol) . The mixture was stirred at room temperature for 2 hours and the resultant solution was concentrated under reduced pressure. Water and ethyl acetate were added. The organic layer was separated and the water phase was extracted twice with ethyl acetate. The combined organic layers were washed with brine, dried over Na 2SO 4 and filtered. The filtrate was concentrated under reduced pressure to give the title compound (7.50 g, 71%yield) .
[0131]
Compound 2: (S) -N- (5-fluoro-6-methylpyridin-2-yl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide:
[0132]
[0133]
LHMDS (2.84 mL, 2.84 mmol, 1 M in THF) was added into a solution consisting of (S) -methyl 2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzoate (150 mg, 0.476 mmol) , oxazol-2-amine (85.7 mg, 0.680 mmol) and THF (5 mL) at 0 ℃ under nitrogen. The reaction mixture was stirred at 0 ℃ for 1 hour. The mixture was quenched with saturated NH 4Cl and the resulting mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over Na 2SO 4 and filtered. The filtrate was concentrated under reduced pressure to give a residue which was purified by prep. TLC to give title compound (61.9 mg, 22.27%yield, purity 99.1%) . LC-MS (ESI) : mass calcd. for C 18H 20FN 3O 5S 409.4, m/z found 410.1 [M+H] +; 1H NMR (400MHz, DMSO-d 6) δ 10.60 (br. s, 1H) , 8.15 -8.02 (m, 2H) , 7.96 -7.86 (m, 2H) , 7.69 (t, J = 8.0 Hz, 1H) , 7.38 (d, J = 8.0 Hz, 1H) , 3.99 (s, 3H) , 3.72 -3.61 (m, 2H) , 3.60 -3.51 (m, 2H) , 3.44 -3.39 (m, 1H) , 2.44 -2.30 (m, 3H) , 1.93 -1.81 (m, 1H) , 1.65 -1.54 (m, 1H) .
[0134]
Method C: (Compound 3 as example) :
[0135]
Intermediate 3.2: (S) -2-Methoxy-5- (N- (tetrahydrofuran-3-yl) sulfanoyl) benzoic acid
[0136]
[0137]
Lithium hydroxide (3.99 g, 95.1 mmol) was added into a solution consisting of (S) -methyl 2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzoate (15 g, 47.6 mmol) in THF (100 mL) and H 2O (25 mL) . The reaction mixture was stirred at room temperature for 2 hour before concentrating it under reduced pressure to remove volatiles. The resultant aqueous phase was adjust to pH=3 with aq. HCl solution and the precipitation was collected and dried to give (S) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzoic acid (11.0 g, 69%yield) .
[0138]
Intermediate 3.3: (S) -2-Methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzoyl chloride
[0139]
[0140]
Oxalyl dichloride (8.99 mL, 106 mmol) was added into a solution consisting of (S) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzoic acid (8.00 g, 26.6 mmol) , DMF (0.5 mL) and DCM (80 mL) at 0 ℃. The reaction was stirred at room temperature for 2 hours. The resultant mixture was concentrated under reduced pressure to give the title compound (8.49g, 90%yield) which was used for the next step directly.
[0141]
Compound 3: (S) -N- (2-Chloro-3-fluorophenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0142]
[0143]
(S) -2-Methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzoyl chloride (200 mg, 0.625 mmol) was dissolved in dry DCM (2 mL) and the resultant solution was added drop-wise to a well stirred solution consisting of 2-chloro-3-fluoroaniline (109 mg, 0.749 mmol) , TEA (0.3 mL) and DCM (2 mL) at room temperature. The reaction mixture was stirred at room temperature for 1 hour and then diluted with DCM (15 mL) . Water (10 mL) was added. The organic phase was separated, dried over Na 2SO 4 and filtered. The filtrate was concentrated under reduced pressure to give a residue which was purified by trituration in DCM (2~3 mL) . The solid was filtered and then dried in vacuum. The resultant product was purified by prep. SFC separation (Column: ChiralPak AD 250×30mm I.D., 10 μm, Daicel Chemical Industries, Ltd; Mobile phase: A: Supercritical CO 2, B: EtOH (0.1%NH 3. H 2O) , A: B =55: 45 at 80mL/min; Column Temp: 38℃; Nozzle Pressure: 100Bar; Nozzle Temp: 60℃; Evaporator Temp: 20℃; Trimmer Temp: 25℃; Wavelength: 220nm) . The pure fractions were collected and the volatiles were removed under vacuum. The residue was partitioned between CH 3CN (1 ml) and water (5 ml) . The solution was lyophilized to give title compound.
[0144]
LC-MS (ESI) : R T = 4.93 min, mass calcd. for C 18H 18ClFN 2O 5S 428.06, m/z found 429.0 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.53 (br. s, 1H) , 8.48 -8.38 (m, 1H) , 8.25 -8.15 (m, 1H) , 8.05 -7.95 (m, 2H) , 7.56 -7.40 (m, 2H) , 7.25 (t, J = 8.8 Hz, 1H) , 4.15 (s, 3H) , 3.75 -3.50 (m, 4H) , 3.40 -3.30 (m, 1H) , 1.96 -1.85 (m, 1H) , 1.68 -1.56 (m, 1H) .
[0145]
Method D: (Compound 4 as example) :
[0146]
Compound 4: (S) -N- (4-Fluoro-3-methylphenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide.
[0147]
[0148]
HATU (608.4 mg, 1.60 mmol) was added into a mixture consisting of (S) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzoic acid (400.1 mg, 1.33 mmol) , 4-fluoro-3-methylaniline (166.4 mg, 1.33 mmol) , TEA (0.56 mL, 4.02 mmol) and DMF (5 mL) . The reaction mixture was stirred at room temperature for 12 hours before pouring it into water. The aqueous layer was extracted three times with ethyl acetate (20 mL x 3) . The combined organic layers were washed with brine, dried over Na 2SO 4 and filtered. The filtrate was concentrated to dryness to give a residue which was purified by prep. HPLC (Column: Gemini 150 x 25mm x 5um, Flow rate: 30ml/min, Mobile Phase A: Base water (containing 0.05%NH3. H2O) , Mobile Phase B: Acetonitrile) to give the title compound (100.7 mg, yield 18.1%) .
[0149]
LC-MS (ESI) : mass calcd. for C 19H 21FN 2O 5S 408.12, m/z found 409.1 [M+H] +, 1H NMR (400MHz, DMSO-d 6) δ 10.21 (br. s, 1H) , 8.00 (d, J = 2.3 Hz, 1H) , 7.96-7.876 (m, 2H) , 7.63 (dd, J = 7.0 Hz, J = 2.3 Hz 1H) , 7.58-7.53 (m, 1H) , 7.38 (d, J = 9.0 Hz, 1H) , 7.13 (t, J = 9.1 Hz, 1H) , 3.97 (s, 3H) , 3.74-3.65 (m, 2H) , 3.64-3.55 (m, 2H) , 3.38-3.35 (m, 1H) , 2.24 (s, 3H) , 1.96-1.85 (m, 1H) , 1.67-1.57 (m, 1H) .
[0150]
General procedure LCMS analystical methods
[0151]
M 1: reverse phase LC-MS was carried out on a YMC-PACK ODS-AQ, 50 x 2.0 mm 5 μm column with a flow rate of 0.8 mL/min, eluting with a gradient of 0%to 60%acetonitrile containing 0.05%TFA (solvent B) and water containing 0.1%TFA (solvent A) . The eluent composition was kept at 100%A for 1 minute, followed by increasing to 60%B over the course of 4 minutes. The eluent was kept at 60%B for 2.5 minutes before returning to 100%A over the course of 0.5 minutes. Total run time was 8 minutes.
[0152]
M2: reverse phase LC-MS was carried out on a Agilent TC-C18, 50 x 2.1 mm, 5 μm column with a flow rate of 0.8 mL/min, eluting with a gradient of 0%to 85%acetonitrile containing 0.05%TFA (solvent B) and water containing 0.1%TFA (solvent A) . The eluent composition was kept at 100%A for 1 minute, followed by increasing to 40%B over the course of 4 minutes. The eluent was further increased to 85%B over the course of 2.5 minutes before returning to 100%A over the course of 2 minutes. Total run time was 9.5 minutes.
[0153]
M3: reverse phase LC-MS was carried out on a Agilent TC-C18, 50 x 2.1 mm, 5 μm column with a flow rate of 0.8 mL/min, eluting with a gradient of 10%to 80%acetonitrile containing 0.05%TFA (solvent B) and water containing 0.1%TFA (solvent A) . The eluent composition was kept at 10%B for 0.8 minutes, followed by increasing to 80%B over the course of 3.7 minutes. The eluent was kept at 80%B for 3 minutes before returning to 10%B over the course of 2 minutes. Total run time was 9.5 minutes.
[0154]
M4: reverse phase LC-MS was carried out on a X-Bridge Shield RP18, 50 x 2.1 mm 5 μm with a flow rate of 0.8 mL/min, eluting with a gradient of 0%to 95%acetonitrile (solvent B) and water with 0.05%NH 3. H 2O (solvent A) . The eluent composition was kept at 100%A for 1 minute, followed by increasing to 60%B over the course of 4 minutes. The eluent was increased to 95%B over the course of 2 minutes before returning to 100%A over the course of 2 minutes. Total run time was 9.5 minutes.
[0155]
General methods of preparation HPLC:
[0156]
NH 3H 2O: (Column: Agela DuraShell C18 150 mm x 25 mm, 5 μm; mobile phase: CH 3CN in water (0.05%NH 3H 2Owater) from 43%to 73%, flow rate: 30 mL/min) .
[0157]
NH 4HCO 3: (Column: Agela DuraShell C18 150 mm x 25 mm, 5 μm; mobile phase: CH 3CN in water (0.5%NH 4HCO 3water) from 20%to 60%, flow rate: 30 mL/min) .
[0158]
Formic acid: (Column: Phenomenex Synergi Max-RP 250mm x 80mm, 10μm; mobile phase: CH 3CN in water (0.225%formic acid water) from 1%to 25%, flow rate: 80ml/min)
[0159]
HCl: (Column: Gemini C18 150 mm x 25 mm, 5 μm; mobile phase: CH 3CN in water (0.05%HCl water) from 35%to 65%, flow rate: 25 mL/min) .
[0160]
TFA: (Column: Phenomenex Synergi C18 150mm x 30mm, 4μm (eluent: CH 3CN/H 2O (0.1%TFA water ) from 65%to 75%, flow rate: 30ml/min) .
[0161]
General SFC Separation Methods:
[0162]
Method 1: Separation condition: Column: AD 250×30mm I.D., 5um, Daicel Chemical Industries, Ltd; Mobile phase: A: Supercritical CO 2, B: MeOH (0.1%NH 3H 2O)
[0163]
Method 2: Separation condition: Column: ChiralPak OJ-H 250×30mm I.D., 5um, Daicel Chemical Industries, Ltd; Mobile phase: A: Supercritical CO 2, B: EtOH (0.1%NH 3H 2O)
[0164]
Method 3: Separation condition: Column: ChiralPak AD 250 × 30mm I.D., 20um, Daicel Chemical Industries, Ltd; Mobile phase: A: Supercritical CO 2, B: EtOH (0.1%NH 3H 2O)
[0165]
Method 4: Separation condition: Column: ChiralPak AD, Daicel Chemical Industries, Ltd, 250 h 30mm I.D., 10μm; Mobile phase: A: Supercritical CO 2, B: methanol (0.1%NH 3H 2O)
[0166]
Method 5: Separation condition: Column: AD (250mm*30mm, 5um) ; Mobile phase: A: Supercritical CO 2, B: EtOH (0.1%NH 3H 2O) ;
[0167]
Method 6: Separation condition: Column: ChiralPak AD 250 h 30mm I.D., 10 μm, Daicel Chemical Industries, Ltd; Mobile phase: A: Supercritical CO 2, B: EtOH (0.1%NH 3H 2O)
[0168]
Method 7: Column: Chiralpak AD-3 50*4.6mm I.D., 3um Mobile phase: 60%ethanol (0.05%DEA) in CO 2.
[0169]
Method 8: separation condition: Column: ChiralPak OJ-H, Daicel Chemical Industries, Ltd, 250×30mm I.D., 5μm; Mobile phase: A: Supercritical CO 2, B: Methanol (0.1%NH 3H 2O)
[0170]
Table 1
[0171]
[0172]
[0173]
[0174]
[0175]
[0176]
[0177]
[0178]
[0179]
[0180]
[0181]
[0182]
[0183]
[0184]
[0185]
[0186]
[0187]
Compound 5: N- (4-Fluoro-3-methylphenyl) -2-methoxy-5- (N- (oxetan-3-yl) sulfamoyl) benzamide
[0188]
LC-MS (ESI) : mass calcd. for C 18H 19FN 2O 5S 394.10, m/z found 395.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.21 (br. s., 1H) , 8.51 (br. s., 1H) , 7.95 (d, J=2.4 Hz, 1H) , 7.87 (dd, J=2.4, 8.8 Hz, 1H) , 7.65 -7.60 (m, 1H) , 7.58 -7.52 (m, 1H) , 7.36 (d, J=8.8 Hz, 1H) , 7.13 (t, J=9.2 Hz, 1H) , 4.51 (t, J=6.8 Hz, 2H) , 4.41 -4.32 (m, 1H) , 4.25 (t, J=6.8 Hz, 2H) , 3.96 (s, 3H) , 2.24 (s, 3H) .
[0189]
Compound 6a: N- (4-Fluoro-3-methylphenyl) -5- (N- ( (trans) -3-hydroxycyclobutyl) sulfamoyl) -2- methoxybenzamide
[0190]
LC-MS (ESI) : mass calcd. for C 19H 21FN 2O 5S 408.12, m/z found 409.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.21 (br. s, 1H) , 7.95 (d, J=2.4 Hz, 1H) , 7.90 -7.83 (m, 2H) , 7.65 -7.61 (m, 1H) , 7.58 -7.52 (m, 1H) , 7.36 (d, J=8.8 Hz, 1H) , 7.13 (t, J=9.6 Hz, 1H) , 4.95 (d, J=5.2 Hz, 1H) , 4.16 -4.09 (m, 1H) , 3.97 (s, 3H) , 3.75 -3.64 (m, 1H) , 2.24 (s, 3H) , 2.00 -1.86 (m, 4H) .
[0191]
Compound 6b: N- (4-Fluoro-3-methylphenyl) -5- (N- ( (cis) -3-hydroxycyclobutyl) sulfamoyl) -2- methoxybenzamide
[0192]
LC-MS (ESI) : mass calcd. for C 19H 21FN 2O 5S 408.12, m/z found 409.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.20 (br. s, 1H) , 7.97 (d, J=2.4 Hz, 1H) , 7.89 -7.82 (m, 2H) , 7.65 -7.61 (m, 1H) , 7.58 -7.53 (m, 1H) , 7.36 (d, J=8.8 Hz, 1H) , 7.13 (t, J=9.0 Hz, 1H) , 5.02 (d, J=5.5 Hz, 1H) , 3.97 (s, 3H) , 3.69 -3.62 (m, 1H) , 3.14 -3.03 (m, 1H) , 2.27 -2.29 (m, 5H) , 1.61 -1.53 (m, 2H) .
[0193]
Compound 7: N- (4-Fluoro-3-methylphenyl) -2-methoxy-5- (N- (3-methylcyclobutyl) sulfamoyl) benzamide
[0194]
LC-MS (ESI) : mass calcd. for C 20H 23FN 2O 4S 406.14, m/z found 407.1 [M+H] +. 1H NMR (400 MHz, DMSO-d 6) δ 10.21 (s, 1H) , 7.97 (d, J=2.21 Hz, 1H) , 7.95 -7.82 (m, 2H) , 7.67 -7.60 (m, 1H) , 7.59 -7.51 (m, 1H) , 7.35 (d, J=9.04 Hz, 1H) , 7.13 (t, J=9.26 Hz, 1H) , 3.97 (s, 3H) , 3.81 -3.73 (m, 1H, trans) , 3.47 -3.42 (m, 1H, cis) , 2.24 (s, 3H) , 2.15 -2.05 (m, 3H, cis) , 1.96 -1.82 (m, 3H, trans) , 1.68 -1.59 (m, 1H) , 1.37 -1.27 (m, 1H) , 1.00 (d, J=1.00 Hz, 1.5H) , 0.91 (d, J=6.62 Hz, 1.5H) .
[0195]
Compound 7a: N- (4-Fluoro-3-methylphenyl) -2-methoxy-5- (N- ( (cis) -3-methylcyclobutyl) sulfamoyl) benzamide
[0196]
LC-MS (ESI) : mass calcd. for C 20H 23FN 2O 4S 406.14, m/z found 407.1 [M+H] +. 1H NMR (400 MHz, DMSO-d 6) δ 10.19 (s, 1H) , 7.95 (d, J=2.21 Hz, 1H) , 7.86 (dd, J=8.82, 2.43 Hz, 1H) , 7.84 -7.76 (m, 1H) , 7.64 -7.58 (m, 1H) , 7.54 (m, 1H) , 7.33 (d, J=8.82 Hz, 1H) , 7.11 (t, J=9.15 Hz, 1H) , 3.94 (s, 3H) , 3.43-3.38 (m, 1H) , 2.22 (s, 3H) , 2.13 -2.02 (m, 2H) , 1.86 -1.75 (m, 1H) , 1.35 -1.25 (m, 2H) , 0.89 (d, J=6.39 Hz, 3H) .
[0197]
Compound 7b: N- (4-Fluoro-3-methylphenyl) -2-methoxy-5- (N- ( (trans) -3-methylcyclobutyl) sulfamoyl) benzamide
[0198]
LC-MS (ESI) : mass calcd. for C 20H 23FN 2O 4S 406.14, m/z found 407.1 [M+H] +. 1H NMR (400 MHz, DMSO-d 6) δ 10.19 (s, 1H) , 7.96 (d, J=2.01 Hz, 1H) , 7.91 (m, J=7.50 Hz, 1H) , 7.87 (dd, J=8.53, 2.51 Hz, 1H) , 7.66 -7.60 (m, 1H) , 7.58 -7.51 (m, 1H) , 7.35 (d, J=9.03 Hz, 1H) , 7.12 (t, J=9.03 Hz, 1H) , 3.96 (s, 3H) , 3.82 -3.70 (m, 1H) , 2.23 (s, 3H) , 2.12 (m, 1H) , 1.95 -1.85 (m, 2H) , 1.68 -1.58 (m, 2H) , 0.99 (d, J=7.03 Hz, 3H) .
[0199]
Compound 8: N- (4-Fluoro-3-methylphenyl) -5- (N-isopropylsulfamoyl) -2-methoxybenzamide
[0200]
LC-MS (ESI) : mass calcd. for C 18H 21FN 2O 4S 380.12, m/z found 381.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.22 (s, 1H) , 8.00 (d, J = 2.4 Hz, 1H) , 7.91 (dd, J = 2.3, 8.7 Hz, 1H) , 7.66 -7.61 (m, 1H) , 7.60 -7.52 (m, 2H) , 7.37 (d, J = 8.8 Hz, 1H) , 7.13 (t, J = 9.3 Hz, 1H) , 3.97 (s, 3H) , 3.27 -3.17 (m, 1H) , 2.24 (s, 3H) , 0.97 (d, J = 6.4 Hz, 6H) .
[0201]
Compound 9: N- (4-Fluoro-3-methylphenyl) -2-methoxy-5- (N- (3-methyloxetan-3-yl) sulfamoyl) benzamide
[0202]
LC-MS (ESI) : mass calcd. for C 19H 21FN 2O 5S 408.12, m/z found 409.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.22 (s, 1H) , 8.33 (s, 1H) , 8.00 (d, J = 2.4 Hz, 1H) , 7.92 (dd, J = 2.4, 8.8 Hz, 1H) , 7.63 (dd, J = 2.2, 7.1 Hz, 1H) , 7.59 -7.52 (m, 1H) , 7.37 (d, J = 8.8 Hz, 1H) , 7.13 (t, J = 9.2 Hz, 1H) , 4.54 (d, J = 6.0 Hz, 2H) , 4.12 (d, J = 6.2 Hz, 2H) , 3.97 (s, 3H) , 2.24 (s, 3H) , 1.43 (s, 3H) .
[0203]
Compound 10: N- (4-Fluoro-3-methylphenyl) -5- (N- (1-hydroxypropan-2-yl) sulfamoyl) -2- methoxybenzamide
[0204]
LC-MS (ESI) : mass calcd. for C 18H 21FN 2O 5S 396.12, m/z found 397.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.21 (s, 1H) , 8.01 (d, J = 2.4 Hz, 1H) , 7.92 (dd, J = 2.3, 8.7 Hz, 1H) , 7.67 -7.60 (m, 1H) , 7.59 -7.49 (m, 2H) , 7.36 (d, J = 8.8 Hz, 1H) , 7.13 (t, J = 9.2 Hz, 1H) , 4.73 (t, J = 5.4 Hz, 1H) , 3.97 (s, 3H) , 3.34 -3.28 (m, 1H) , 3.16 -3.02 (m, 2H) , 2.24 (s, 3H) , 0.91 (d, J = 6.2 Hz, 3H) .
[0205]
Compound 10a: (S) -N- (4-Fluoro-3-methylphenyl) -5- (N- (1-hydroxypropan-2-yl) sulfamoyl) -2- methoxybenzamide
[0206]
LC-MS (ESI) : mass calcd. for C 18H 21FN 2O 5S 396.12, m/z found 397.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.21 (s, 1H) , 8.01 (d, J = 2.2 Hz, 1H) , 7.92 (dd, J = 2.2, 8.8 Hz, 1H) , 7.66 -7.60 (m, 1H) , 7.59 -7.48 (m, 2H) , 7.36 (d, J = 9.0 Hz, 1H) , 7.13 (t, J = 9.2 Hz, 1H) , 4.71 (t, J = 5.4 Hz, 1H) , 3.97 (s, 3H) , 3.34 -3.26 (m, 1H) , 3.15 -3.02 (m, 2H) , 2.24 (s, 3H) , 0.91 (d, J = 6.0 Hz, 3H) .
[0207]
Compound 10b: (R) -N- (4-Fluoro-3-methylphenyl) -5- (N- (1-hydroxypropan-2-yl) sulfamoyl) -2 – methoxybenzamide
[0208]
Compound 11a: (S*) -5- (N- (1-Cyanopropan-2-yl) sulfamoyl) -N- (4-fluoro-3-methylphenyl) -2- methoxybenzamide
[0209]
LC-MS (ESI) : mass calcd. for C 19H 20FN 3O 4S 405.12, m/z found 406.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) 10.20 (s, 1H) , 8.02 (d, J = 2.2 Hz, 2H) , 7.94 (dd, J = 2.4, 8.8 Hz, 1H) , 7.63 (dd, J = 2.1, 7.0 Hz, 1H) , 7.58 -7.52 (m, 1H) , 7.38 (d, J = 8.8 Hz, 1H) , 7.12 (t, J = 9.2 Hz, 1H) , 3.97 (s, 3H) , 3.46 -3.38 (m, 1H) , 2.76 -2.66 (m, 1H) , 2.66 -2.57 (m, 1H) , 2.24 (s, 3H) , 1.00 (d, J = 6.6 Hz, 3H) .
[0210]
Compound 11b: (R*) -5- (N- (1-Cyanopropan-2-yl) sulfamoyl) -N- (4-fluoro-3-methylphenyl) -2 - methoxybenzamide
[0211]
LC-MS (ESI) : mass calcd. for C 19H 20FN 3O 4S 405.12, m/z found 406.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.20 (s, 1H) , 8.03 (br. s., 1H) , 8.01 (d, J = 2.4 Hz, 1H) , 7.94 (dd, J = 2.4, 8.8 Hz, 1H) , 7.66 -7.60 (m, 1H) , 7.59 -7.50 (m, 1H) , 7.38 (d, J = 8.8 Hz, 1H) , 7.12 (t, J = 9.2 Hz, 1H) , 3.97 (s, 3H) , 3.47 -3.39 (m, 1H) , 2.75 -2.66 (m, 1H) , 2.66 -2.57 (m, 1H) , 2.24 (s, 3H) , 1.00 (d, J = 6.6 Hz, 3H) .
[0212]
Compound 12: 5- (N- (1-Amino-1-oxopropan-2-yl) sulfamoyl) -N- (4-fluoro-3-methylphenyl) -2- methoxybenzamide
[0213]
[0214]
LC-MS (ESI) : mass calcd. for C 18H 20FN 3O 5S 409.11, m/z found 410.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.18 (s, 1H) , 8.00 (d, J = 2.2 Hz, 1H) , 7.90 (dd, J = 2.4, 8.8 Hz, 1H) , 7.87 (br. s., 1H) , 7.66 -7.60 (m, 1H) , 7.59 -7.52 (m, J = 4.0, 7.9 Hz, 1H) , 7.35 (d, J = 8.8 Hz, 1H) , 7.29 (br. s., 1H) , 7.13 (t, J = 9.3 Hz, 1H) , 7.00 (br. s., 1H) , 3.96 (s, 3H) , 3.67 (q, J = 6.8 Hz, 1H) , 2.24 (s, 3H) , 1.07 (d, J = 7.1 Hz, 3H) .
[0215]
Compound 12a: (S) -5- (N- (1-Amino-1-oxopropan-2-yl) sulfamoyl) -N- (4-fluoro-3-methylphenyl) -2-methoxybenzamide
[0216]
LC-MS (ESI) : mass calcd. for C 18H 20FN 3O 5S 409.11, m/z found 410.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.18 (s, 1H) , 8.01 (d, J = 2.2 Hz, 1H) , 7.95 -7.84 (m, 2H) , 7.67 -7.60 (m, 1H) , 7.59 -7.51 (m, 1H) , 7.35 (d, J = 8.8 Hz, 1H) , 7.29 (br. s., 1H) , 7.13 (t, J = 9.2 Hz, 1H) , 7.00 (br. s., 1H) , 3.96 (s, 3H) , 3.74 -3.61 (m, J = 4.9 Hz, 1H) , 2.24 (s, 3H) , 1.08 (d, J = 7.1 Hz, 3H) .
[0217]
Compound 12b: (R) -5- (N- (1-Amino-1-oxopropan-2-yl) sulfamoyl) -N- (4-fluoro-3-methylphenyl) -2-methoxybenzamide
[0218]
LC-MS (ESI) : mass calcd. for C 18H 20FN 3O 5S 409.11, m/z found 410.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.18 (s, 1H) , 8.00 (d, J = 2.2 Hz, 1H) , 7.93 -7.86 (m, 2H) , 7.63 (dd, J = 2.0, 6.8 Hz, 1H) , 7.59 -7.52 (m, 1H) , 7.35 (d, J = 9.0 Hz, 1H) , 7.29 (br. s., 1H) , 7.13 (t, J = 9.3 Hz, 1H) , 7.00 (br. s., 1H) , 3.96 (s, 3H) , 3.68 (q, J = 6.9 Hz, 1H) , 2.24 (s, 3H) , 1.07 (d, J = 7.1 Hz, 3H) .
[0219]
Compound 13: N- (4-Fluoro-3-methylphenyl) -5- (N- (3- (hydroxymethyl) oxetan-3-yl) sulfamoyl) -2 -methoxybenzamide
[0220]
LC-MS (ESI) : mass calcd. for C 19H 21FN 2O 6S 424.11, m/z found 425.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.21 (s, 1H) , 8.31 (br. s., 1H) , 8.02 (d, J = 2.0 Hz, 1H) , 7.94 (dd, J = 2.3, 8.8 Hz, 1H) , 7.66 -7.60 (m, 1H) , 7.59 -7.52 (m, 1H) , 7.36 (d, J = 8.5 Hz, 1H) , 7.13 (t, J = 9.3 Hz, 1H) , 5.17 (t, J = 5.5 Hz, 1H) , 4.47 (d, J = 6.5 Hz, 2H) , 4.36 (d, J = 6.0 Hz, 2H) , 3.97 (s, 3H) , 3.52 (d, J = 5.5 Hz, 2H) , 2.24 (s, 3H) .
[0221]
Compound 14: 5- (N- (3, 3-Dimethylcyclobutyl) sulfamoyl) -N- (4-fluoro-3-methylphenyl) -2 -methoxybenzamide
[0222]
LC-MS (ESI) : mass calcd. For C 21H 25FN 2O 4S 420.15, m/z found 421.0 [M+H] +; 1H NMR (400MHz, DMSO-d 6) δ 10.19 (s, 1H) , 7.96 (d, J = 2.0 Hz, 1H) , 7.88 (dd, J = 2.3, 8.8 Hz, 1H) , 7.84 (d, J = 8.5 Hz, 1H) , 7.66 -7.60 (m, 1H) , 7.58 -7.51 (m, 1H) , 7.35 (d, J = 9.0 Hz, 1H) , 7.12 (t, J = 9.3 Hz, 1H) , 3.96 (s, 3H) , 3.70 -3.54 (m, 1H) , 2.24 (s, 3H) , 1.86 -1.72 (m, 2H) , 1.61 - 1.47 (m, 2H) , 0.99 (s, 3H) , 0.97 (s, 3H) .
[0223]
Compound 15a: N- (4-Fluoro-3-methylphenyl) -5- (N- ( (cis) -3-hydroxycyclopentyl) sulfamoyl) -2 - methoxybenzamide
[0224]
LC-MS (ESI) : mass calcd. for C 20H 23FN 2O 5S 422.13, m/z found 423.0 [M+H] +; 1H NMR (400MHz, DMSO-d 6) δ 10.20 (s, 1H) , 8.00 (d, J = 2.0 Hz, 1H) , 7.90 (dd, J = 2.0, 8.8 Hz, 1H) , 7.64 (t, J = 8.8 Hz, 2H) , 7.59 -7.51 (m, 1H) , 7.36 (d, J = 8.8 Hz, 1H) , 7.12 (t, J = 9.2 Hz, 1H) , 4.57 (d, J = 3.9 Hz, 1H) , 3.97 (s, 3H) , 3.94 -3.87 (m, 1H) , 2.24 (s, 3H) , 1.98 -1.86 (m, 1H) , 1.64 -1.49 (m, 2H) , 1.49 -1.37 (m, 2H) , 1.27 -1.16 (m, 1H) .
[0225]
Compound 15b: N- (4-Fluoro-3-methylphenyl) -5- (N- ( (cis) -3-hydroxycyclopentyl) sulfamoyl) -2 -methoxybenzamide
[0226]
LC-MS (ESI) : mass calcd. for C 20H 23FN 2O 5S 422.13, m/z found 423.1 [M+H] +; 1H NMR (400MHz, DMSO-d 6) δ 10.20 (s, 1H) , 8.01 (d, J = 1.5 Hz, 1H) , 7.95 -7.87 (m, 1H) , 7.70 -7.60 (m, 2H) , 7.59 -7.51 (m, 1H) , 7.36 (d, J = 8.5 Hz, 1H) , 7.13 (t, J = 9.0 Hz, 1H) , 4.65 (d, J = 4.0 Hz, 1H) , 3.97 (s, 3H) , 3.95 -3.88 (m, 1H) , 2.24 (s, 3H) , 1.98 -1.88 (m, 1H) , 1.64 -1.38 (m, 4H) , 1.28 -1.17 (m, 1H) .
[0227]
Compound 16a: (S*) -N- (5-Fluoro-6-methylpyridin-2-yl) -2-methoxy-5- (N- (tetrahydro-2H-pyran -3-yl) sulfamoyl) benzamide
[0228]
LC-MS (ESI) : mass calcd. for C 19H 22FN 3O 5S 423.13, m/z found 424.1 [M+H] +; 1H NMR (400MHz, DMSO-d 6) δ 10.60 (s, 1H) , 8.14 (d, J = 2.3 Hz, 1H) , 8.11 -8.06 (m, 1H) , 7.95 (dd, J = 2.5, 8.8 Hz, 1H) , 7.81 (br. s., 1H) , 7.71 (t, J = 8.9 Hz, 1H) , 7.39 (d, J = 8.8 Hz, 1H) , 4.01 (s, 3H) , 3.64 -3.53 (m, 2H) , 3.24 -3.15 (m, 1H) , 3.06 -2.94 (m, 2H) , 2.40 (d, J = 2.8 Hz, 3H) , 1.69 -1.53 (m, 2H) , 1.44 -1.28 (m, 2H) .
[0229]
Compound 16b: (R*) -N- (5-Fluoro-6-methylpyridin-2-yl) -2-methoxy-5- (N- (tetrahydro-2H- pyran-3-yl) sulfamoyl) benzamide
[0230]
LC-MS (ESI) : mass calcd. for C 19H 22FN 3O 5S 423.13, m/z found 424.1 [M+H] +; 1H NMR (400MHz, DMSO-d 6) δ 10.60 (s, 1H) , 8.14 (d, J = 2.5 Hz, 1H) , 8.12 -8.07 (m, 1H) , 7.95 (dd, J = 2.5, 8.8 Hz, 1H) , 7.83 -7.78 (m, 1H) , 7.71 (t, J = 9.0 Hz, 1H) , 7.39 (d, J = 9.0 Hz, 1H) , 4.01 (s, 3H) , 3.63 -3.54 (m, 2H) , 3.24 -3.16 (m, 1H) , 3.06 -2.94 (m, 2H) , 2.41 (d, J = 3.0 Hz, 3H) , 1.70 -1.53 (m, 2H) , 1.42 -1.27 (m, 2H) .
[0231]
Compound 17: N- (5-Fluoro-6-methylpyridin-2-yl) -2-methoxy-5- (N- (tetrahydro-2H-pyran-4-yl) sulfamoyl) benzamide
[0232]
LC-MS (ESI) : mass calcd. for C 19H 22FN 3O 5S 423.13, m/z found 424.1 [M+H] +. 1H NMR (400 MHz, DMSO-d 6) δ 10.58 (s, 1H) , 8.16 (d, J = 2.3 Hz, 1H) , 8.13 -8.07 (m, 1H) , 7.95 (dd, J = 2.5, 8.8 Hz, 1H) , 7.80 (d, J = 7.0 Hz, 1H) , 7.71 (t, J = 8.9 Hz, 1H) , 7.39 (d, J = 8.8 Hz, 1H) , 4.02 (s, 3H) , 3.76 -3.68 (m, 2H) , 3.27 -3.21 (m, 2H) , 3.16 (d, J = 4.8 Hz, 1H) , 2.41 (d, J = 2.8 Hz, 3H) , 1.54 (d, J = 10.8 Hz, 2H) , 1.42 -1.30 (m, 2H) .
[0233]
Compound 18: (trans) -N- (5-Fluoro-6-methylpyridin-2-yl) -5- (N- (-4-hydroxycyclohexyl) sulfamoyl) -2-methoxybenzamid
[0234]
LC-MS (ESI) : mass calcd. for C 20H 24FN 3O 5S 437.14, m/z found 438.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.58 (s, 1H) , 8.14 (d, J = 2.4 Hz, 1H) , 8.12 -8.07 (m, 1H) , 7.93 (dd, J = 2.4, 8.8 Hz, 1H) , 7.71 (t, J = 9.0 Hz, 1H) , 7.62 (d, J = 7.0 Hz, 1H) , 7.38 (d, J = 8.8 Hz, 1H) , 4.49 (d, J = 4.3 Hz, 1H) , 4.01 (s, 3H) , 3.29 -3.26 (m, 1H) , 2.92 -2.81 (m, 1H) , 2.41 (d, J = 2.8 Hz, 3H) , 1.74 -1.66 (m, 2H) , 1.64 -1.57 (m, 2H) , 1.19 -1.02 (m, 4H) .
[0235]
Compound 19: N- (5-Fluoro-6-methylpyridin-2-yl) -2-methoxy-5- (N- (1-methylpiperidin-4-yl) sulfamoyl) benzamide
[0236]
LC-MS (ESI) : mass calcd. for C 20H 25FN 4O 4S 436.16, m/z found 437.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.55 (s, 1H) , 8.16 (d, J = 2.3 Hz, 1H) , 8.09 (d, J = 5.5 Hz, 1H) , 7.94 (dd, J = 2.4, 8.7 Hz, 1H) , 7.74 -7.64 (m, 2H) , 7.39 (d, J = 8.8 Hz, 1H) , 4.02 (s, 3H) , 2.94 -2.83 (m, 1H) , 2.63 -2.56 (m, 2H) , 2.41 (d, J = 2.8 Hz, 3H) , 2.08 (s, 3H) , 1.86 -1.76 (m, 2H) , 1.58 -1.49 (m, 2H) , 1.44 -1.32 (m, 2H) .
[0237]
Compound 20: 5- (N-Cyclohexylsulfamoyl) -N- (5-fluoro-6-methylpyridin-2-yl) -2–methoxy benzamide
[0238]
LC-MS (ESI) : mass calcd. for C 20H 24FN 3O 4S 421.15, m/z found 422.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.57 (s, 1H) , 8.16 (s, 1H) , 8.13 -8.07 (m, 1H) , 7.94 (d, J = 8.5 Hz, 1H) , 7.71 (t, J = 8.7 Hz, 1H) , 7.64 (d, J = 7.3 Hz, 1H) , 7.38 (d, J = 8.5 Hz, 1H) , 4.02 (s, 3H) , 2.98 -2.87 (m, 1H) , 2.41 (d, J = 2.3 Hz, 3H) , 1.64 -1.53 (m, 4H) , 1.48 -1.40 (m, 1H) , 1.19 -1.01 (m, 5H) .
[0239]
Compound 21: 5- (N-Cyclopropylsulfamoyl) -N- (5-fluoro-6-methylpyridin-2-yl) -2-methoxy benzamide
[0240]
LC-MS (ESI) : mass calcd. for C 17H 18FN 3O 4S 379.10, m/z found 380.0 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ10.60 (s, 1H) , 8.15 (d, J = 2.0 Hz, 1H) , 8.13 -8.07 (m, 1H) , 7.96 -7.89 (m, 2H) , 7.71 (t, J = 9.0 Hz, 1H) , 7.42 (d, J = 8.8 Hz, 1H) , 4.02 (s, 3H) , 2.41 (d, J = 2.8 Hz, 3H) , 2.14 -2.06 (m, 1H) , 0.52 -0.45 (m, 2H) , 0.42 -0.35 (m, 2H) .
[0241]
Compound 22: N- (5-Fluoro-6-methylpyridin-2-yl) -2-methoxy-5-sulfamoylbenzamide
[0242]
LC-MS (ESI) : mass calcd. for C 14H 14FN 3O 4S 339.07, m/z found 340.0 [M+H] +, 1H NMR (400MHz, DMSO-d 6) δ 10.57 (br. s, 1H) , 8.21 (s, 1H) , 8.11 (d, J = 6.4 Hz, 1H) , 7.95 (m, J = 7.6 Hz, 1H) , 7.71 (t, J = 9.2 Hz, 1H) , 7.33-7.43 (m, 3H) , 4.02 (s, 3H) , 2.41 (s, 3H) .
[0243]
Compound 23a: (R*) -N- (5-fluoro-6-methylpyridin-2-yl) -2-methoxy-5- (N- (3, 3, 3-trifluoro-2 -hydroxypropyl ) sulfamoyl) benzamide
[0244]
LC-MS (ESI) : mass calcd. for C 17H 17F 4N 3O 5S 451.08, m/z found 452.1 [M+H] +, 1H NMR (400MHz, DMSO-d 6) δ 10.60 (br. s, 1H) , 8.07-8.15 (m, 2H) , 7.91-8.00 (m, 2H) , 7.72 (t, J = 9.2 Hz, 1H) , 7.41 (d, J = 8.8 Hz, 1H) , 6.63 (s, 1H) , 4.01 (s, 4H) , 2.98 (dd, J = 13.6 Hz, J = 4.0 Hz, 1H) , 2.82 (dd, J = 13.6 Hz, J = 8.0 Hz, 1H) , 2.41 (d, J = 2.4 Hz, 3H) .
[0245]
Compound 23b: (S*) -N- (5-fluoro-6-methylpyridin-2-yl) -2-methoxy-5- (N- (3, 3, 3-trifluoro-2 -hydroxypropyl) sulfamoyl) benzamide
[0246]
LC-MS (ESI) : mass calcd. for C 17H 17F 4N 3O 5S 451.08, m/z found 452.1 [M+H] + 1H NMR (400MHz, DMSO-d 6) δ 10.61 (br. s, 1H) , 8.07-8.16 (m, 2H) , 7.91-8.01 (m, 2H) , 7.72 (t, J = 8.8 Hz, 1H) , 7.41 (d, J = 8.8 Hz, 1H) , 6.63 (s, 1H) , 4.01 (s, 4H) , 2.98 (dd, J = 13.6 Hz, J = 4.0 Hz, 1H) , 2.82 (dd, J = 13.6 Hz, J = 8.0 Hz, 1H) , 2.41 (d, J = 2.4 Hz, 3H) .
[0247]
Compound 24: N- (5-Fluoro-6-methylpyridin-2-yl) -2-methoxy-5- (N-methylsulfamoyl) benzamide
[0248]
LC-MS (ESI) : mass calcd. for C 15H 16FN 3O 4S 353.08, m/z found 354.1 [M+H] +. 1H NMR (400MHz, DMSO-d6) 10.61 (br. s, 1H) , 8.12 -8.07 (m, 2H) , 7.91 (dd, J = 2.4 Hz, J = 8.8 Hz, 1H) , 7.71 (t, J = 8.8 Hz, 1H) , 7.48 -7.38 (m, 2H) , 4.01 (s, 3H) , 2.44 -2.36 (m, 6H) .
[0249]
Compound 25: N- (5-Fluoro-6-methylpyridin-2-yl) -5- (N-isopropylsulfamoyl) -2-methoxy benzamide
[0250]
LC-MS (ESI) : mass calcd. for C 17H 20FN 3O 4S 381.12, m/z found 382.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) 10.58 (s, 1H) , 8.19 -8.05 (m, 2H) , 7.93 (dd, J = 2.5, 8.5 Hz, 1H) , 7.71 (t, J = 9.0 Hz, 1H) , 7.59 (d, J = 7.0 Hz, 1H) , 7.39 (d, J = 8.5 Hz, 1H) , 4.01 (s, 3H) , 3.30-3.15 (m, 1H) , 2.40 (d, J = 2.5 Hz, 3H) , 0.96 (d, J = 6.5 Hz, 6H) .
[0251]
Compound 26: 5- (N-Ethylsulfamoyl) -N- (5-fluoro-6-methylpyridin-2-yl) -2-methoxybenzamide
[0252]
LC-MS (ESI) : mass calcd. for C 16H 18FN 3O 4S 367.10, m/z found 368.1 [M+H] +. 1H NMR (400MHz, DMSO-d6) 10.59 (br. s, 1H) , 8.15 -8.05 (m, 2H) , 7.91 (dd, J = 2.4 Hz, J = 8.8 Hz, 1H) , 7.71 (t, J = 8.8 Hz, 1H) , 7.55 (t, J = 5.6 Hz, 1H) , 7.39 (d, J = 8.8 Hz, 1H) , 4.01 (s, 3H) , 2.80 -2.70 (m, 2H) , 2.40 (d, J = 2.8 Hz, 3H) , 0.98 (t, J = 7.2 Hz, 3H) .
[0253]
Compound 27: N- (5-Fluoro-6-methylpyridin-2-yl) -5- (N- ( (cis) -4-hydroxycyclohexyl) sulfamoyl) - 2-methoxybenzamide
[0254]
LC-MS (ESI) : mass calcd. for C 20H 24FN 3O 5S 437.14, m/z found 438.1 [M+H] +. 1H NMR (400 MHz, DMSO-d 6) δ 10.56 (s, 1H) , 8.21 -8.00 (m, 2H) , 7.92 (s, 1H) , 7.80 -7.50 (m, 2H) , 7.36 (d, J = 7.1 Hz, 1H) , 4.40 -4.25 (m, 1H) , 3.99 (s, 3H) , 3.60 -3.50 (m, 1H) , 3.00 -2.90 (m, 1H) , 2.39 (s, 3H) , 1.60 -1.40 (m, 4H) , 1.40 -1.20 (m, 4H) .
[0255]
Compound 28a: N- (5-Fluoro-6-methylpyridin-2-yl) -5- (N- ( (trans) -2-hydroxycyclohexyl) sulfamoyl) -2-methoxybenzamide
[0256]
LC-MS (ESI) : mass calcd. for C 20H 24FN 3O 5S 437.14, m/z found 438.2 [M+H] +. 1H NMR (400 MHz, DMSO-d 6) δ 10.55 (s, 1H) , 8.19 (d, J = 2.4 Hz, 1H) , 8.15-8.05 (m, 1H) , 7.96 (dd, J = 8.8, 2.5 Hz, 1H) , 7.71 (t, J = 9.0 Hz, 1H) , 7.52 -7.42 (m, 1H) , 7.36 (d, J = 8.9 Hz, 1H) , 4.50 (d, J = 4.6 Hz, 1H) , 4.01 (s, 3H) , 3.25 -3.15 (m, 1H) , 2.82 -2.72 (m, 1H) , 2.41 (d, J = 2.8 Hz, 3H) , 1.80 -1.72 (m, 1H) , 1.70 -1.62 (m, 1H) , 1.56 -1.42 (m, 2H) , 1.19 -1.02 (m, 4H) .
[0257]
Compound 28b: N- (5-Fluoro-6-methylpyridin-2-yl) -5- (N- ( (trans) -2-hydroxycyclohexyl) sulfamoyl) -2-methoxybenzamide
[0258]
LC-MS (ESI) : mass calcd. for C 20H 24FN 3O 5S 437.14, m/z found 438.2 [M+H] +. 1H NMR (400 MHz, DMSO-d 6) δ 10.55 (s, 1H) , 8.19 (d, J = 2.4 Hz, 1H) , 8.15 -8.05 (m, 1H) , 7.96 (dd, J = 8.8, 2.5 Hz, 1H) , 7.71 (t, J = 9.0 Hz, 1H) , 7.52 -7.42 (m, 1H) , 7.36 (d, J = 8.9 Hz, 1H) , 4.50 (d, J = 4.6 Hz, 1H) , 4.01 (s, 3H) , 3.25 -3.15 (m, 1H) , 2.82 -2.72 (m, 1H) , 2.41 (d, J = 2.8 Hz, 3H) , 1.80 -1.72 (m, 1H) , 1.70 -1.62 (m, 1H) , 1.56 -1.42 (m, 2H) , 1.19 -1.02 (m, 4H) .
[0259]
Compound 29a: (S*) -N- (5-Fluoro-6-methylpyridin-2-yl) -2-methoxy-5- (N- (1, 1, 1-trifluoropropan -2-yl) sulfamoyl) benzamide
[0260]
LC-MS (ESI) : mass calcd. for C 17H 17F 4N 3O 4S 435.09, m/z found 436.1 [M+H] +; 1H NMR (400MHz, DMSO-d 6) δ 10.62 (s, 1H) , 8.50 (d, J = 8.8 Hz, 1H) , 8.16 (d, J = 2.0 Hz, 1H) , 8.10 (d, J = 6.2 Hz, 1H) , 7.98 (dd, J = 2.4, 8.8 Hz, 1H) , 7.72 (t, J = 8.9 Hz, 1H) , 7.41 (d, J = 9.0 Hz, 1H) , 4.12 -4.04 (m, 1H) , 4.02 (s, 3H) , 2.41 (d, J = 2.4 Hz, 3H) , 1.01 (d, J = 7.1 Hz, 3H) .
[0261]
Compound 29b: (R*) -N- (5-Fluoro-6-methylpyridin-2-yl) -2-methoxy-5- (N- (1, 1, 1-trifluoropropan -2-yl) sulfamoyl) benzamide
[0262]
LC-MS (ESI) : mass calcd. for C 17H 17F 4N 3O 4S 435.09, m/z found 436.1 [M+H] +; 1H NMR (400MHz, DMSO-d 6) δ 10.62 (s, 1H) , 8.50 (d, J = 5.3 Hz, 1H) , 8.16 (d, J = 2.2 Hz, 1H) , 8.10 (d, J = 6.4 Hz, 1H) , 7.98 (dd, J = 2.4, 8.8 Hz, 1H) , 7.72 (t, J = 9.0 Hz, 1H) , 7.41 (d, J = 9.0 Hz, 1H) , 4.13 -4.04 (m, J = 6.6 Hz, 1H) , 4.02 (s, 3H) , 2.41 (d, J = 2.4 Hz, 3H) , 1.01 (d, J = 6.8 Hz, 3H) .
[0263]
Compound 30: N- (5-Fluoro-6-methylpyridin-2-yl) -2-methoxy-5- (pyrrolidin-1-ylsulfonyl) benzamide
[0264]
LC-MS (ESI) : mass calcd. for C 18H 20FN 3O 4S 393.43, m/z found 394.1 [M+H] +; 1H NMR (400 MHz, DMSO-d 6) δ 10.65 (br. s, 1H) , 8.09 (d, J = 6.8 Hz, 1H) , 8.02 (s, 1H) , 7.94 (dd, J = 8.8 Hz, J = 2.4 Hz, 1H) , 7.71 (t, J = 8.8 Hz, 1H) , 7.41 (d, J = 4.8 Hz, 1H) , 4.00 (s, 3H) , 3.49 -3.05 (m, 4H) , 2.45 -2.35 (m, 3H) , 1.73 -1.60 (m, 4H) .
[0265]
Compound 31: N- (5-fluoro-6-methylpyridin-2-yl) -5- (N- ( (cis) -3-hydroxy-3-methylcyclobutyl) sulfamoyl) -2-methoxybenzamide
[0266]
LC-MS (ESI) : mass calcd. for C 19H 22FN 3O 5S 423.13, m/z found 424.1 [M+H] +; 1H NMR (400MHz, DMSO-d 6) δ 10.56 (s, 1H) , 8.12 (d, J = 2.0 Hz, 1H) , 8.11 -8.05 (m, 1H) , 7.89 (dd, J = 2.3, 8.8 Hz, 1H) , 7.85 (d, J = 7.3 Hz, 1H) , 7.70 (t, J = 9.0 Hz, 1H) , 7.37 (d, J = 8.8 Hz, 1H) , 4.89 (s, 1H) , 4.00 (s, 3H) , 3.23 -3.12 (m, 1H) , 2.39 (d, J = 2.5 Hz, 3H) , 2.01 -1.93 (m, 2H) , 1.81 -1.72 (m, 2H) , 1.09 (s, 3H) .
[0267]
Compound 32a: (R*) -N- (3- (Difluoromethyl) -4-fluorophenyl) -2-methoxy-5- (N- (1- methoxypropan-2-yl) sulfamoyl) benzamide
[0268]
LC-MS (ESI) : mass calcd. for C 19H 21F 3N 2O 5S 446.11, m/z found 447.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.47 (s, 1H) , 8.07 (d, J = 4.4 Hz, 1H) , 8.01 (d, J = 2.0 Hz, 1H) , 7.93 (dd, J = 2.4, 8.8 Hz, 1H) , 7.90 -0.783 (m, 1H) , 7.68 (d, J = 7.6 Hz, 1H) , 7.43 -7.33 (m, 2H) , 7.24 (t, J = 54.4 Hz, 1H) , 3.96 (s, 3H) , 3.29 -3.07 (m, 3H) , 3.14 (s, 3H) , 0.91 (d, J = 6.8 Hz, 3H) .
[0269]
Compound 32b: (S*) -N- (3- (Difluoromethyl) -4-fluorophenyl) -2-methoxy-5- (N- (1 -methoxypropan-2-yl) sulfamoyl) benzamide
[0270]
LC-MS (ESI) : mass calcd. for C 19H 21F 3N 2O 5S 446.11, m/z found 447.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.47 (s, 1H) , 8.07 (d, J = 4.0 Hz, 1H) , 8.01 (d, J = 2.0 Hz, 1H) , 7.93 (dd, J = 2.4, 8.8 Hz, 1H) , 7.83 -7.89 (m, 1H) , 7.68 (d, J = 7.2 Hz, 1H) , 7.43 -7.34 (m, 2H) , 7.24 (t, J = 54.0 Hz, 1H) , 3.96 (s, 3H) , 3.22 -3.07 (m, 3H) , 3.14 (s, 3H) , 0.92 (d, J = 6.8 Hz, 3H) .
[0271]
Compound 33a: N- (3- (Difluoromethyl) -4-fluorophenyl) -5- (N- ( (cis) -3-hydroxycyclopentyl) sulfamoyl) -2-methoxybenzamide
[0272]
LC-MS (ESI) : mass calcd. for C 20H 21F 3N 2O 5S 458.11, m/z found 459.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.48 (s, 1H) , 8.11 -8.05 (m, 1H) , 8.00 (d, J = 2.4 Hz, 1H) , 7.92 (dd, J = 2.4, 8.8 Hz, 1H) , 7.90 -7.83 (m, 1H) , 7.67 (d, J = 7.2 Hz, 1H) , 7.43 -7.35 (m, 2H) , 7.24 (t, J = 54.4 Hz, 1H) , 4.60 (d, J = 4.0 Hz, 1H) , 3.97 (s, 3H) , 3.91 (dd, J = 4.6, 9.8 Hz, 1H) , 1.96 -1.88 (m, 1H) , 1.60 -1.41 (m, 4H) , 1.28 -1.18 (m, 2H) .
[0273]
Compound 33b: N- (3- (Difluoromethyl) -4-fluorophenyl) -5- (N- ( (cis) -3-hydroxycyclopentyl) sulfamoyl) -2-methoxybenzamide
[0274]
LC-MS (ESI) : mass calcd. for C 20H 21F 3N 2O 5S 458.11, m/z found 459.0 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.48 (s, 1H) , 8.11 -8.05 (m, 1H) , 8.00 (d, J = 2.4 Hz, 1H) , 7.92 (dd, J = 2.4, 8.8 Hz, 1H) , 7.89 -7.84 (m, 1H) , 7.67 (d, J = 7.2 Hz, 1H) , 7.43 -7.35 (m, 2H) , 7.24 (t, J = 54.4 Hz, 1H) , 4.60 (d, J = 4.4 Hz, 1H) , 3.97 (s, 3H) , 3.92 (dd, J = 4.4, 10.4 Hz, 1H) , 1.96 -1.89 (m, 1H) , 1.60 -1.41 (m, 4H) , 1.31 -1.17 (m, 2H) .
[0275]
Compound 34a: (S) -5- (N- (1-Amino-1-oxopropan-2-yl) sulfamoyl) -N- (3- (difluoromethyl) -4 -fluorophenyl) -2-methoxybenzamide
[0276]
LC-MS (ESI) : mass calcd. for C 18H 18F 3N 3O 5S 445.09, m/z found 446.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.49 (s, 1H) , 8.09 (dd, J = 2.4, 6.4 Hz, 1H) , 8.00 (d, J = 2.4 Hz, 1H) , 7.93 (dd, J = 2.4, 8.8 Hz, 1H) , 7.89 -7.85 (m, 2H) , 7.42 -7.33 (m, 3H) , 7.24 (t, J = 54.4 Hz, 1H) , 6.99 (s, 1H) , 3.96 (s, 3H) , 3.68 (q, J = 6.8 Hz, 1H) , 1.09 (d, J = 6.8 Hz, 3H) .
[0277]
Compound 34b: (R) -5- (N- (1-Amino-1-oxopropan-2-yl) sulfamoyl) -N- (3- (difluoromethyl) -4 -fluorophenyl) -2-methoxybenzamide
[0278]
LC-MS (ESI) : mass calcd. for C 18H 18F 3N 3O 5S 445.09, m/z found 446.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.45 (s, 1H) , 8.08 (dd, J = 2.4, 6.4 Hz, 1H) , 8.01 (d, J = 2.4 Hz, 1H) , 7.92 (dd, J = 2.4, 8.8 Hz, 1H) , 7.89 -7.85 (m, 2H) , 7.41 -7.35 (m, 3H) , 7.24 (t, J = 54.4 Hz, 1H) , 6.99 (s, 1H) , 3.96 (s, 3H) , 3.68 (t, J = 5.6, 6.8 Hz, 1H) , 1.08 (d, J = 7.2 Hz, 3H) .
[0279]
Compound 35a: (S) -N- (3- (Difluoromethyl) -4-fluorophenyl) -5- (N- (1-hydroxypropan-2-yl) sulfamoyl) -2-methoxybenzamide
[0280]
LC-MS (ESI) : mass calcd. for C 18H 19F 3N 2O 5S 432.10, m/z found 433.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.48 (s, 1H) , 8.08 (dd, J = 2.4, 6.4 Hz, 1H) , 8.01 (d, J = 2.8 Hz, 1H) , 7.93 (dd, J = 2.4, 8.8 Hz, 1H) , 7.89 -7.84 (m, 1H) , 7.53 (d, J = 6.0 Hz, 1H) , 7.41-7.36 (m, 2H) , 7.24 (t, J = 54.4 Hz, 1H) , 4.71 (t, J = 5.2, 6 Hz, 1H) , 3.96 (s, 3H) , 3.14 -3.05 (m, 2H) , 0.91 (d, J = 6.4 Hz, 3H) .
[0281]
Compound 35b: (R) -N- (3- (Difluoromethyl) -4-fluorophenyl) -5- (N- (1-hydroxypropan-2-yl) sulfamoyl) -2-methoxybenzamide
[0282]
LC-MS (ESI) : mass calcd. for C 18H 19F 3N 2O 5S 432.10, m/z found 433.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.48 (s, 1H) , 8.08 (dd, J = 2.4, 6.4 Hz, 1H) , 8.01 (d, J = 2.4 Hz, 1H) , 7.93 (dd, J = 2.4, 8.8 Hz, 1H) , 7.88 -7.84 (m, 1H) , 7.53 (d, J = 6.0 Hz, 1H) , 7.42 -7.36 (m, 2H) , 7.24 (t, J = 54.4 Hz, 1H) , 4.71 (t, J = 5.6 Hz, 1H) , 3.96 (s, 3H) , 3.14 -3.08 (m, 2H) , 0.91 (d, J = 6.0 Hz, 3H) .
[0283]
Compound 36: N- (3- (Difluoromethyl) -4-fluorophenyl) -2-methoxy-5- (N- (3-methyloxetan-3-yl) sulfamoyl) benzamide
[0284]
LC-MS (ESI) : mass calcd. for C 19H 19F 3N 2O 5S 444.10, m/z found 445.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.50 (s, 1H) , 8.37 (s, 1H) , 8.08 (dd, J=2.4, 6.2 Hz, 1H) , 8.00 (d, J=2.4 Hz, 1H) , 7.93 (dd, J=2.4, 8.8 Hz, 1H) , 7.90 -7.83 (m, 1H) , 7.42 -7.09 (m, 3H) , 4.54 (d, J=6.0 Hz, 2H) , 4.12 (d, J=6.4 Hz, 2H) , 3.96 (s, 3H) , 1.43 (s, 3H) .
[0285]
Compound 37: (S) -N- (3- (Difluoromethyl) -4-fluorophenyl) -2-methoxy-5- (N- (tetrahydro-2H- pyran-3-yl) sulfamoyl) benzamide
[0286]
LC-MS (ESI) : mass calcd. for C 20H 21F 3N 2O 5S 458.11, m/z found 459.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.49 (s, 1H) , 8.07 (d, J = 4.0 Hz, 1H) , 8.01 (d, J = 2.0 Hz, 1H) , 7.95 (dd, J = 2.5, 9.0 Hz, 1H) , 7.89 -7.83 (m, 1H) , 7.80 (d, J = 7.0 Hz, 1H) , 7.42 -7.35 (m, 2.25H) , 7.24 (s, 0.50H) , 7.11 (s, 0.26H) , 3.97 (s, 3H) , 3.65 -3.54 (m, 2H) , 3.26 -3.16 (m, 1H) , 3.08 -2.94 (m, 2H) , 1.71 -1.54 (m, 2H) , 1.45 -1.28 (m, 2H) .
[0287]
Compound 38: N- (3- (Difluoromethyl) -4-fluorophenyl) -5- (N- ( (cis) -4-hydroxycyclohexyl) sulfamoyl) -2-methoxybenzamide
[0288]
LC-MS (ESI) : mass calcd. for C 21H 23F 3N 2O 5S 472.13, m/z found 473.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.49 (s, 1H) , 8.11 -8.04 (m, 1H) , 8.04 -7.98 (m, 1H) , 7.96 -7.90 (m, 1H) , 7.89 -7.82 (m, 1H) , 7.67 -7.54 (m, 1H) , 7.42 -7.34 (m, 1H) , 7.24 (s, 1H) , 7.10 (s, 1H) , 3.96 (s, 3H) , 3.60 -3.54 (m, 2H) , 3.00 -2.92 (m, 1H) , 1.61 -1.44 (m, 4H) , 1.41 -1.27 (m, 4H) .
[0289]
Compound 39: N- (3- (Difluoromethyl) -4-fluorophenyl) -2-methoxy-5- (N- (oxetan-3-yl) sulfamoyl) benzamide
[0290]
LC-MS (ESI) : mass calcd. for C 18H 17F 3N 2O 5S 430.08, m/z found 431.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.50 (s, 1H) , 8.56 (d, J = 8.0 Hz, 1H) , 8.11 -8.04 (m, 1H) , 7.98 -7.94 (m, J = 2.5 Hz, 1H) , 7.92 -7.84 (m, 2H) , 7.44 -7.33 (m, 2 H) , 7.33-7.10 (m, 1H) , 4.51 (t, J = 6.5 Hz, 2H) , 4.43 -4.32 (m, 1H) , 4.31 -4.25 (m, 2H) , 3.96 (s, 3H) .
[0291]
Compound 40a: (S*) -N- (4-Fluorophenyl) -2-methoxy-5- (N- (1-methoxypropan-2-yl) sulfamoyl) benzamide
[0292]
LC-MS (ESI) : mass calcd. for C 18H 21FN 2O 5S 396.12, m/z found 397.1 [M+H] +, 1H NMR (400 MHz, DMSO-d 6) δ 10.29 (s, 1H) , 8.00 (d, J = 2.5 Hz, 1H) , 7.92 (dd, J = 2.5, 8.8 Hz, 1H) , 7.77 -7.72 (m, 2H) , 7.68 (d, J = 7.0 Hz, 1H) , 7.35 (d, J = 8.8 Hz, 1H) , 7.20 (t, J = 8.9 Hz, 2H) , 3.96 (s, 3H) , 3.30 -3.23 (m, 1H) , 3.23 -3.18 (m, 1H) , 3.14 (s, 3H) , 3.12 -3.07 (m, 1H) , 0.91 (d, J = 6.5 Hz, 3H) .
[0293]
Compound 40b: (R*) -N- (4-Fluorophenyl) -2-methoxy-5- (N- (1-methoxypropan-2-yl) sulfamoyl) benzamide
[0294]
LC-MS (ESI) : mass calcd. for C 18H 21FN 2O 5S 396.12, m/z found 397.1 [M+H] +, 1H NMR (400 MHz, DMSO-d 6) δ 10.29 (s, 1H) , 8.00 (d, J = 2.5 Hz, 1H) , 7.92 (dd, J = 2.5, 8.8 Hz, 1H) , 7.77 -7.72 (m, 2H) , 7.68 (d, J = 7.3 Hz, 1H) , 7.36 (d, J = 8.8 Hz, 1H) , 7.23 -7.17 (m, 2H) , 3.96 (s, 3H) , 3.27 (td, J = 6.4, 12.6 Hz, 1H) , 3.23 -3.17 (m, 1H) , 3.14 (s, 3H) , 3.12 -3.06 (m, 1H) , 0.91 (d, J = 6.5 Hz, 3H) .
[0295]
Compound 41: (S) -N- (4-Fluorophenyl) -2-methoxy-5- (N- (tetrahydro-2H-pyran-3-yl) sulfamoyl) benzamide
[0296]
LC-MS (ESI) : mass calcd. for C 19H 21FN 2O 5S 408.12, m/z found 409.1 [M+H] +. 1H NMR (400 MHz, DMSO-d 6) δ 10.31 (s, 1H) , 8.00 (d, J = 2.3 Hz, 1H) , 7.94 (dd, J = 2.5, 8.8 Hz, 1H) , 7.83 -7.71 (m, 3H) , 7.37 (d, J = 9.0 Hz, 1H) , 7.20 (t, J = 8.9 Hz, 2H) , 3.96 (s, 3H) , 3.64 -3.54 (m, 2H) , 3.25 -3.17 (m, 1H) , 3.07 -2.93 (m, 2H) , 1.71 -1.52 (m, 2H) , 1.44 -1.27 (m, 2H) .
[0297]
Compound 42: N- (4-Fluorophenyl) -2-methoxy-5- (N- (3-methyloxetan-3-yl) sulfamoyl) benzamide
[0298]
LC-MS (ESI) : mass calcd. for C 18H 19FN 2O 5S 394.10, m/z found 395.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.30 (s, 1H) , 8.30 (br. s., 1H) , 8.00 (d, J = 2.4 Hz, 1H) , 7.92 (dd, J = 2.4, 8.8 Hz, 1H) , 7.78 -7.71 (m, 2H) , 7.37 (d, J = 8.8 Hz, 1H) , 7.20 (t, J = 8.8 Hz, 2H) , 4.54 (d, J = 6.0 Hz, 2H) , 4.12 (d, J = 6.4 Hz, 2H) , 3.97 (s, 3H) , 1.43 (s, 3H) .
[0299]
Compound 43: N- (4-Fluorophenyl) -2-methoxy-5- (N- (oxetan-3-yl) sulfamoyl) benzamide
[0300]
LC-MS (ESI) : mass calcd. for C 17H 17FN 2O 5S 380.08, m/z found 381.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.29 (s, 1H) , 8.51 (d, J = 6.8 Hz, 1H) , 7.95 (d, J = 2.5 Hz, 1H) , 7.88 (dd, J = 2.5, 8.8 Hz, 1H) , 7.77 -7.71 (m, 2H) , 7.36 (d, J = 8.8 Hz, 1H) , 7.24 -7.17 (m, 2H) , 4.51 (t, J = 6.8 Hz, 2H) , 4.42 -4.32 (m, 1H) , 4.30 -4.24 (m, 2H) , 3.96 (s, 3H) .
[0301]
Compound 44a (S*) -N- (4-Fluorophenyl) -2-methoxy-5- (N- (3, 3, 3-trifluoro-2-hydroxypropyl) sulfamoyl) benzamide
[0302]
LC-MS (ESI) : mass calcd. for C 17H 16F 4N 2O 5S 436.07, m/z found 437.0 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ10.32 (s, 1H) , 8.02 -7.90 (m, 3H) , 7.78 -7.70 (m, 2H) , 7.38 (d, J = 9.0 Hz, 1H) , 7.21 (t, J = 8.9 Hz, 2H) , 6.64 (d, J = 6.0 Hz, 1H) , 4.04 (br. s., 1H) , 3.97 (s, 3H) , 3.03 -2.94 (m, 1H) , 2.86 -2.77 (m, 1H) .
[0303]
Compound 44b: (R*) -N- (4-Fluorophenyl) -2-methoxy-5- (N- (3, 3, 3-trifluoro-2-hydroxypropyl) sulfamoyl) benzamide
[0304]
LC-MS (ESI) : mass calcd. for C 17H 16F 4N 2O 5S 436.07, m/z found 437.0 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.32 (s, 1H) , 8.02 -7.89 (m, 3H) , 7.79 -7.71 (m, 2H) , 7.38 (d, J = 8.8 Hz, 1H) , 7.21 (t, J = 8.9 Hz, 2H) , 6.64 (d, J = 6.3 Hz, 1H) , 4.10 -3.99 (m, 1H) , 3.97 (s, 3H) , 3.02 -2.94 (m, 1H) , 2.86 -2.77 (m, 1H) .
[0305]
Compound 45a: N- (4-Fluorophenyl) -5- (N- ( (cis) -3-hydroxycyclopentyl) sulfamoyl) -2 -methoxybenzamide
[0306]
LC-MS (ESI) : mass calcd. for C 19H 21FN 2O 5S 408.12, m/z found 409.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) 10.29 (s, 1H) , 7.99 (d, J = 2.0 Hz, 1H) , 7.91 (dd, J = 2.3, 8.8 Hz, 1H) , 7.75 (dd, J = 5.0, 8.5 Hz, 2H) , 7.66 (d, J = 7.0 Hz, 1H) , 7.36 (d, J = 9.0 Hz, 1H) , 7.20 (t, J = 8.8 Hz, 2H) , 4.59 (d, J = 4.0 Hz, 1H) , 3.96 (s, 3H) , 3.94 -3.86 (m, J = 4.8, 9.8 Hz, 1H) , 1.96 -1.86 (m, 1H) , 1.64 -1.37 (m, 4H) , 1.25 -1.17 (m, 1H) .
[0307]
Compound 45b: N- (4-Fluorophenyl) -5- (N- ( (cis) -3-hydroxycyclopentyl) sulfamoyl) -2 -methoxybenzamide
[0308]
LC-MS (ESI) : mass calcd. for C 19H 21FN 2O 5S 408.12, m/z found 409.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) 10.29 (s, 1H) , 7.99 (d, J = 2.5 Hz, 1H) , 7.91 (dd, J = 2.3, 8.8 Hz, 1H) , 7.75 (dd, J = 5.0, 9.0 Hz, 2H) , 7.66 (d, J = 6.5 Hz, 1H) , 7.36 (d, J = 8.5 Hz, 1H) , 7.20 (t, J = 8.8 Hz, 2H) , 4.59 (d, J = 4.0 Hz, 1H) , 3.96 (s, 3H) , 3.94 -3.86 (m, 1H) , 3.34 -3.29 (m, 1H) , 1.97 -1.86 (m, 1H) , 1.63 -1.37 (m, 4H) , 1.25 -1.17 (m, 1H) .
[0309]
Compound 46a: (R) -5- (N- (1-Amino-1-oxopropan-2-yl) sulfamoyl) -N- (4-fluorophenyl) -2 -methoxybenzamide
[0310]
LC-MS (ESI) : mass calcd. for C 17H 18FN 3O 5S 395.10, m/z found 396.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) 10.28 (s, 1H) , 8.00 (d, J = 2.2 Hz, 1H) , 7.95 -7.85 (m, 2H) , 7.75 (dd, J = 5.1, 8.8 Hz, 2H) , 7.35 (d, J = 8.8 Hz, 1H) , 7.31 (br. s., 1H) , 7.21 (t, J = 8.8 Hz, 2H) , 7.01 (br. s., 1H) , 3.96 (s, 3H) , 3.73 -3.62 (m, 1H) , 1.07 (d, J = 7.1 Hz, 3H) .
[0311]
Compound 46b: (S) -5- (N- (1-Amino-1-oxopropan-2-yl) sulfamoyl) -N- (4-fluorophenyl) -2 -methoxybenzamide
[0312]
LC-MS (ESI) : mass calcd. for C 17H 18FN 3O 5S 395.10, m/z found 396.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) 10.27 (s, 1H) , 8.00 (d, J = 2.0 Hz, 1H) , 7.94 -7.85 (m, 2H) , 7.75 (dd, J = 5.0, 8.5 Hz, 2H) , 7.35 (d, J = 9.0 Hz, 1H) , 7.30 (br. s., 1H) , 7.20 (t, J = 8.8 Hz, 2H) , 7.00 (br. s., 1H) , 3.96 (s, 3H) , 3.68 (q, J = 7.0 Hz, 1H) , 1.07 (d, J = 7.0 Hz, 3H) .
[0313]
Compound 47: 5- (N-Cyclobutylsulfamoyl) -N- (4-fluorophenyl) -2-methoxybenzamide
[0314]
LC-MS (ESI) : mass calcd. for C 18H 19FN 2O 4S 378.10, m/z found 379.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) 10.28 (s, 1H) , 7.97 (s, 1H) , 7.94 (d, J = 8.5 Hz, 1H) , 7.91 -7.85 (m, 1H) , 7.75 (dd, J = 5.0, 8.5 Hz, 2H) , 7.35 (d, J = 8.5 Hz, 1H) , 7.20 (t, J = 8.8 Hz, 2H) , 3.96 (s, 3H) , 3.67 -3.56 (m, 1H) , 1.98 -1.85 (m, 2H) , 1.81 -1.66 (m, 2H) , 1.56 -1.41 (m, 2H) .
[0315]
Compound 48: 5- (N-Cyclopropylsulfamoyl) -N- (4-fluorophenyl) -2-methoxybenzamide
[0316]
LC-MS (ESI) : mass calcd. for C 17H 17FN 2O 4S 364.09, m/z found 365.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) 10.31 (s, 1H) , 7.99 (d, J = 2.0 Hz, 1H) , 7.96 -7.86 (m, 2H) , 7.74 (dd, J = 5.0, 8.5 Hz, 2H) , 7.39 (d, J = 8.5 Hz, 1H) , 7.20 (t, J = 9.0 Hz, 2H) , 3.97 (s, 3H) , 2.14 -2.05 (m, 1H) , 0.54 -0.45 (m, 2H) , 0.43 -0.35 (m, 2H) .
[0317]
Compound 49a: (S) -N- (4-Fluorophenyl) -5- (N- (1-hydroxypropan-2-yl) sulfamoyl) -2 -methoxybenzamide
[0318]
LC-MS (ESI) : mass calcd. for C 17H 19FN 2O 5S 382.10, m/z found 383.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) 10.29 (s, 1H) , 8.01 (d, J = 2.5 Hz, 1H) , 7.92 (dd, J = 2.3, 8.8 Hz, 1H) , 7.75 (dd, J = 5.0, 9.0 Hz, 2H) , 7.52 (d, J = 6.0 Hz, 1H) , 7.37 (d, J = 9.0 Hz, 1H) , 7.20 (t, J = 8.8 Hz, 2H) , 4.75 -4.68 (m, 1H) , 3.97 (s, 3H) , 3.33 -3.27 (m, 1H) , 3.16 -3.03 (m, 2H) , 0.91 (d, J = 6.0 Hz, 3H) .
[0319]
Compound 49b: (R) -N- (4-Fluorophenyl) -5- (N- (1-hydroxypropan-2-yl) sulfamoyl) -2 -methoxybenzamide
[0320]
LC-MS (ESI) : mass calcd. for C 17H 19FN 2O 5S 382.10, m/z found 383.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) 10.30 (s, 1H) , 8.01 (d, J = 2.0 Hz, 1H) , 7.92 (dd, J = 2.3, 8.8 Hz, 1H) , 7.75 (dd, J = 5.0, 9.0 Hz, 2H) , 7.52 (d, J = 5.0 Hz, 1H) , 7.37 (d, J = 9.0 Hz, 1H) , 7.20 (t, J = 9.0 Hz, 2H) , 4.75 -4.67 (m, 1H) , 3.97 (s, 3H) , 3.34 -3.27 (m, 1H) , 3.15 -3.03 (m, 2H) , 0.91 (d, J = 6.5 Hz, 3H) .
[0321]
Compound 50: N- (4-Fluorophenyl) -2-methoxy-5- (N- (1- (trifluoromethyl) cyclopropyl) sulfamoyl) benzamide
[0322]
LC-MS (ESI) : mass calcd. for C 18H 16F 4N 2O 4S 432.08, m/z found 433.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) 10.31 (s, 1H) , 9.13 (br. s., 1H) , 7.97 (d, J = 2.4 Hz, 1H) , 7.89 (dd, J = 2.3, 8.7 Hz, 1H) , 7.78 -7.72 (m, 2H) , 7.37 (d, J = 8.8 Hz, 1H) , 7.21 (t, J = 8.9 Hz, 2H) , 3.97 (s, 3H) , 1.22 -1.16 (m, 2H) , 1.08 -0.98 (m, 2H) .
[0323]
Compound 51: 5- (N-Cyclopentylsulfamoyl) -N- (4-fluorophenyl) -2-methoxybenzamide
[0324]
LC-MS (ESI) : mass calcd. for C 19H 21FN 2O 4S 392.12, m/z found 393.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) 10.29 (s, 1H) , 7.99 (d, J = 2.0 Hz, 1H) , 7.91 (dd, J = 2.3, 8.8 Hz, 1H) , 7.79 -7.70 (m, 2H) , 7.62 (d, J = 7.0 Hz, 1H) , 7.36 (d, J = 8.5 Hz, 1H) , 7.20 (t, J = 8.8 Hz, 2H) , 3.96 (s, 3H) , 3.44 -3.36 (m, 1H) , 1.67 -1.49 (m, 4H) , 1.45 -1.25 (m, 4H) .
[0325]
Compound 52a: (S) -N- (4-fluorophenyl) -5- (N- (1-hydroxypropan-2-yl) sulfamoyl) -2 -methoxybenzamide
[0326]
LC-MS (ESI) : mass calcd. for C 17H 19FN 2O 5S 382.10, m/z found 383.1 [M+H] +; NMR (400MHz, DMSO-d 6) δ 10.29 (s, 1H) , 8.01 (d, J = 2.5 Hz, 1H) , 7.93 (dd, J = 2.3, 8.8 Hz, 1H) , 7.80 -7.71 (m, 2H) , 7.51 (br. s., 1H) , 7.37 (d, J = 9.0 Hz, 1H) , 7.20 (t, J = 9.0 Hz, 2H) , 4.74 -4.67 (m, 1H) , 3.97 (s, 3H) , 3.16 -3.03 (m, 2H) , 0.91 (d, J = 6.0 Hz, 3H) .
[0327]
Compound 52b: (R) -N- (4-fluorophenyl) -5- (N- (1-hydroxypropan-2-yl) sulfamoyl) -2 -methoxybenzamide
[0328]
LC-MS (ESI) : mass calcd. for C 17H 19FN 2O 5S 382.10, m/z found 383.1 [M+H] +; NMR (400MHz, DMSO-d 6) δ 10.30 (s, 1H) , 8.00 (d, J = 2.3 Hz, 1H) , 7.92 (dd, J = 2.1, 8.7 Hz, 1H) , 7.75 (dd, J = 5.1, 8.9 Hz, 2H) , 7.51 (br. s., 1H) , 7.36 (d, J = 8.8 Hz, 1H) , 7.20 (t, J = 8.9 Hz, 2H) , 4.77 -4.66 (m, 1H) , 3.96 (s, 3H) , 3.14 -3.04 (m, 2H) , 0.91 (d, J = 6.0 Hz, 3H) .
[0329]
Compound 53: N- (4-Fluorophenyl) -5- (N- ( (cis) -4-hydroxycyclohexyl) sulfamoyl) -2 -methoxybenzamide
[0330]
LC-MS (ESI) : mass calcd. for C 20H 23FN 2O 5S 422.13, m/z found 423.1 [M+H] +; 1H NMR (400 MHz, DMSO-d 6) δ 10.29 (s, 1H) , 8.00 (d, J = 2.5 Hz, 1H) , 7.92 (dd, J = 2.5, 8.8 Hz, 1H) , 7.77 -7.72 (m, 2H) , 7.68 (d, J = 7.0 Hz, 1H) , 7.35 (d, J = 8.8 Hz, 1H) , 7.20 (t, J = 8.9 Hz, 2H) , 4.36 (s, 1H) , 3.97 (s, 3H) , 3.59 (m, 1H) , 2.94 (m, 1H) , 1.54 (m, 4H) , 1.36 (m, 4H) .
[0331]
Compound 54a: (S*) -N- (2-Chlorophenyl) -2-methoxy-5- (N- (1-methyl-2-oxopyrrolidin-3-yl) sulfamoyl) benzamide
[0332]
LC-MS (ESI) : mass calcd. for C 19H 20ClN 3O 5S 437.08, m/z found 438.1 [M+H] +; 1H NMR (400 MHz, DMSO-d 6) δ 10.48 (br. s., 1H) , 8.48 (br. s., 1H) , 8.39 (d, J = 7.8 Hz, 1H) , 8.15 (d, J = 8.1 Hz, 1H) , 8.05 (d, J = 8.6 Hz, 1H) , 7.59 (d, J = 7.8 Hz, 1H) , 7.48 (d, J = 8.8 Hz, 1H) , 7.41 (t, J = 7.3 Hz, 1H) , 7.21 (t, J = 7.5 Hz, 1H) , 4.15 (br. s., 3H) , 3.98 -3.88 (m, 1H) , 3.21 -3.12 (m, 2H) , 2.68 (s, 3H) , 2.10 -1.99 (m, 1H) , 1.64 -1.50 (m, 1H) .
[0333]
Compound 54b: (R*) -N- (2-Chlorophenyl) -2-methoxy-5- (N- (1-methyl-2-oxopyrrolidin-3-yl) sulfamoyl) benzamide
[0334]
LC-MS (ESI) : mass calcd. for C 19H 20ClN 3O 5S 437.08, m/z found 438.1 [M+H] +; 1H NMR (400 MHz, DMSO-d 6) δ 10.48 (br. s., 1H) , 8.48 (br. s., 1H) , 8.39 (d, J = 7.8 Hz, 1H) , 8.15 (d, J = 7.6 Hz, 1H) , 8.05 (d, J = 8.6 Hz, 1H) , 7.59 (d, J = 7.8 Hz, 1H) , 7.48 (d, J = 8.3 Hz, 1H) , 7.42 (t, J = 7.5 Hz, 1H) , 7.21 (t, J = 7.2 Hz, 1H) , 4.15 (br. s., 3H) , 3.98 -3.88 (m, 1H) , 3.21 -3.11 (m, 2H) , 2.67 (s, 3H) , 2.10 -1.98 (m, 1H) , 1.63 -1.50 (m, 1H) .
[0335]
Compound 55a: (S) -N- (2-Chlorophenyl) -5- (N- (1-hydroxypropan-2-yl) sulfamoyl) -2-methoxy benzamide
[0336]
LC-MS (ESI) : mass calcd. for C 17H 19ClN 2O 5S 398.07, m/z found 399.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.49 (s, 1H) , 8.47 (d, J = 2.3 Hz, 1H) , 8.39 (d, J = 8.0 Hz, 1H) , 8.01 (dd, J = 2.4, 8.7 Hz, 1H) , 7.65 -7.56 (m, 2H) , 7.49 (d, J = 8.8 Hz, 1H) , 7.41 (t, J = 7.5 Hz, 1H) , 7.21 (dt, J = 1.5, 7.7 Hz, 1H) , 4.70 (t, J = 5.5 Hz, 1H) , 4.15 (s, 3H) , 3.35 -3.26 (m, 1H) , 3.17 -3.04 (m, 2H) , 0.90 (d, J = 6.3 Hz, 3H) .
[0337]
Compound 55b: (R) -N- (2-Chlorophenyl) -5- (N- (1-hydroxypropan-2-yl) sulfamoyl) -2-methoxy benzamide
[0338]
LC-MS (ESI) : mass calcd. for C 17H 19ClN 2O 5S 398.07, m/z found 399.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.49 (s, 1H) , 8.47 (d, J = 2.3 Hz, 1H) , 8.39 (d, J = 8.0 Hz, 1H) , 8.01 (dd, J = 2.3, 8.8 Hz, 1H) , 7.64 -7.55 (m, 2H) , 7.49 (d, J = 8.8 Hz, 1H) , 7.41 (t, J = 7.8 Hz, 1H) , 7.23 -7.17 (m, 1H) , 4.70 (t, J = 5.5 Hz, 1H) , 4.15 (s, 3H) , 3.34 -3.27 (m, 1H) , 3.15 -3.05 (m, 2H) , 0.90 (d, J = 6.3 Hz, 3H) .
[0339]
Compound 56a: N- (2-Chlorophenyl) -5- (N- ( (cis) -4-hydroxytetrahydrofuran-3-yl) sulfamoyl) -2 -methoxybenzamide
[0340]
LC-MS (ESI) : mass calcd. for C 18H 19ClN 2O 6S 426.07, m/z found 427.0 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.47 (s, 1H) , 8.48 (d, J = 2.0 Hz, 1H) , 8.38 (d, J = 8.0 Hz, 1H) , 8.05 -7.95 (m, 2H) , 7.58 (d, J = 8.0 Hz, 1H) , 7.51 (d, J = 8.8 Hz, 1H) , 7.41 (t, J = 7.8 Hz, 1H) , 7.20 (t, J = 7.7 Hz, 1H) , 5.24 (d, J = 4.0 Hz, 1H) , 4.15 (s, 3H) , 4.01 (br. s., 1H) , 3.81 -3.70 (m, 2H) , 3.47 -3.39 (m, 3H) .
[0341]
Compound 56b: N- (2-Chlorophenyl) -5- (N- ( (cis) -4-hydroxytetrahydrofuran-3-yl) sulfamoyl) -2 -methoxybenzamide
[0342]
LC-MS (ESI) : mass calcd. for C 18H 19ClN 2O 6S 426.07, m/z found 427.0 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.48 (s, 1H) , 8.48 (d, J = 2.5 Hz, 1H) , 8.38 (d, J = 8.3 Hz, 1H) , 8.05 -7.97 (m, 2H) , 7.58 (dd, J = 1.3, 8.0 Hz, 1H) , 7.51 (d, J = 9.0 Hz, 1H) , 7.41 (t, J = 7.3 Hz, 1H) , 7.21 (dt, J = 1.5, 7.7 Hz, 1H) , 5.24 (d, J = 4.0 Hz, 1H) , 4.16 (s, 3H) , 4.04 -3.99 (m, 1H) , 3.80 -3.70 (m, 2H) , 3.47 -3.37 (m, 3H) .
[0343]
Compound 57a: N- (2-Chlorophenyl) -5- (N- ( (cis) -3-hydroxycyclopentyl) sulfamoyl) -2-methoxy benzamide
[0344]
LC-MS (ESI) : mass calcd. for C 19H 21ClN 2O 5S 424.09, m/z found 425.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.48 (s, 1H) , 8.46 (d, J = 2.0 Hz, 1H) , 8.39 (d, J = 8.0 Hz, 1H) , 8.00 (dd, J = 2.0, 8.5 Hz, 1H) , 7.76 (d, J = 7.5 Hz, 1H) , 7.58 (d, J = 7.5 Hz, 1H) , 7.49 (d, J = 8.5 Hz, 1H) , 7.41 (t, J = 7.8 Hz, 1H) , 7.21 (t, J = 7.0 Hz, 1H) , 4.57 (d, J = 4.0 Hz, 1H) , 4.15 (s, 3H) , 3.95 -3.86 (m, 1H) , 3.46 -3.37 (m, 1H) , 1.96 -1.86 (m, 1H) , 1.64 -1.37 (m, 4H) , 1.26 -1.16 (m, 1H) .
[0345]
Compound 57b: N- (2-Chlorophenyl) -5- (N- ( (cis) -3-hydroxycyclopentyl) sulfamoyl) -2-methoxy benzamide
[0346]
LC-MS (ESI) : mass calcd. for C 19H 21ClN 2O 5S 424.09, m/z found 425.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.49 (s, 1H) , 8.46 (d, J = 2.0 Hz, 1H) , 8.39 (d, J = 8.0 Hz, 1H) , 8.00 (dd, J = 2.3, 8.8 Hz, 1H) , 7.76 (d, J = 7.5 Hz, 1H) , 7.58 (d, J = 8.0 Hz, 1H) , 7.49 (d, J = 8.5 Hz, 1H) , 7.41 (t, J = 7.5 Hz, 1H) , 7.21 (t, J = 7.0 Hz, 1H) , 4.58 (d, J = 4.0 Hz, 1H) , 4.15 (s, 3H) , 3.95 -3.86 (m, 1H) , 3.41 -3.37 (m, 1H) , 1.96 -1.86 (m, 1H) , 1.63 -1.38 (m, 4H) , 1.22 -1.16 (m, 1H) .
[0347]
Compound 58: N- (2-Chlorophenyl) -2-methoxy-5- (N- (3-methyloxetan-3-yl) sulfamoyl) benzamide
[0348]
LC-MS (ESI) : mass calcd. for C 18H 19ClN 2O 5S 410.07, m/z found 411.0 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.48 (br. s., 1H) , 8.45 (d, J = 6.2 Hz, 2H) , 8.38 (d, J = 7.7 Hz, 1H) , 8.01 (d, J = 6.8 Hz, 1H) , 7.59 (d, J = 7.7 Hz, 1H) , 7.50 (d, J = 8.6 Hz, 1H) , 7.42 (t, J = 7.4 Hz, 1H) , 7.22 (t, J = 7.1 Hz, 1H) , 4.54 (d, J = 5.5 Hz, 2H) , 4.15 (s, 3H) , 4.13 (d, J = 6.0 Hz, 2H) , 1.43 (s, 3H) .
[0349]
Compound 59a: (S) -5- (N- (1-Amino-1-oxopropan-2-yl) sulfamoyl) -N- (2-chlorophenyl) -2 -methoxybenzamide
[0350]
LC-MS (ESI) : mass calcd. for C 17H 18ClN 3O 5S 411.07, m/z found 412.1 [M+H] +. 1H NMR (400MHz, DMSO-d6) δ 10.48 (s, 1H) , 8.46 (d, J = 1.5 Hz, 1H) , 8.40 (d, J = 8.0 Hz, 1H) , 8.03 - 7.94 (m, 2H) , 7.59 (d, J = 8.0 Hz, 1H) , 7.48 (d, J = 9.0 Hz, 1H) , 7.42 (t, J = 7.5 Hz, 1H) , 7.29 (br. s., 1H) , 7.21 (t, J = 7.3 Hz, 1H) , 6.98 (br. s., 1H) , 4.15 (s, 3H) , 3.71 (quin, J = 7.0 Hz, 1H) , 1.09 (d, J = 7.0 Hz, 3H) .
[0351]
Compound 59b: (R) -5- (N- (1-amino-1-oxopropan-2-yl) sulfamoyl) -N- (2-chlorophenyl) -2-methoxy benzamide
[0352]
LC-MS (ESI) : mass calcd. for C 17H 18ClN 3O 5S 411.07, m/z found 412.1 [M+H] +. 1H NMR (400MHz, DMSO-d6) δ 10.47 (br. s., 1H) , 8.46 (br. s., 1H) , 8.39 (d, J=8.0 Hz, 1H) , 8.05 -7.92 (m, 2H) , 7.59 (d, J=8.0 Hz, 1H) , 7.48 (d, J=8.5 Hz, 1H) , 7.42 (t, J=7.5 Hz, 1H) , 7.29 (br. s., 1H) , 7.21 (t, J=7.3 Hz, 1H) , 6.98 (br. s., 1H) , 4.15 (s, 3H) , 3.77 -3.64 (m, 1H) , 1.08 (d, J=7.0 Hz, 3H) .
[0353]
Compound 60a: (S*) -N- (2-Chlorophenyl) -5- (N- (1-cyanopropan-2-yl) sulfamoyl) -2-methoxy benzamide
[0354]
LC-MS (ESI) : mass calcd. for C 18H 18ClN 3O 4S 407.07, m/z found 408.1 [M+H] +. 1H NMR (400MHz, DMSO-d6) δ 10.47 (s, 1H) , 8.47 (d, J = 2.2 Hz, 1H) , 8.38 (d, J = 7.8 Hz, 1H) , 8.13 (br. s., 1H) , 8.03 (dd, J = 2.2, 8.8 Hz, 1H) , 7.59 (d, J = 7.8 Hz, 1H) , 7.51 (d, J = 8.8 Hz, 1H) , 7.42 (t, J = 7.6 Hz, 1H) , 7.25 -7.15 (m, 1H) , 4.16 (s, 3H) , 3.49 -3.39 (m, 1H) , 2.75 -2.56 (m, 2H) , 1.00 (d, J = 6.6 Hz, 3H) .
[0355]
Compound 60b: (R*) -N- (2-chlorophenyl) -5- (N- (1-cyanopropan-2-yl) sulfamoyl) -2-methoxy benzamide
[0356]
LC-MS (ESI) : mass calcd. for C 18H 18ClN 3O 4S 407.07, m/z found 408.0 [M+H] +. 1H NMR (400MHz, DMSO-d6) δ 10.47 (s, 1H) , 8.47 (d, J = 2.0 Hz, 1H) , 8.39 (d, J = 8.1 Hz, 1H) , 8.13 (br. s., 1H) , 8.04 (dd, J = 2.1, 8.7 Hz, 1H) , 7.59 (d, J = 8.1 Hz, 1H) , 7.51 (d, J = 8.8 Hz, 1H) , 7.41 (t, J = 7.6 Hz, 1H) , 7.21 (t, J = 7.3 Hz, 1H) , 4.16 (s, 3H) , 3.50 -3.39 (m, 1H) , 2.74 -2.57 (m, 2H) , 1.00 (d, J = 6.6 Hz, 3H) .
[0357]
Compound 61a: N- (2-Chlorophenyl) -5- (N- ( (1s, 2r) -2-hydroxycyclopentyl) sulfamoyl) -2-methoxy benzamide
[0358]
LC-MS (ESI) : mass calcd. for C 19H 21ClN 2O 5S 424.09, m/z found 425.1 [M+H] +. 1H NMR (400 MHz, DMSO-d 6) 10.48 (s, 1H) , 8.49 (d, J = 2.2 Hz, 1H) , 8.39 (d, J = 7.9 Hz, 1H) , 8.05 (dd, J = 8.8, 2.3 Hz, 1H) , 7.57 (d, J = 8.0 Hz, 1H) , 7.46 (d, J = 8.8 Hz, 1H) , 7.41 (t, J = 6.7 Hz, 2H) , 7.24 -7.15 (m, 1H) , 4.61 (d, J = 4.0 Hz, 1H) , 4.14 (s, 3H) , 3.80 -3.72 (m, 1H) , 3.30 -3.19 (m, 1H) , 1.66 -1.51 (m, 2H) , 1.50 -1.23 (m, 4H) .
[0359]
Compound 61b: N- (2-Chlorophenyl) -5- (N- ( (trans) -2-hydroxycyclopentyl) sulfamoyl) -2-methoxy benzamide
[0360]
LC-MS (ESI) : mass calcd. for C 19H 21ClN 2O 5S 424.09, m/z found 425.1 [M+H] +. 1H NMR (400 MHz, DMSO-d 6) 10.48 (s, 1H) , 8.47 (d, J = 2.3 Hz, 1H) , 8.39 (d, J = 7.6 Hz, 1H) , 8.01 (dd, J = 8.7, 2.4 Hz, 1H) , 7.63 (d, J = 6.3 Hz, 1H) , 7.58 (dd, J = 8.0, 1.2 Hz, 1H) , 7.49 (d, J = 8.8 Hz, 1H) , 7.41 (t, J = 7.4 Hz, 1H) , 7.20 (td, J = 7.8, 1.5 Hz, 1H) , 4.68 (d, J = 4.3 Hz, 1H) , 4.15 (s, 3H) , 3.83 -3.75 (m, 1H) , 3.20 -3.12 (m, 1H) , 1.78 -1.61 (m, 2H) , 1.56 -1.45 (m, 2H) , 1.40 -1.29 (m, 1H) , 1.27 -1.17 (m, 1H) .
[0361]
Compound 61c: N- (2-chlorophenyl) -5- (N- ( (trans) -2-hydroxycyclopentyl) sulfamoyl) -2-methoxy benzamide
[0362]
LC-MS (ESI) : mass calcd. for C 19H 21ClN 2O 5S 424.09, m/z found 425.1 [M+H] +. 1H NMR (400 MHz, DMSO-d 6) 10.49 (s, 1H) , 8.47 (d, J = 2.2 Hz, 1H) , 8.39 (d, J = 8.0 Hz, 1H) , 8.01 (dd, J = 8.7, 2.3 Hz, 1H) , 7.63 (d, J = 6.6 Hz, 1H) , 7.58 (d, J = 8.0 Hz, 1H) , 7.49 (d, J = 8.8 Hz, 1H) , 7.41 (t, J = 7.8 Hz, 1H) , 7.20 (dd, J = 11.1, 4.3 Hz, 1H) , 4.68 (d, J = 4.3 Hz, 1H) , 4.15 (s, 3H) , 3.81 -3.75 (m, 1H) , 3.20 -3.11 (m, 1H) , 1.79 -1.61 (m, 2H) , 1.56 -1.45 (m, 2H) , 1.40 -1.30 (m, 1H) , 1.28 -1.19 (m, 1H) .
[0363]
Compound 62: N- (2-Chlorophenyl) -2-methoxy-5- (N- (oxetan-3-yl) sulfamoyl) benzamide
[0364]
LC-MS (ESI) : mass calcd. for C 17H 17ClN 2O 5S 396.05, m/z found 397.1 [M+H] +. 1H NMR (400 MHz, DMSO-d 6) 10.45 (s, 1H) , 8.62 (s, 1H) , 8.39 (dd, J = 17.0, 5.0 Hz, 2H) , 7.97 (dd, J = 8.8, 2.4 Hz, 1H) , 7.57 (dd, J = 8.0, 1.1 Hz, 1H) , 7.47 (d, J = 8.8 Hz, 1H) , 7.41 (t, J = 7.5 Hz, 1H) , 7.20 (td, J = 7.9, 1.5 Hz, 1H) , 4.51 (t, J = 6.7 Hz, 2H) , 4.43 -4.33 (m, 1H) , 4.27 (t, J = 6.3 Hz, 2H) , 4.14 (s, 3H) .
[0365]
Compound 63: 5- (N-Cyclobutylsulfamoyl) -N- (4-fluoro-3-methylphenyl) -2-methoxybenzamide.
[0366]
LC-MS (ESI) : mass calcd. for C 19H 21FN 2O 4S 392.12, m/z found 393.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.20 (br. s., 1H) , 8.03 -7.83 (m, 3H) , 7.68 -7.52 (m, 2H) , 7.35 (d, J=8.4 Hz, 1H) , 7.13 (t, J=8.8 Hz, 1H) , 3.96 (s, 3H) , 3.64 -3.58 (m, 1H) , 2.24 (s, 3H) , 1.98 -1.87 (m, 2H) , 1.81 -1.66 (m, 2H) , 1.56 -1.44 (m, 2H) .
[0367]
Compound 64: (S) -2-Methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) -N- (thiazol-2-yl) benzamide:
[0368]
LC-MS (ESI) : mass calcd. for C 15H 17N 3O 5S 2 383.06, m/z found 384.0 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 12.15 (br. s, 1H) , 8.04 (d, J = 2.4 Hz, 1H) , 7.89-7.97 (m, 2H) , 7.55 (d, J = 3.2 Hz, 1H) , 7.40 (d, J = 8.8 Hz, 1H) , 7.32 (d, J = 3.6 Hz, 1H) , 3.98 (s, 3H) , 3.66-3.74 (m, 2H) , 3.55-3.64 (m, 2H) , 3.39-3.41 (m, 1H) , 1.86-1.96 (m, 1H) , 1.57-1.66 (m, 1H) .
[0369]
Compound 65: (S) -N- (2, 4-Difluorophenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide:
[0370]
LC-MS (ESI) : mass calcd. for C 18H 18F 2N 2O 5S 412.09, m/z found 413.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.12 (br. s, 1H) , 8.23 (d, J = 2.4 Hz, 1H) , 7.92-8.00 (m, 3H) , 7.35-7.45 (m, 2H) , 7.10-7.17 (m, 1H) , 3.93 (s, 3H) , 3.65-3.74 (m, 2H) , 3.55-3.64 (m, 2H) , 3.35-3.36 (m, 1H) 1.85-1.95 (m, 1H) , 1.52-1.66 (m, 1H) .
[0371]
Compound 66: (S) -N- (2-Chloro-4-fluorophenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide:
[0372]
LC-MS (ESI) : mass calcd. for C 18H 18ClFN 2O 5S 428.06, m/z found 429.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.12 (br. s, 1H) , 8.23 (d, J = 2.4 Hz, 1H) , 7.92-8.00 (m, 3H) , 7.35-7.45 (m, 2H) , 7.10-7.17 (m, 1H) , 4.12 (s, 3H) , 3.65-3.74 (m, 2H) , 3.55-3.64 (m, 2H) , 3.35-3.36 (m, 1H) 1.85-1.95 (m, 1H) , 1.52-1.66 (m, 1H) .
[0373]
Compound 67: (S) -N- (3, 5-Difluorophenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide:
[0374]
LC-MS (ESI) : mass calcd. for C 18H 18F 2N 2O 5S 412.09, m/z found 413.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.57 (br. s, 1H) , 7.83-7.89 (m, 3H) , 7.44 (d, J = 7.6 Hz, 2H) , 7.36 (d, J = 8.8 Hz, 1H) , 6.90-7.00 (m, 1H) , 3.93 (s, 3H) , 3.62-3.70 (m, 2H) , 3.52-3.61 (m, 2H) , 3.30-3.34 (m, 1H) , 1.82-1.92 (m, 1H) , 1.54-1.64 (m, 1H) .
[0375]
Compound 68: (S) -N- (3-Chloro-5-fluorophenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide:
[0376]
LC-MS (ESI) : mass calcd. for C 18H 18ClFN 2O 5S 428.06, m/z found 429.0 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.59 (br. s, 1H) , 8.00 (d, J = 2.4 Hz, 1H) , 7.91-7.97 (m, 2H) , 7.68 (s, 1H) , 7.60-7.65 (m, 1H) , 7.40 (d, J = 8.8 Hz, 1H) , 7.16-7.21 (m, 1H) , 3.97 (s, 3H) , 3.65-3.73 (m, 2H) , 3.56-3.64 (m, 2H) , 3.30-3.34 (m, 1H) , 1.86-1.94 (m, 1H) , 1.58-1.66 (m, 1H) .
[0377]
Compound 69: (S) -N- (2, 5-Difluorophenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide:
[0378]
LC-MS (ESI) : mass calcd. for C 18H 18F 2N 2O 5S 412.09, m/z found 413.1 [M+H] +. 1H NMR (400MHz, DMSO-d6) δ 10.59 (br. s, 1H) , 8.00 (d, J = 2.4 Hz, 1H) , 7.91-7.97 (m, 2H) , 7.68 (s, 1H) , 7.60-7.65 (m, 1H) , 7.40 (d, J = 8.8 Hz, 1H) , 7.16-7.21 (m, 1H) , 3.97 (s, 3H) , 3.65-3.73 (m, 2H) , 3.56-3.64 (m, 2H) , 3.30-3.34 (m, 1H) , 1.86-1.94 (m, 1H) , 1.58-1.66 (m, 1H) .
[0379]
Compound 70: (S) -N- (2-Chloro-5-fluorophenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide:
[0380]
LC-MS (ESI) : mass calcd. for C 18H 18ClFN 2O 5S 428.06, m/z found 429.0 [M+H] +. 1H NMR (400MHz, DMSO-d6) δ 10.61 (br. s, 1H) , 8.48 (d, J = 2.0 Hz, 1H) , 8.32 (dd, J = 11.2 Hz, J = 2.4 Hz, 1H) , 7.97-8.07 (m, 2H) , 7.65 (dd, J = 8.8 Hz, J = 6.0 Hz, 1H) , 7.52 (d, J = 8.8 Hz, 1H) , 7.04-7.14 (m, 1H) , 4.17 (s, 3H) , 3.66-3.74 (m, 2H) , 3.55-3.65 (m, 2H) , 3.33-3.35 (m, 1H) , 1.85-1.95 (m, 1H) , 1.56-1.66 (m, 1H) .
[0381]
Compound 71: (S) -N- (2, 5-Dichlorophenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide:
[0382]
LC-MS (ESI) : mass calcd. for C 18H 18Cl 2N 2O 5S 444.03, m/z found 445.0 [M+H] +. 1H NMR (400MHz, DMSO-d6) δ 10.58 (br. s, 1H) , 8.50 (d, J = 2.0 Hz, 1H) , 8.46 (d, J = 2.0 Hz, 1H) , 7.98-8.10 (m, 2H) , 7.64 (d, J = 8.4 Hz, 1H) , 7.52 (d, J = 8.8 Hz, 1H) , 8.00 (dd, J = 8.4 Hz, J = 2.4 Hz, 1H) , 4.16 (s, 3H) , 3.66-3.74 (m, 2H) , 3.54-3.65 (m, 2H) , 3.33-3.36 (m, 1H) , 1.85-1.96 (m, 1H) , 1.56-1.67 (m, 1H) .
[0383]
Compound 72: (S) -N- (3, 4-Dichlorophenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0384]
LC-MS (ESI) : mass calcd. for C 18H 18Cl 2N 2O 5S 444.03, m/z found 445.0 [M+H] +. 1H NMR (400MHz, DMSO-d6) δ 10.53 (br. s, 1H) , 8.10 (d, J = 2.0 Hz, 1H) , 8.00 (d, J = 2.4 Hz, 1H) , 7.88-7.97 (m, 2H) , 7.58-7.71 (m, 2H) , 7.40 (d, J = 8.8 Hz, 1H) , 3.97 (s, 3H) , 3.65-3.74 (m, 2H) , 3.55-3.64 (m, 2H) , 3.36-3.39 (m, 1H) , 1.86-1.96 (m, 1H) , 1.57-1.67 (m, 1H) .
[0385]
Compound 73: (S) -N- (4-Cyano-2-fluorophenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0386]
LC-MS (ESI) : mass calcd. for C 19H 18FN 3O 5S 419.10, m/z found 420.1 [M+H] +. 1H NMR (400MHz, DMSO-d6) δ 10.53 (br. s., 1H) , 8.43 (t, J=7.9 Hz, 1H) , 8.27 (s, 1H) , 8.00 (d, J=10.5 Hz, 3H) , 7.76 (d, J=8.0 Hz, 1H) , 7.47 (d, J=8.8Hz, 1H) , 4.07 (s, 3H) , 3.74 -3.53 (m, 4H) , 3.39 -3.36 (m, 1H) , 1.96 -1.85 (m, 1H) , 1.67 -1.57 (m, 1H) .
[0387]
Compound 74: (S) -2-Methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) -N- (2, 4, 5-trifluorophenyl) benzamide
[0388]
LC-MS (ESI) : mass calcd. for C 18H 17F 3N 2O 5S 430.08, m/z found 431.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.26 (br. s, 1H) , 8.24 (d, J=2.3 Hz, 1H) , 8.16 (td, J=8.1, 12.0 Hz, 1H) , 8.01 -7.94 (m, 2H) , 7.74 (m, 1H) , 7.45 (d, J=9.0 Hz, 1H) , 4.05 (s, 3H) , 3.74 -3.65 (m, 2H) , 3.64 -3.54 (m, 2H) , 3.38 -3.34 (m, 1H) , 1.96 -1.85 (m, 1H) , 1.67 -1.57 (m, 1H) .
[0389]
Compound 75: (S) -N- (5-Chloro-2, 4-difluorophenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0390]
LC-MS (ESI) : mass calcd. for C 18H 17ClF 2N 2O 5S 446.05, m/z found 447.0 [M+H] +. 1H NMR (400MHz, DMSO-d6) δ 10.24 (br. s, 1H) , 8.28 -8.20 (m, 2H) , 8.01 -7.93 (m, 2H) , 7.72 (t, J=9.9 Hz, 1H) , 7.44 (d, J=9.0 Hz, 1H) , 4.04 (s, 3H) , 3.73 -3.65 (m, 2H) , 3.64 -3.55 (m, 2H) , 3.38-3.34 (m, 1H) , 1.95 -1.85 (m, 1H) , 1.64 -1.59 (m, 1H) .
[0391]
Compound 76: (S) -2-Methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) -N- (2, 4, 6-trifluorophenyl) benzamide
[0392]
LC-MS (ESI) : mass calcd. for C 18H 17F 3N 2O 5S 430.08, m/z found 431.1 [M+H] +. 1H NMR (400MHz, DMSO-d6) δ 9.86 (br., s, 1H) , 8.18 (d, J=2.5 Hz, 1H) , 8.00 -7.91 (m, 2H) , 7.42 (d, J=8.8 Hz, 1H) , 7.34 (t, J=8.5 Hz, 2H) , 4.01 (s, 3H) , 3.73 -3.56 (m, 4H) , 3.37 (s, 1H) , 1.96 -1.84 (m, 1H) , 1.66 -1.57 (m, 1H) .
[0393]
Compound 77: (S) -N- (3-Chloro-2, 4-difluorophenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0394]
LC-MS (ESI) : mass calcd. for C 18H 17ClF 2N 2O 5S 446.05, m/z found 447.0 [M+H] +. 1H NMR (400MHz, DMSO-d6) δ 10.23 (s, 1H) , 8.22 (d, J=2.0 Hz, 1H) , 8.02 -7.86 (m, 3H) , 7.49 -7.33 (m, 2H) , 4.04 (s, 3H) , 3.75 -3.53 (m, 4H) , 3.39 -3.35 (m, 1H) , 1.95 -1.85 (m, 1H) , 1.67 -1.57 (m, 1H) .
[0395]
Compound 78: (S) -N- (2-Chloro-4, 6-difluorophenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0396]
LC-MS (ESI) : mass calcd. for C 18H 17ClF 2N 2O 5S 446.05, m/z found 447.0 [M+H] +. 1H NMR (400MHz, DMSO-d6) δ 9.94 (br. s., 1H) , 8.19 (d, J=2.5 Hz, 1H) , 7.98 (dd, J=2.4, 8.7 Hz, 2H) , 7.57 -7.46 (m, 2H) , 7.43 (d, J=9.0 Hz, 1H) , 4.03 (s, 3H) , 3.74 -3.54 (m, 4H) , 3.39 -3.36 (m, 1H) , 1.96 -1.85 (m, 1H) , 1.67 -1.58 (m, 1H) .
[0397]
Compound 79: (S) -2-Methoxy-N- (1-methyl-1H-pyrazol-3-yl) -5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0398]
LC-MS (ESI) : mass calcd. for C 16H 20N 4O 5S 380.12, m/z found 381.1 [M+H] +. 1H NMR (400 MHz, DMSO-d 6) δ 10.45 (s, 1H) , 8.09 (d, J = 2.5 Hz, 1H) , 7.95 -7.88 (m, 2H) , 7.62 (d, J = 2.2 Hz, 1H) , 7.38 (d, J = 8.9 Hz, 1H) , 6.58 (d, J = 2.2 Hz, 1H) , 3.99 (s, 3H) , 3.77 (s, 3H) , 3.71 -3.55 (m, 4H) , 3.35 -3.31 (m, 1H) , 1.93 -1.86 (m, 1H) , 1.65 -1.58 (m, 1H) .
[0399]
Compound 80: (S) -N- (4-cyano-2, 6-difluorophenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0400]
LC-MS (ESI) : mass calcd. for C 19H 17F 2N 3O 5S 437.09, m/z found 438.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) 10.25 (s, 1H) , 8.16 (d, J=1.5 Hz, 1H) , 8.00 (dd, J=2.4, 8.8 Hz, 1H) , 7.93 (m, 3H) , 7.43 (d, J=8.8 Hz, 1H) , 4.01 (s, 3H) , 3.74 -3.60 (m, 4H) , 3.39 -3.33 (m, 1H) , 1.97 -1.86 (m, 1H) , 1.67 -1.57 (m, 1H) .
[0401]
Compound 81: (S) -N- (2, 6-Dichlorophenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0402]
LC-MS (ESI) : mass calcd. for C 18H 18Cl 2N 2O 5S 444.03, m/z found 445.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.11 (br. s, 1H) , 8.18 (d, J = 2.8 Hz, 1H) , 7.97 (dd, J = 2.4 Hz, J = 8.8 Hz, 2H) , 7.59 (d, J = 8.0 Hz, 2H) , 7.45 -7.35 (m, 2H) , 4.02 (s, 3H) , 3.74 -3.54 (m, 4H) , 3.40 -3.30 (m, 1H) , 1.96 -1.85 (m, 1H) , 1.68 -1.56 (m, 1H) .
[0403]
Compound 82: (S) -2-methoxy-N- (4-methylthiazol-2-yl) -5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0404]
LC-MS (ESI) : mass calcd. for C 16H 19N 3O 5S 2 397.47, m/z found 398.0 [M+H] +, reverse phase 1H NMR (400MHz, DMSO-d 6) δ 12.02 (s, 1H) , 8.05 (d, J = 2.0 Hz, 1H) , 7.89-7.98 (m, 2H) , 7.40 (d, J = 8.8 Hz, 1H) , 6.85 (s, 1H) , 3.98 (s, 3H) , 3.65-3.74 (m, 2H) , 3.54-3.64 (m, 2H) , 3.35-3.38 (m, 1H) , 2.29 (s, 3H) , 1.85-1.96 (m, 1H) , 1.57-1.67 (m, 1H) .
[0405]
Compound 83: (S) -N- (4, 5-dimethylthiazol-2-yl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0406]
LC-MS (ESI) : R T = 4.12 min, mass calcd. for C 17H 21N 3O 5S 2 411.50, m/z found 412.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 11.83 (s, 1H) , 8.04 (d, J = 2.4 Hz, 1H) , 7.88-7.98 (m, 2H) , 7.39 (d, J = 8.8 Hz, 1H) , 3.98 (s, 3H) , 3.65-3.73 (m, 2H) , 3.54-3.64 (m, 2H) , 3.35-3.38 (m, 1H) , 2.28 (s, 3H) , 2.19 (s, 3H) , 1.85-1.97 (m, 1H) , 1.57-1.66 (m, 1H) .
[0407]
Compound 84 : (S) -2-methoxy-N- (5-methylthiazol-2-yl) -5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0408]
LC-MS (ESI) : R T = 3.95 min, mass calcd. for C 16H 19N 3O 5S 2 397.47, m/z found 398.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 11.94 (s, 1H) , 8.04 (d, J = 2.4 Hz, 1H) , 7.89-7.98 (m, 2H) , 7.40 (d, J = 8.8 Hz, 1H) , 7.21 (s, 1H) , 3.98 (s, 3H) , 3.65-3.73 (m, 2H) , 3.55-3.64 (m, 2H) , 3.35-3.38 (m, 1H) , 2.39 (s, 3H) , 1.85-1.95 (m, 1H) , 1.57-1.67 (m, 1H) .
[0409]
Compound 85: (S) -N- (2, 4-Dichlorophenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0410]
LC-MS (ESI) : mass calcd. for C 18H 18Cl 2N 2O 5S 444.03, m/z found 445.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.50 (br. s, 1H) , 8.44 (d, J = 2.4 Hz, 1H) , 8.39 (d, J = 8.8 Hz, 1H) , 8.05 -7.95 (m, 2H) , 7.77 (d, J = 2.4 Hz, 1H) , 7.50 (dd, J = 2.0 Hz, J = 9.2 Hz, 2H) , 4.15 (s, 3H) , 3.74 -3.54 (m, 4H) , 3.40 -3.30 (m, 1H) , 1.96 -1.85 (m, 1H) , 1.68 -1.56 (m, 1H) .
[0411]
Compound 86: (S) -N- (3, 5-Dichlorophenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0412]
LC-MS (ESI) : mass calcd. for C 18H 18Cl 2N 2O 5S 444.03, m/z found 445.0 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ10.56 (br. s, 1H) , 8.00 (d, J = 2.4 Hz, 1H) , 7.98 -7.90 (m, 2H) , 7.82 (d, J = 1.6 Hz, 2H) , 7.40 (d, J = 8.8 Hz, 1H) , 7.36 (t, J = 1.6 Hz, 1H) , 3.98 (s, 3H) , 3.74 -3.54 (m, 4H) , 3.40 -3.30 (m, 1H) , 1.96 -1.85 (m, 1H) , 1.68 -1.56 (m, 1H) .
[0413]
Compound 87: (S) -N- (3-Cyano-5-fluorophenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0414]
LC-MS (ESI) : mass calcd. for C 19H 18FN 3O 5S 419.10, m/z found 420.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.73 (br. s, 1H) , 8.10 -7.90 (m, 5H) , 7.62 (d, J = 8.4 Hz, 1H) , 7.41 (d, J = 8.8 Hz, 1H) , 3.98 (s, 3H) , 3.74 -3.54 (m, 4H) , 3.40 -3.30 (m, 1H) , 1.96 -1.85 (m, 1H) , 1.68 -1.56 (m, 1H) .
[0415]
Compound 88: (S) -2-Methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) -N- (2, 3, 4-trifluorophenyl) benzamide
[0416]
LC-MS (ESI) : mass calcd. for C 18H 17F 3N 2O 5S 430.08, m/z found 431.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.24 (br. s, 1H) , 8.20 (d, J = 2.4 Hz, 1H) , 8.02 -7.92 (m, 2H) , 7.80 -7.70 (m, 1H) , 7.43 (d, J = 8.8 Hz, 1H) , 7.42 -7.32 (m, 1H) , 4.04 (s, 3H) , 3.74 -3.54 (m, 4H) , 3.40 -3.30 (m, 1H) , 1.96 -1.85 (m, 1H) , 1.68 -1.56 (m, 1H) .
[0417]
Compound 89: (S) -N- (3-Chloro-4-cyanophenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0418]
LC-MS (ESI) : mass calcd. for C 19H 18ClN 3O 5S 435.07, m/z found 436.0 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.83 (br. s, 1H) , 8.15 (d, J = 2.0 Hz, 1H) , 8.02 -7.88 (m, 4H) , 7.80 (dd, J = 2.0 Hz, J = 8.4 Hz, 1H) , 7.41 (d, J = 8.8 Hz, 1H) , 3.97 (s, 3H) , 3.74 -3.54 (m, 4H) , 3.40 -3.30 (m, 1H) , 1.96 -1.85 (m, 1H) , 1.68 -1.56 (m, 1H) .
[0419]
Compound 90: (S) -N- (4-Cyano-3-fluorophenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0420]
LC-MS (ESI) : mass calcd. for C 19H 18FN 3O 5S 419.10, m/z found 420.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.89 (br. s, 1H) , 8.02 -7.84 (m, 5H) , 7.63 (d, J = 8.8 Hz, 1H) , 7.41 (d, J = 8.8 Hz, 1H) , 3.96 (s, 3H) , 3.74 -3.54 (m, 4H) , 3.40 -3.30 (m, 1H) , 1.96 -1.85 (m, 1H) , 1.68 -1.56 (m, 1H) .
[0421]
Compound 91: (S) -N- (4-Chloro-2, 6-difluorophenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0422]
LC-MS (ESI) : mass calcd. for C 18H 17ClF 2N 2O 5S 446.05, m/z found 447.0 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 9.95 (br. s, 1H) , 8.17 (d, J = 2.4 Hz, 1H) , 8.02 -7.92 (m, 2H) , 7.52 (d, J = 7.6 Hz, 2H) , 7.42 (d, J = 9.2 Hz, 1H) , 4.01 (s, 3H) , 3.74 -3.54 (m, 4H) , 3.40 -3.30 (m, 1H) , 1.96 -1.85 (m, 1H) , 1.68 -1.56 (m, 1H) .
[0423]
Compound 92: (S) -N- (3-Cyano-2-fluorophenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0424]
LC-MS (ESI) : mass calcd. for C 19H 18FN 3O 5S 419.10, m/z found 420.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.39 (br. s, 1H) , 8.35 (t, J = 7.6 Hz, 1H) , 8.23 (d, J = 2.0 Hz, 1H) , 8.10 -7.94 (m, 2H) , 7.80 -7.70 (m, 1H) , 7.50 -7.40 (m, 2H) , 4.06 (s, 3H) , 3.74 -3.54 (m, 4H) , 3.40 -3.30 (m, 1H) , 1.96 -1.85 (m, 1H) , 1.68 -1.56 (m, 1H) .
[0425]
Compound 93: (S) -N- (3-Chloro-2, 6-difluorophenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0426]
LC-MS (ESI) : mass calcd. for C 18H 17ClF 2N 2O 5S 446.05, m/z found 447.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.07 (br. s, 1H) , 8.18 (d, J = 2.4 Hz, 1H) , 8.05 -7.90 (m, 2H) , 7.70 - 7.60 (m, 1H) , 7.43 (d, J = 8.8 Hz, 1H) , 7.32 (t, J = 8.4 Hz, 1H) , 4.02 (s, 3H) , 3.74 -3.54 (m, 4H) , 3.40 -3.30 (m, 1H) , 1.96 -1.85 (m, 1H) , 1.68 -1.56 (m, 1H) .
[0427]
Compound 94: (S) -N- (3-Chloro-5-cyanophenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0428]
LC-MS (ESI) : mass calcd. for C 19H 18ClN 3O 5S 435.07, m/z found 436.0 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.69 (br. s, 1H) , 8.16 (t, J = 2.0 Hz, 1H) , 8.11 (t, J = 1.6 Hz, 1H) , 8.03 (d, J = 2.4 Hz, 1H) , 8.00 -7.90 (m, 2H) , 7.79 (dd, J = 1.2 Hz, J = 2.0 Hz, 1H) , 7.41 (d, J = 8.8 Hz, 1H) , 3.98 (s, 3H) , 3.74 -3.54 (m, 4H) , 3.40 -3.30 (m, 1H) , 1.96 -1.85 (m, 1H) , 1.68 -1.56 (m, 1H) .
[0429]
Compound 95: (S) -N- (3-Cyano-4-fluorophenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0430]
LC-MS (ESI) : mass calcd. for C 19H 18FN 3O 5S 419.10, m/z found 420.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.59 (br. s, 1H) , 8.26 -8.20 (m, 1H) , 8.08 -8.00 (m, 2H) , 8.00 -7.90 (m, 2H) , 7.56 (t, J = 9.2 Hz, 1H) , 7.40 (d, J = 8.8 Hz, 1H) , 3.98 (s, 3H) , 3.74 -3.54 (m, 4H) , 3.40 -3.30 (m, 1H) , 1.96 -1.85 (m, 1H) , 1.68 -1.56 (m, 1H) .
[0431]
Compound 96: (S) -N- (2-Chloro-3, 5-difluorophenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0432]
LC-MS (ESI) : mass calcd. for C 18H 17ClF 2N 2O 5S 446.05, m/z found 447.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.68 (br. s, 1H) , 8.45 (d, J = 2.8 Hz, 1H) , 8.19 (d, J = 10.8 Hz, 1H) , 8.06 -8.00 (m, 2H) , 7.52 (d, J = 9.2 Hz, 1H) , 7.40 -7.30 (m, 1H) , 4.17 (s, 3H) , 3.74 -3.54 (m, 4H) , 3.40 -3.30 (m, 1H) , 1.96 -1.85 (m, 1H) , 1.68 -1.56 (m, 1H) .
[0433]
Compound 97: (S) -2-Methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) -N- (3, 4, 5-trifluorophenyl) benzamide
[0434]
LC-MS (ESI) : mass calcd. for C 18H 17F 3N 2O 5S 430.08, m/z found 431.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.58 (br. s, 1H) , 8.02 -7.88 (m, 3H) , 7.66 (dd, J = 6.4 Hz, J = 10.4 Hz, 2H) , 7.40 (d, J = 8.8 Hz, 1H) , 3.97 (s, 3H) , 3.74 -3.54 (m, 4H) , 3.40 -3.30 (m, 1H) , 1.96 -1.85 (m, 1H) , 1.68 -1.56 (m, 1H) .
[0435]
Compound 98: (S) -N- (4-Cyano-2, 5-difluorophenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0436]
LC-MS (ESI) : mass calcd. for C 19H 17F 2N 3O 5S 437.09, m/z found 438.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.69 (br. s, 1H) , 8.41 (dd, J = 6.0 Hz, J = 11.2 Hz, 1H) , 8.25 (d, J = 2.8 Hz, 1H) , 8.13 (dd, J = 6.0 Hz, J = 10.8 Hz, 1H) , 8.05 -7.95 (m, 2H) , 7.47 (d, J = 9.2 Hz, 1H) , 4.06 (s, 3H) , 3.74 -3.54 (m, 4H) , 3.40 -3.30 (m, 1H) , 1.96 -1.85 (m, 1H) , 1.68 -1.56 (m, 1H) .
[0437]
Compound 99: (S) -N- (2-Fluorophenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0438]
LC-MS (ESI) : mass calcd. for C 18H 19FN 2O 5S 394.10, m/z found 395.1 [M+H] +. 1H NMR (400 MHz, DMSO-d 6) δ 10.19 (s, 1H) , 8.28 (d, J = 2.4 Hz, 1H) , 8.15 -8.06 (m, 1H) , 8.12 -7.90 (m, 2H) , 7.45 (d, J = 8.8 Hz, 1H) , 7.38 -7.30 (m, 1H) , 7.28 -7.17 (m, 2H) , 4.07 (s, 3H) , 3.75 -3.66 (m, 2H) , 3.65 -3.54 (m, 2H) , 3.42 -3.38 (m, 1H) , 1.97 -1.84 (m, 1H) , 1.68 -1.55 (m, 1H) .
[0439]
Compound 100: (S) -N- (3-Fluorophenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0440]
LC-MS (ESI) : mass calcd. for C 18H 19FN 2O 5S 394.10, m/z found 395.1 [M+H] +. 1H NMR (400 MHz, DMSO-d 6) δ 10.46 (s, 1H) , 7.99 (d, J = 2.4 Hz, 1H) , 7.96 -7.89 (m, 2H) , 7.75 -7.68 (m, 1H) , 7.47 (d, J = 8.7 Hz, 1H) , 7.43 -7.36 (m, 2H) , 6.98 -6.93 (m, 1H) , 3.97 (s, 3H) , 3.75 -3.64 (m, 2H) , 3.63 -3.55 (m, 2H) , 3.39 -3.36 (m, 1H) , 1.96 -1.85 (m, 1H) , 1.68 -1.55 (m, 1H) .
[0441]
Compound 101: (S) -2-Methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) -N- (4- (trifluoromethyl) phenyl) benzamide
[0442]
LC-MS (ESI) : mass calcd. for C 19H 19F 3N 2O 5S 444.10, m/z found 444.9 [M+H] +. 1H NMR (400 MHz, DMSO-d 6) δ 10.60 (s, 1H) , 8.02 -7.86 (m, 5H) , 7.77 -7.70 (m, 2H) , 7.40 (d, J = 8.8 Hz, 1H) , 3.97 (s, 3H) , 3.74 -3.66 (m, 2H) , 3.64 -3.55 (m, 2H) , 3.41 -3.38 (m, 1H) , 1.96 -1.86 (m, 1H) , 1.68 -1.58 (m, 1H) .
[0443]
Compound 102: (S) -N- (3-cyanophenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0444]
LC-MS (ESI) : mass calcd. for C 19H 19N 3O 5S 401.10, m/z found 402.0 [M+H] +. 1H NMR (400 MHz, DMSO-d 6) δ 10.57 (s, 1H) , 8.21 (s, 1H) , 8.02 (d, J = 2.4 Hz, 1H) , 8.01 -7.89 (m, 3H) , 7.59 -7.57 (m, 2H) , 7.40 (d, J = 8.9 Hz, 1H) , 3.98 (s, 3H) , 3.74 -3.67 (m, 2H) , 3.65 -3.57 (m, 2H) , 3.37 (dd, J = 8.7, 4.2 Hz, 1H) , 1.97 -1.86 (m, 1H) , 1.68 -1.61 (m, 1H) .
[0445]
Compound 103: (S) -N- (2-Chloro-6-fluorophenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0446]
LC-MS (ESI) : mass calcd. for C 18H 18ClFN 2O 5S 428.06, m/z found 429.0 [M+H] +. 1H NMR (400 MHz, DMSO-d 6) δ 9.97 (s, 1H) , 8.20 (d, J = 2.4 Hz, 1H) , 8.01 -7.96 (m, 2H) , 7.49 -7.30 (m, 4H) , 4.03 (s, 3H) , 3.73 -3.66 (m, 2H) , 3.65 -3.54 (m, 2H) , 3.40 -3.37 (m, 1H) , 1.96 -1.87 (m, 1H) , 1.68 -1.57 (m, 1H) .
[0447]
Compound 104: (S) -N- (4-Cyanophenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0448]
LC-MS (ESI) : mass calcd. for C 19H 19N 3O 5S 401.10, m/z found 401.9 [M+H] +. 1H NMR (400 MHz, DMSO-d 6) δ 10.68 (s, 1H) , 8.01 -7.88 (m, 5H) , 7.85 -7.81 (m, 2H) , 7.40 (d, J = 8.8 Hz, 1H) , 3.97 (s, 3H) , 3.74 -3.67 (m, 2H) , 3.66 -3.55 (m, 2H) , 3.38 -3.35 (m, 1H) , 1.97 -1.86 (m, 1H) , 1.67 -1.58 (m, 1H) .
[0449]
Compound 105: (S) -N- (2, 6-Difluorophenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0450]
LC-MS (ESI) : mass calcd. for C 18H 18F 2N 2O 5S 412.09, m/z found 413.1 [M+H] +. 1H NMR (400 MHz, DMSO-d 6) δ 9.91 (s, 1H) , 8.18 (d, J = 2.4 Hz, 1H) , 8.01 -7.91 (m, 2H) , 7.47 -7.36 (m, 2H) , 7.27 -7.15 (m, 2H) , 4.02 (s, 3H) , 3.73 -3.65 (m, 2H) , 3.64 -3.54 (m, 2H) , 3.38 -3.35 (m, 1H) , 1.95 -1.85 (m, 1H) , 1.66 -1.56 (m, 1H) .
[0451]
Compound 106: (S) -N- (4- (Difluoromethoxy) phenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0452]
LC-MS (ESI) : mass calcd. for C 19H 20F 2N 2O 6S 442.10, m/z found 443.0 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.34 (br. s, 1H) , 8.00 (d, J=2.2 Hz, 1H) , 7.95 -7.90 (m, 2H) , 7.78 -7.73 (m, 2H) , 7.41 -7.35 (m, 1H) , 7.21 -7.16 (m, 3H) , 3.97 (s, 3H) , 3.73 -3.66 (m, 2H) , 3.64 -3.56 (m, 2H) , 3.50 -3.44 (m, 1H) , 1.96 -1.87 (m, 1H) , 1.66 -1.58 (m, 1H) .
[0453]
Compound 107: (S) -N- (3- (Difluoromethoxy) phenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide:
[0454]
LC-MS (ESI) : mass calcd. for C 19H 20F 2N 2O 6S 442.10, m/z found 442.9 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.44 (br. s, 1H) , 7.98 (d, J=2.4 Hz, 1H) , 7.96 -7.87 (m, 2H) , 7.73 -7.67 (m, 1H) , 7.53 (d, J=8.3 Hz, 1H) , 7.43 -7.37 (m, 2H) , 7.23 (s, 1H) , 6.93 (dd, J=2.0, 8.1 Hz, 1H) , 3.97 (s, 3H) , 3.70 -3.57 (m, 4H) , 3.39 -3.38 (m, 1H) , 1.94 -1.86 (m, 1H) , 1.66 -1.59 (m, 1H) .
[0455]
Compound 108: (S) -N- (4-Chlorophenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide:
[0456]
LC-MS (ESI) : mass calcd. for C 18H 19ClN 2O 5S 410.07, m/z found 411.0 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.38 (br. s, 1H) , 7.99 (d, J=2.4 Hz, 1H) , 7.95 -7.89 (m, 2H) , 7.79 -7.73 (m, 2H) , 7.44 -7.36 (m, 3H) , 3.96 (s, 3H) , 3.73 -3.66 (m, 2H) , 3.62 -3.55 (m, 2H) , 3.38 -3.38 (m, 1H) , 1.95 -1.85 (m, 1H) , 1.66 -1.59 (m, 1H) .
[0457]
Compound 109: (S) -2-Methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) -N- (3- (trifluoromethyl) phenyl) benzamide
[0458]
LC-MS (ESI) : mass calcd. for C 19H 19F 3N 2O 5S 444.10, m/z found 445.0 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.58 (br. s., 1H) , 8.21 (s, 1H) , 8.01 (d, J=2.2 Hz, 1H) , 7.97 -7.87 (m, 3H) , 7.61 (t, J=7.9 Hz, 1H) , 7.48 (d, J=7.6 Hz, 1H) , 7.40 (d, J=8.8 Hz, 1H) , 3.97 (s, 3H) , 3.72 -3.66 (m, 2H) , 3.63 -3.57 (m, 2H) , 3.41 (br. s., 1H) , 1.96 -1.88 (m, 1H) , 1.67 -1.59 (m, 1H) .
[0459]
Compound 110: (S) -2-Methoxy-N- (1-methyl-1H-indazol-4-yl) -5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0460]
LC-MS (ESI) : mass calcd. for C 20H 22N 4O 5S 430.13, m/z found 431.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.43 (s, 1H) , 8.21 (s, 1H) , 8.12 (d, J=2.0 Hz, 1H) , 7.99 -7.90 (m, 2H) , 7.84 (d, J=4.5 Hz, 1H) , 7.46 -7.34 (m, 3H) , 4.04 (s, 3H) , 4.04 (s, 3H) , 3.74 -3.66 (m, 2H) , 3.66 -3.55 (m, 2H) , 3.42 -3.39 (m, 1H) , 1.98 -1.85 (m, 1H) , 1.70 -1.59 (m, 1H) .
[0461]
Compound 111: (S) -N- (3, 4-Difluorophenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0462]
LC-MS (ESI) : mass calcd. for C 18H 18F 2N 2O 5S 412.09, m/z found 413.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.46 (s, 1H) , 8.00 (d, J=2.5 Hz, 1H) , 7.96 -7.86 (m, 3H) , 7.51 -7.42 (m, 2H) , 7.39 (d, J=9.0 Hz, 1H) , 3.97 (s, 3H) , 3.74 -3.65 (m, 2H) , 3.65 -3.55 (m, 2H) , 3.42 -3.39 (m, 1H) , 1.96 -1.85 (m, 1H) , 1.68 -1.57 (m, 1H) .
[0463]
Compound 112: (S) -N- (3-Chloro-4-fluorophenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0464]
LC-MS (ESI) : mass calcd. for C 18H 18ClFN 2O 5S 428.06, m/z found 429.0 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.45 (s, 1H) , 8.04 (dd, J=2.5, 7.0 Hz, 1H) , 8.00 (d, J=2.5 Hz, 1H) , 7.97 -7.89 (m, 2H) , 7.70 -7.62 (m, 1H) , 7.47 -7.36 (m, 2H) , 3.97 (s, 3H) , 3.74 -3.65 (m, 2H) , 3.65 -3.55 (m, 2H) , 3.36 -3.34 (m, 1H) , 1.96 -1.85 (m, 1H) , 1.68 -1.58 (m, 1H) .
[0465]
Compound 113: (S) -N- (2, 3-Difluorophenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0466]
LC-MS (ESI) : mass calcd. for C 18H 18F2N 2O 5S 412.09, m/z found 429.0 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.30 (s, 1H) , 8.23 (d, J=2.0 Hz, 1H) , 8.03 -7.91 (m, 2H) , 7.87 -7.77 (m, 1H) , 7.44 (d, J=8.5 Hz, 1H) , 7.32 -7.20 (m, 2H) , 4.05 (s, 3H) , 3.74 -3.65 (m, 2H) , 3.64 -3.54 (m, 2H) , 3.42 -3.39 (m, 1H) , 1.95 -1.85 (m, 1H) , 1.67 -1.57 (m, 1H) .
[0467]
Compound 114: (S) -N- (4-Chloro-2-fluorophenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0468]
LC-MS (ESI) : mass calcd. for C 18H 18ClFN 2O 5S 428.06, m/z found 429.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.23 (s, 1H) , 8.25 (d, J=2.5 Hz, 1H) , 8.10 (t, J=8.8 Hz, 1H) , 8.01 -7.87 (m, 2H) , 7.58 (dd, J=2.0, 10.5 Hz, 1H) , 7.44 (d, J=9.0 Hz, 1H) , 7.34 (d, J=8.5 Hz, 1H) , 4.05 (s, 3H) , 3.74 -3.64 (m, 2H) , 3.64 -3.54 (m, 2H) , 3.35 -3.33 (m, 1H) , 1.95 -1.84 (m, 1H) , 1.67 -1.57 (m, 1H) .
[0469]
Compound 115: (S) -N- (4-Chloro-3-fluorophenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0470]
LC-MS (ESI) : mass calcd. for C 18H 18ClFN 2O 5S 428.06, m/z found 428.9 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.57 (s, 1H) , 7.99 (d, J=2.5 Hz, 1H) , 7.97 -7.86 (m, 3H) , 7.60 -7.54 (m, 1H) , 7.54 -7.49 (m, 1H) , 7.39 (d, J=8.5 Hz, 1H) , 3.96 (s, 3H) , 3.74 -3.64 (m, 2H) , 3.64 -3.55 (m, 2H) , 3.36 -3.34 (m, 1H) , 1.96 -1.85 (m, 1H) , 1.67 -1.57 (m, 1H) .
[0471]
Compound 116: (S) -N- (5-Fluoropyridin-2-yl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0472]
LC-MS (ESI) : mass calcd. for C 17H 18FN 3O 5S 395.10, m/z found 396.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.70 (br. s, 1H) , 8.39 (d, J = 3.2 Hz, 1H) , 8.28 (dd, J = 4.0, 9.2 Hz, 1H) , 8.16 (d, J = 2.4 Hz, 1H) , 8.00 -7.90 (m, 2H) , 7.83 (td, J = 3.2, 8.8 Hz, 1H) , 7.42 (d, J = 8.8 Hz, 1H) , 4.03 (s, 3H) , 3.74 -3.54 (m, 4H) , 3.40 -3.30 (m, 1H) , 1.96 -1.85 (m, 1H) , 1.68 -1.56 (m, 1H) .
[0473]
Compound 117: (S) -N- (5-Fluoropyrimidin-2-yl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0474]
LC-MS (ESI) : mass calcd. for C 16H 17FN 4O 5S 396.09, m/z found 397.0 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 11.02 (br. s, 1H) , 8.77 (s, 2H) , 7.98 (d, J = 2.4 Hz, 1H) , 7.92 (dd, J = 2.4, 8.4 Hz, 2H) , 7.34 (d, J = 8.8 Hz, 1H) , 3.90 (s, 3H) , 3.74 -3.54 (m, 4H) , 3.40 -3.30 (m, 1H) , 1.96 -1.85 (m, 1H) , 1.68 -1.56 (m, 1H) .
[0475]
Compound 118: (S) -N- (3, 5-Difluoropyridin-2-yl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide:
[0476]
LC-MS (ESI) : mass calcd. for C 17H 17F 2N 3O 5S 413.09, m/z found 414.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.49 (brs, 1H) , 8.40 (d, J = 2.0 Hz, 1H) , 8.17 -8.05 (m, 2H) , 8.00 -7.91 (m, 2H) , 7.40 (d, J = 8.0, 1H) , 3.98 (s, 3H) , 3.74 -3.55 (m, 4H) , 3.40 -3.30 (m, 1H) , 1.96 -1.85 (m, 1H) , 1.67 -1.57 (m, 1H) .
[0477]
Compound 119: ( (S) -N- (3-Chloro-5-fluoropyridin-2-yl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide:
[0478]
LC-MS (ESI) : mass calcd. for C 17H 17ClFN 3O 5S 429.06, m/z found 430.0 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.49 (br. s., 1H) , 8.50 (d, J = 2.5 Hz, 1H) , 8.25 (dd, J = 2.5, 8.0 Hz, 1H) , 8.17 (d, J = 2.5 Hz, 1H) , 7.96 (dd, J = 2.3, 8.8 Hz, 2H) , 7.40 (d, J = 8.5 Hz, 1H) , 4.00 (s, 3H) , 3.74 -3.54 (m, 4H) , 3.39 -3.35 (m, 1H) , 1.96 -1.85 (m, 1H) , 1.62 (dt, J = 6.3, 12.4 Hz, 1H) .
[0479]
Compound 120: (S) -N- (5-Chloro-3-fluoropyridin-2-yl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide:
[0480]
LC-MS (ESI) : mass calcd. for C 17H 17ClFN 3O 5S 429.06, m/z found 430.0 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.58 (br. s., 1H) , 8.42 -8.36 (m, 1H) , 8.21 (d, J = 9.5 Hz, 1H) , 8.10 (br. s., 1H) , 8.00 -7.89 (m, 2H) , 7.39 (d, J = 9.0 Hz, 1H) , 3.97 (br. s., 3H) , 3.73 -3.56 (m, 4H) , 3.37 (br. s., 1H) , 1.89 (d, J = 5.5 Hz, 1H) , 1.62 (d, J = 6.0 Hz, 1H) .
[0481]
Compound 121: (S) -N- (3-Chloropyridin-2-yl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide:
[0482]
LC-MS (ESI) : mass calcd. for C 17H 18ClN 3O 5S 411.07, m/z found 412.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.52 (s, 1H) , 8.41 (dd, J = 1.4, 4.8 Hz, 1H) , 8.18 (d, J = 2.4 Hz, 1H) , 8.06 (dd, J = 1.4, 8.0 Hz, 1H) , 7.96 (dd, J = 2.4, 8.8 Hz, 2H) , 7.43 -7.32 (m, 2H) , 4.00 (s, 3H) , 3.73 -3.55 (m, 4H) , 3.39 -3.35 (m, 1H) , 1.95 -1.84 (m, 1H) , 1.62 (dt, J = 5.4, 12.4 Hz, 1H) .
[0483]
Compound 122: (S) -N- (4-Fluorophenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide:
[0484]
LC-MS (ESI) : mass calcd. for C 18H 19FN 2O 5S 394.10, m/z found 395.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.30 (brs, 1H) , 8.00 (d, J=2.3 Hz, 1H) , 7.96 -7.88 (m, 2H) , 7.80 -7.71 (m, 2H) , 7.38 (d, J = 8.8 Hz, 1H) , 7.20 (t, J = 8.9 Hz, 2H) , 3.97 (s, 3H) , 3.74 -3.54 (m, 4H) , 3.39 -3.35 (m, 1H) , 1.97 -1.84 (m, 1H) , 1.68 -1.58 (m, 1H) .
[0485]
Compound 123: (S) -N- (2-Bromophenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide:
[0486]
LC-MS (ESI) : mass calcd. for C 18H 19BrN 2O 5S 454.02, m/z found 454.9 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.42 (s, 1H) , 8.48 (d, J=2.4 Hz, 1H) , 8.37 (d, J = 8.0 Hz, 1H) , 8.02 (dd, J = 2.4, 8.8 Hz, 1H) , 7.73 (dd, J = 1.4, 8.0 Hz, 1H) , 7.51 (d, J = 8.8 Hz, 1H) , 7.44 (t, J = 7.8 Hz, 1H) , 7.14 (dt, J=1.4, 7.8 Hz, 1H) , 4.18 (s, 3H) , 3.73 -3.55 (m, 4H) , 3.38 -3.36 (m, 1H) , 1.97 -1.82 (m, 1H) , 1.68 -1.56 (m, 1H) .
[0487]
Compound 124: (S) -N- (3-Bromophenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide:
[0488]
LC-MS (ESI) : mass calcd. for C 18H 19BrN 2O 5S 454.02, m/z found 455.0 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.40 (s, 1H) , 8.08 -8.04 (m, 1H) , 7.99 (d, J = 2.4 Hz, 1H) , 7.95 -7.88 (m, 2H) , 7.67 (td, J=2.4, 6.8 Hz, 1H) , 7.39 (d, J = 8.4 Hz, 1H) , 7.35 -7.28 (m, 2H) , 3.97 (s, 3H) , 3.74 -3.65 (m, 2H) , 3.64 -3.55 (m, 2H) , 3.40 -3.34 (m, 1H) , 1.96 -1.85 (m, 1H) , 1.68 -1.58 (m, 1H) .
[0489]
Compound 125: (S) -N- (4-Bromophenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide:
[0490]
LC-MS (ESI) : mass calcd. for C 18H 19BrN 2O 5S 454.02, m/z found 455.0 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.37 (s, 1H) , 8.02 -7.97 (m, 1H) , 7.95 -7.88 (m, 2H) , 7.74 -7.67 (m, 2H) , 7.57 -7.51 (m, 2H) , 7.38 (d, J = 9.0 Hz, 1H) , 3.96 (s, 3H) , 3.74 -3.54 (m, 4H) , 3.40 -3.34 (m, 1H) , 1.96 -1.85 (m, 1H) , 1.68 -1.58 (m, 1H) .
[0491]
Compound 126: (S) -N- (3-Chlorophenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0492]
LC-MS (ESI) : mass calcd. for C 18H 19ClN 2O 5S 410.07, m/z found 410.9 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.43 (br. s, 1H) , 7.99 (d, J = 2.2 Hz, 1H) , 7.96 -7.87 (m, 3H) , 7.62 (d, J = 8.3 Hz, 1H) , 7.42 -7.35 (m, 2H) , 7.21 -7.16 (m, 1H) , 3.97 (s, 3H) , 3.74 -3.55 (m, 4H) , 3.41 -3.35 (m, 1H) , 1.96 -1.86 (m, 1H) , 1.68 -1.61 (m, 1H) .
[0493]
Compound 127: (S) -N- (2-Chlorophenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0494]
LC-MS (ESI) : mass calcd. for C 18H 19ClN 2O 5S 410.07, m/z found 411.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.47 (s, 1H) , 8.45 (d, J = 2.5 Hz, 1H) , 8.37 (d, J = 7.3 Hz, 1H) , 8.01 (dd, J = 2.5, 8.8 Hz, 2H) , 7.59 (dd, J = 1.4, 8.2 Hz, 1H) , 7.51 (d, J = 8.8 Hz, 1H) , 7.42 (t, J = 7.8 Hz, 1H) , 7.21 (dt, J = 1.6, 7.7 Hz, 1H) , 4.15 (s, 3H) , 3.73 -3.65 (m, 2H) , 3.64 -3.54 (m, 2H) , 3.33 -3.30 (m, 1H) , 1.97 -1.87 (m, 1H) , 1.66 -1.57 (m, 1H) .
[0495]
Compound 128: (S) -N- (2- (Difluoromethoxy) phenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0496]
LC-MS (ESI) : mass calcd. for C 19H 20F 2N 2O 6S 442.10, m/z found 443.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.44 (s, 1H) , 8.50 -8.44 (m, 2H) , 8.04 -7.97 (m, 2H) , 7.51 (d, J = 8.8 Hz, 1H) , 7.36 (s, 1H) , 7.35 -7.29 (m, 2H) , 7.25 -7.19 (m, 1H) , 7.18 (s, 0.25H) , 4.14 (s, 3H) , 3.73 -3.64 (m, 2H) , 3.64 -3.54 (m, 2H) , 3.39 -3.35 (m, 1H) , 1.95 -1.84 (m, 1H) , 1.66 -1.57 (m, 1H) .
[0497]
Compound 129: (S) -2-Methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) -N- (p-tolyl) benzamide
[0498]
LC-MS (ESI) : mass calcd. for C 19H 22N 2O 5S 390.12, m/z found 391.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.16 (s, 1H) , 8.01 (d, J = 2.5 Hz, 1H) , 7.94 -7.88 (m, 2H) , 7.61 (d, J = 8.3 Hz, 2H) , 7.37 (d, J = 9.0 Hz, 1H) , 7.16 (d, J = 8.3 Hz, 2H) , 3.97 (s, 3H) , 3.73 -3.55 (m, 4H) , 3.39 -3.35 (m, 1H) , 2.28 (s, 3H) , 1.96 -1.85 (m, 1H) , 1.68 -1.58 (m, 1H) .
[0499]
Compound 130: (S) -N- (2-Fluoro-6-methoxyphenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0500]
LC-MS (ESI) : mass calcd. for C 19H 21FN 2O 6S 424.11, m/z found 425.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 9.52 (s, 1H) , 8.22 (d, J = 2.0 Hz, 1H) , 7.99 -7.91 (m, 2H) , 7.41 (d, J = 8.8 Hz, 1H) , 7.35 -7.27 (m, 1H) , 6.98 -6.86 (m, 2H) , 4.03 (s, 3H) , 3.83 (s, 3H) , 3.73 -3.66 (m, 2H) , 3.64 -3.55 (m, 2H) , 3.39 -3.32 (m, 1H) , 1.96 -1.84 (m, 1H) , 1.67 -1.56 (m, 1H) .
[0501]
Compound 131: (S) -N- (4-Fluoro-2-methylphenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0502]
LC-MS (ESI) : mass calcd. for C 19H 21FN 2O 5S 408.12, m/z found 409.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 9.82 (s, 1H) , 8.24 (d, J = 2.3 Hz, 1H) , 7.98 -7.91 (m, 2H) , 7.73 (dd, J = 5.5, 8.8 Hz, 1H) , 7.43 (d, J = 9.0 Hz, 1H) , 7.16 (dd, J = 2.9, 9.7 Hz, 1H) , 7.07 (dt, J = 3.0, 8.7 Hz, 1H) , 4.05 (s, 3H) , 3.73 -3.65 (m, 2H) , 3.64 -3.55 (m, 2H) , 3.39 -3.35 (m, 1H) , 2.31 (s, 3H) , 1.96 -1.86 (m, 1H) , 1.67 -1.58 (m, 1H) .
[0503]
Compound 132: (S) -N- (5-fluoro-3-methylpyridin-2-yl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0504]
LC-MS (ESI) : mass calcd. for C 18H 20FN 3O 5S 409.11, m/z found 410.1 [M+H] +. 1H NMR (400 MHz, DMSO-d 6) δ 10.29 (br. s, 1H) , 8.27 (s, 1H) , 8.08 (s, 1H) , 7.93 (dd, J = 8.8, 2.3 Hz, 1H) , 7.75 (dd, J = 9.0, 2.8 Hz, 1H) , 7.37 (d, J = 8.5 Hz, 1H) , 3.97 (s, 3H) , 3.76 -3.51 (m, 5H) , 2.28 (s, 3H) , 1.96 -1.82 (m, 1H) , 1.68 -1.54 (m, 1H) .
[0505]
Compound 133: (S) -2-Methoxy-N- (3-methylpyridin-2-yl) -5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0506]
LC-MS (ESI) : mass calcd. for C 18H 21N 3O 5S 391.12, m/z found 392.1 [M+H] +. 1H NMR (400 MHz, DMSO-d 6) δ 10.27 (br. s, 1H) , 8.26 (s, 1H) , 8.09 (s, 1H) , 7.93 (dd, J = 2.0, 8.8 Hz, 1H) , 7.73 (d, J = 7.3 Hz, 1H) , 7.36 (d, J = 8.6 Hz, 1H) , 7.30 -7.16 (m, 1H) , 3.96 (s, 3H) , 3.75 -3.53 (m, 5H) , 2.26 (s, 3H) , 1.96 -1.84 (m, 1H) , 1.68 -1.55 (m, 1H) .
[0507]
Compound 134: (S) -N- (3-fluoro-2-methoxyphenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0508]
LC-MS (ESI) : mass calcd. for C 19H 21FN 2O 6S 424.11, m/z found 425.1 [M+H] +. 1H NMR (400 MHz, DMSO-d 6) δ 10.68 (s, 1H) , 8.52 (d, J = 2.5 Hz, 1H) , 8.29 (dd, J = 10.8, 3.1 Hz, 1H) , 8.07 -7.95 (m, 2H) , 7.51 (d, J = 8.9 Hz, 1H) , 7.12 (dd, J = 9.1, 5.1 Hz, 1H) , 6.94 (td, J = 8.6, 3.2 Hz, 1H) , 4.17 (s, 3H) , 3.96 (s, 3H) , 3.75 -3.52 (m, 4H) , 3.40 -3.35 (m, 1H) , 1.96 -1.83 (m, 1H) , 1.65 -1.55 (m, 1H) .
[0509]
Compound 135: (S) -N- (4-fluoro-2-methoxyphenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0510]
LC-MS (ESI) : mass calcd. for C 19H 21FN 2O 6S 424.11, m/z found 425.1 [M+H] +. 1H NMR (400 MHz, DMSO-d 6) δ 10.45 (s, 1H) , 8.49 (d, J = 2.4 Hz, 1H) , 8.43 -8.32 (m, 1H) , 8.06 -7.90 (m, 2H) , 7.49 (d, J = 8.8 Hz, 1H) , 7.07 (dd, J = 10.7, 2.7 Hz, 1H) , 6.82 (td, J = 8.7, 2.7 Hz, 1H) , 4.15 (s, 3H) , 3.97 (s, 3H) , 3.74 -3.64 (m, 2H) , 3.64 -3.53 (m, 2H) , 3.33 -3.26 (m, 1H) , 1.95 -1.82 (m, 1H) , 1.67 -1.54 (m, 1H) .
[0511]
Compound 136: (S) -N- (2-ethoxyphenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0512]
LC-MS (ESI) : mass calcd. for C 20H 24N 2O 6S 420.14, m/z found 421.1 [M+H] +. 1H NMR (400 MHz, DMSO-d 6) δ 10.43 (s, 1H) , 8.53 (d, J = 2.5 Hz, 1H) , 8.48 (d, J = 7.6 Hz, 1H) , 8.05 -7.95 (m, 2H) , 7.50 (d, J = 8.9 Hz, 1H) , 7.15 -7.04 (m, 2H) , 7.00 -6.90 (m, 1H) , 4.23 -4.17 (m, 2H) , 4.16 (s, 3H) , 3.73 -3.64 (m, 2H) , 3.64 -3.53 (m, 2H) , 3.33 -3.30 (m, 1H) , 1.93 -1.83 (m, 1H) , 1.65 -1.57 (m, 1H) , 1.47 (t, J = 7.0 Hz, 3H) .
[0513]
Compound 137a: N- (2-chloro-5-methylphenyl) -5- (N- ( (trans) -3-hydroxycyclobutyl) sulfamoyl) -2 -methoxybenzamide
[0514]
LC-MS (ESI) : mass calcd. for C 19H 21ClN 2O 5S 424.1, m/z found 425.0 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.41 (br. s., 1H) , 8.41 (br. s, 1H) , 8.22 (br. s, 1H) , 8.08 -7.83 (m, 2H) , 7.47 (dd, J = 8.4, 15.0 Hz, 2H) , 7.13 -6.93 (m, J = 7.8 Hz, 1H) , 4.96 (s, 1H) , 4.14 (br. s., 3H) , 3.84 -3.64 (m, 1H) , 3.55 -3.43 (m, 1H) , 2.34 (br. s., 3H) , 2.13 -1.75 (m, 4H) .
[0515]
Compound 137b: N- (2-Chloro-5-methylphenyl) -5- (N- ( (cis) -3-hydroxycyclobutyl) sulfamoyl) -2 -methoxybenzamide
[0516]
LC-MS (ESI) : mass calcd. for C 19H 21ClN 2O 5S 424.1, m/z found 425.0 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.42 (s, 1H) , 8.42 (s, 1H) , 8.22 (s, 1H) , 8.02 -7.85 (m, 2H) , 7.53 -7.40 (m, 2H) , 7.03 (dd, J = 1.5, 8.1 Hz, 1H) , 5.02 (d, J = 5.6 Hz, 1H) , 4.21 -4.08 (m, 3H) , 3.72 -3.61 (m, 1H) , 3.16 -3.05 (m, 1H) , 2.34 (s, 3H) , 2.30 -2.19 (m, 2H) , 1.64 -1.52 (m, 2H) .
[0517]
Compound 138a: N- (2-Chloro-6-methylphenyl) -5- (N- ( (trans) -3-hydroxycyclobutyl) sulfamoyl) -2-methoxybenzamide
[0518]
LC-MS (ESI) : mass calcd. for C 19H 21ClN 2O 5S 424.1, m/z found 425.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 9.88 (s, 1H) , 8.09 (br. s., 1H) , 7.89 (d, J = 8.6 Hz, 2H) , 7.39 (d, J = 8.8 Hz, 2H) , 7.33 -7.23 (m, 2H) , 4.96 (d, J = 3.9 Hz, 1H) , 4.13 (m, 1H) , 4.01 (s, 3H) , 3.73 (m., 1H) , 2.35 -2.22 (m, 3H) , 2.04 -1.85 (m, 4H) .
[0519]
Compound 138b: N- (2-Chloro-6-methylphenyl) -5- (N- ( (cis) -3-hydroxycyclobutyl) sulfamoyl) -2-methoxybenzamide
[0520]
LC-MS (ESI) : mass calcd. for C 19H 21ClN 2O 5S 424.1, m/z found 425.1 [M+H] +. 1H NMR (400MHz, DMSO-d6) δ 9.87 (s, 1H) , 8.11 (d, J = 2.5 Hz, 1H) , 7.93 -7.85 (m, 2H) , 7.43 -7.35 (m, 2H) , 7.32 -7.23 (m, 2H) , 5.03 (d, J = 6.0 Hz, 1H) , 4.01 (s, 3H) , 3.74 -3.59 (m, 1H) , 3.17 -3.04 (m, 1H) , 2.30 -2.18 (m, 5H) , 1.65 -1.52 (m, 2H) .
[0521]
Compound 139a: N- (2-Chloro-3-methoxyphenyl) -5- (N- ( (trans) -3-hydroxycyclobutyl) sulfamoyl) -2-methoxybenzamide
[0522]
LC-MS (ESI) : mass calcd. for C 19H 21ClN 2O 6S 440.1., m/z found 441.0 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.51 (s, 1H) , 8.43 (d, J = 1.7 Hz, 1H) , 8.05 (d, J = 8.1 Hz, 1H) , 7.96 (dd, J = 2.1, 8.7 Hz, 2H) , 7.49 (d, J = 8.8 Hz, 1H) , 7.37 (t, J = 8.4 Hz, 1H) , 7.00 (d, J = 8.3 Hz, 1H) , 4.95 (d, J = 4.9 Hz, 1H) , 4.20 -4.07 (m, 4H) , 3.90 (s, 3H) , 3.73 (br. s., 1H) , 2.01 -1.84 (m, 4H) .
[0523]
Compound 139b: N- (2-Chloro-3-methoxyphenyl) -5- (N- ( (cis) -3-hydroxycyclobutyl) sulfamoyl) -2 -methoxybe
[0524]
LC-MS (ESI) : mass calcd. for C 19H 21ClN 2O 6S 440.1., m/z found 441.0 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.52 (s, 1H) , 8.44 (d, J = 2.0 Hz, 1H) , 8.05 (d, J = 8.5 Hz, 1H) , 8.00 -7.89 (m, 2H) , 7.49 (d, J = 8.5 Hz, 1H) , 7.36 (t, J = 8.3 Hz, 1H) , 6.99 (d, J = 8.0 Hz, 1H) , 5.02 (d, J = 5.5 Hz, 1H) , 4.16 (s, 3H) , 3.90 (s, 3H) , 3.73 -3.60 (m, 1H) , 3.16 -3.04 (m, 1H) , 2.28 -2.17 (m, 2H) , 1.63 -1.51 (m, 2H) .
[0525]
Compound 140a: N- (2-Chloro-3-methylphenyl) -5- (N- ( (trans) -3-hydroxycyclobutyl) sulfamoyl) -2 -methoxybenzamide
[0526]
LC-MS (ESI) : mass calcd. for C 19H 21ClN 2O 5S 424.1, m/z found 425.1 [M+H] +. 1H NMR (400MHz, DMSO-d6) δ 10.51 (s, 1H) , 8.45 -8.39 (m, 1H) , 8.24 (d, J = 8.0 Hz, 1H) , 8.02 -7.91 (m, 2H) , 7.49 (d, J = 9.0 Hz, 1H) , 7.34 -7.27 (m, 1H) , 7.22 -7.15 (m, 1H) , 4.98 (d, J = 5.0 Hz, 1H) , 4.19 -4.08 (m, 4H) , 3.78 -3.68 (m, 1H) , 2.40 (s, 3H) , 2.04 -1.83 (m, 4H) .
[0527]
Compound 140b: N- (2-Chloro-3-methylphenyl) -5- (N- ( (cis) -3-hydroxycyclobutyl) sulfamoyl) -2 -methoxybenzamide
[0528]
LC-MS (ESI) : mass calcd. for C 19H 21ClN 2O 5S 424.1, m/z found 425.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.51 (s, 1H) , 8.43 (d, J = 2.5 Hz, 1H) , 8.25 (d, J = 8.0 Hz, 1H) , 8.00 -7.87 (m, 2H) , 7.48 (d, J = 9.0 Hz, 1H) , 7.35 -7.26 (m, 1H) , 7.19 (d, J = 7.5 Hz, 1H) , 5.03 (d, J = 5.5 Hz, 1H) , 4.15 (s, 3H) , 3.73 -3.60 (m, 1H) , 3.18 -3.01 (m, 1H) , 2.40 (s, 3H) , 2.29 -2.17 (m, 2H) , 1.62 -1.50 (m, 2H) .
[0529]
Compound 141: (cis) -N- (5-Fluoro-6-methylpyridin-2-yl) -5- (N- (-3-hydroxycyclobutyl) sulfamoyl) -2-methoxybenzamide
[0530]
LC-MS (ESI) : mass calcd. for C 18H 20FN 3O 5S 409.11, m/z found 410.1 [M+H] +, 1H NMR (400 MHz, DMSO-d 6) δ 10.59 (s, 1H) , 8.17 -8.06 (m, 2H) , 7.93 -7.83 (m, 2H) , 7.72 (t, J = 8.9 Hz, 1H) , 7.39 (d, J = 9.0 Hz, 1H) , 5.02 (d, J = 5.6 Hz, 1H) , 4.02 (s, 3H) , 3.71 -3.62 (m, 1H) , 3.14 -3.04 (m, 1H) , 2.41 (d, J = 2.7 Hz, 3H) , 2.29 -2.19 (m, 2H) , 1.64 -1.51 (m, 2H) .
[0531]
Compound 142a: N- (3- (difluoromethyl) -4-fluorophenyl) -5- (N- ( (trans) -3-hydroxycyclobutyl) sulfamoyl) -2-methoxybenzamide
[0532]
LC-MS (ESI) : mass calcd. for C 19H 19F 3N 2O 5S 444.10, m/z found 445.0 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.48 (br. s, 1H) , 8.07 (d, J = 3.6 Hz, 1H) , 7.95 (d, J = 2.4 Hz, 1H) , 7.92 -7.82 (m, 3H) , 7.43 -7.10 (m, 3H) , 4.96 (d, J = 4.8 Hz, 1H) , 4.15 -4.08 (m, 1H) , 3.96 (s, 3H) , 3.75 -3.65 (m, 1H) , 2.02 -1.85 (m, 4H) .
[0533]
Compound 142b: N- (3- (difluoromethyl) -4-fluorophenyl) -5- (N- ( (cis) -3-hydroxycyclobutyl) sulfamoyl) -2-methoxybenzamide
[0534]
LC-MS (ESI) : mass calcd. for C 19H 19F 3N 2O 5S 444.10, m/z found 445.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.48 (br. s, 1H) , 8.08 (dd, J = 2.4 Hz, J = 6.0 Hz, 1H) , 7.96 (d, J = 2.4 Hz, 1H) , 7.92 -7.80 (m, 3H) , 7.43 -7.10 (m, 3H) , 5.03 (d, J = 5.6 Hz, 1H) , 3.96 (s, 3H) , 3.70 -3.60 (m, 1H) , 3.15 -3.05 (m, 1H) , 2.30 -2.18 (m, 2H) , 1.62 -1.50 (m, 2H) .
[0535]
Compound 143a: N- (4-chloro-2-fluorophenyl) -5- (N- ( (trans) -3-hydroxycyclobutyl) sulfamoyl) -2 -methoxybenzamide
[0536]
LC-MS (ESI) : mass calcd. for C 18H 18ClFN 2O 5S 428.06, m/z found 429.0 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.23 (br. s, 1H) , 8.21 (d, J = 2.8 Hz, 1H) , 8.11 (t, J = 8.8 Hz, 1H) , 7.96 -7.88 (m, 2H) , 7.59 (dd, J = 2.4 Hz, J = 10.4 Hz, 1H) , 7.43 (d, J = 9.2 Hz, 1H) , 7.36 -7.30 (m, 1H) , 4.96 (d, J = 4.8 Hz, 1H) , 4.15 -4.09 (m, 1H) , 4.05 (s, 3H) , 3.76 -3.65 (m, 1H) , 2.00 -1.85 (m, 4H) .
[0537]
Compound 143b: N- (4-chloro-2-fluorophenyl) -5- (N- ( (cis) -3-hydroxycyclobutyl) sulfamoyl) -2- methoxybenzamide
[0538]
LC-MS (ESI) : mass calcd. for C 18H 18ClFN 2O 5S 428.06, m/z found 429.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ10.24 (br. s, 1H) , 8.23 (d, J = 2.0 Hz, 1H) , 8.11 (t, J = 8.8 Hz, 1H) , 7.96 -7.88 (m, 2H) , 7.59 (dd, J = 2.0 Hz, J = 10.4 Hz, 1H) , 7.43 (d, J = 8.8 Hz, 1H) , 7.36 -7.30 (m, 1H) , 5.03 (d, J = 5.2 Hz, 1H) , 4.05 (s, 3H) , 3.70 -3.60 (m, 1H) , 3.15 -3.05 (m, 1H) , 2.30 -2.18 (m, 2H) , 1.62 -1.50 (m, 2H) .
[0539]
Compound 144a: N- (2-chloro-4-fluorophenyl) -5- (N- ( (trans) -3-hydroxycyclobutyl) sulfamoyl) -2- methoxybenzamide
[0540]
LC-MS (ESI) : mass calcd. for C 18H 18ClFN 2O 5S 428.06, m/z found 429.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) 10.38 (br. s, 1H) , 8.37 (d, J = 2.8 Hz, 1H) , 8.29 (dd, J = 5.6 Hz, J = 8.8 Hz, 1H) , 8.00 -7.90 (m, 2H) , 7.62 (dd, J = 2.8 Hz, J = 8.4 Hz, 1H) , 7.48 (d, J = 8.8 Hz, 1H) , 7.31 (td, J = 2.8 Hz, J = 8.8 Hz, 1H) , 4.94 (d, J = 4.8 Hz, 1H) , 4.13 (s, 3H) , 4.16 -4.06 (m, 1H) , 3.76 -3.65 (m, 1H) , 2.00 -1.85 (m, 4H) .
[0541]
Compound 144b: N- (2-chloro-4-fluorophenyl) -5- (N- ( (cis) -3-hydroxycyclobutyl) sulfamoyl) -2- methoxybenzamide
[0542]
LC-MS (ESI) : mass calcd. for C 18H 18ClFN 2O 5S 428.06, m/z found 429.0 [M+H] +. 1H NMR (400MHz, DMSO-d 6) 10.38 (br. s, 1H) , 8.39 (d, J = 2.8 Hz, 1H) , 8.29 (dd, J = 2.0 Hz, J = 9.2 Hz, 1H) , 8.00 -7.85 (m, 2H) , 7.62 (dd, J = 2.8 Hz, J = 8.4 Hz, 1H) , 7.47 (d, J = 8.8 Hz, 1H) , 7.31 (td, J = 2.8 Hz, J = 8.8 Hz, 1H) , 5.02 (d, J = 5.6 Hz, 1H) , 4.13 (s, 3H) , 3.70 -3.60 (m, 1H) , 3.16 -3.06 (m, 1H) , 2.30 -2.18 (m, 2H) , 1.62 -1.50 (m, 2H) .
[0543]
Compound 145a: N- (2, 4-difluorophenyl) -5- (N- ( (trans) -3-hydroxycyclobutyl) sulfamoyl) -2 -methoxybenzamide
[0544]
LC-MS (ESI) : mass calcd. for C 18H 18F 2N 2O 5S 412.09, m/z found 413.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.12 (br. s, 1H) , 8.19 (d, J = 2.4 Hz, 1H) , 8.04 -7.86 (m, 3H) , 7.45 -7.35 (m, 2H) , 7.19 -7.10 (m, 1H) , 4.95 (d, J = 4.8 Hz, 1H) , 4.16 -4.06 (m, 1H) , 4.04 (s, 3H) , 3.75 -3.65 (m, 1H) , 2.00 -1.82 (m, 4H) .
[0545]
Compound 145b: N- (2, 4-difluorophenyl) -5- (N- ( (cis) -3-hydroxycyclobutyl) sulfamoyl) -2- methoxybenzamide
[0546]
LC-MS (ESI) : mass calcd. for C 18H 18F 2N 2O 5S 412.09, m/z found 413.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ10.12 (br. s, 1H) , 8.22 (d, J = 2.8 Hz, 1H) , 8.04 -7.86 (m, 3H) , 7.45 -7.35 (m, 2H) , 7.19 -7.10 (m, 1H) , 5.03 (d, J = 5.6 Hz, 1H) , 4.04 (s, 3H) , 3.70 -3.60 (m, 1H) , 3.15 -3.05 (m, 1H) , 2.30 -2.18 (m, 2H) , 1.62 -1.50 (m, 2H) .
[0547]
Compound 146a: N- (2-chloro-5-fluorophenyl) -5- (N- ( (trans) -3-hydroxycyclobutyl) sulfamoyl) -2- methoxybenzamide
[0548]
LC-MS (ESI) : mass calcd. for C 18H 18ClFN 2O 5S 428.06, m/z found 429.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.62 (br. s, 1H) , 8.44 (d, J = 2.4 Hz, 1H) , 8.33 (dd, J = 3.2 Hz, J = 11.2 Hz, 1H) , 8.04 -7.94 (m, 2H) , 7.68 -7.60 (m, 1H) , 7.51 (d, J = 8.8 Hz, 1H) , 7.15 -7.05 (m, 1H) , 4.95 (d, J = 5.2 Hz, 1H) , 4.16 (s, 3H) , 4.15 -4.05 (m, 1H) , 3.78 -3.65 (m, 1H) , 2.00 -1.85 (m, 4H) .
[0549]
Compound 146b: N- (2-chloro-5-fluorophenyl) -5- (N- ( (cis) -3-hydroxycyclobutyl) sulfamoyl) -2- methoxybenzamide
[0550]
LC-MS (ESI) : mass calcd. for C 18H 18ClFN 2O 5S 428.06, m/z found 429.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.63 (br. s, 1H) , 8.45 (d, J = 2.4 Hz, 1H) , 8.33 (dd, J = 2.8 Hz, J = 11.2 Hz, 1H) , 8.02 -7.92 (m, 2H) , 7.70 -7.62 (m, 1H) , 7.50 (d, J = 8.8 Hz, 1H) , 7.15 -7.05 (m, 1H) , 5.03 (d, J = 5.6 Hz, 1H) , 4.17 (s, 3H) , 3.70 -3.60 (m, 1H) , 3.15 -3.05 (m, 1H) , 2.30 -2.18 (m, 2H) , 1.62 -1.50 (m, 2H) .
[0551]
Compound 147a: (S) -N- (2, 4-Difluorophenyl) -2-methoxy-5- (N- (1- (2-methoxyethoxy) propan-2 -yl) sulfamoyl) benzamide
[0552]
LC-MS (ESI) : RT = 5.06 min, mass calcd. for C 20H 24F 2N 2O 6S 458.13, m/z found 459.1 [M+H] +, 1H NMR (400MHz, DMSO-d 6) δ 10.12 (s, 1H) , 8.26 (d, J = 2.0 Hz, 1H) , 8.04 -7.94 (m, 2H) , 7.72 (s, 1H) , 7.47 -7.35 (m, 2H) , 7.15 (t, J = 8.3 Hz, 1H) , 4.05 (s, 3H) , 3.41 -3.38 (m, 2H) , 3.36 -3.31 (m, 2H) , 3.31 -3.23 (m, 2H) , 3.20 (s, 3H) , 3.18 -3.13 (m, 1H) , 0.93 (d, J = 6.0 Hz, 3H) .
[0553]
Compound 147b: (R) -N- (2, 4-Difluorophenyl) -2-methoxy-5- (N- (1- (2-methoxyethoxy) propan-2 -yl) sulfamoyl) benzamide
[0554]
LC-MS (ESI) : mass calcd. for C 20H 24F 2N 2O 6S 458.13, m/z found 459.1 [M+H] +; 1H NMR (400MHz, DMSO-d 6) δ 10.12 (s, 1H) , 8.26 (d, J = 2.4 Hz, 1H) , 8.05 -7.93 (m, 2H) , 7.71 (d, J = 6.8 Hz, 1H) , 7.46 -7.34 (m, 2H) , 7.14 (t, J = 8.2 Hz, 1H) , 4.04 (s, 3H) , 3.39 -3.36 (m, 2H) , 3.36 -3.31 (m, 2H) , 3.31 -3.22 (m, 2H) , 3.20 (s, 3H) , 3.18 -3.13 (m, 1H) , 0.92 (d, J = 6.4 Hz, 3H) .
[0555]
Compound 148: N- (2, 4-Difluorophenyl) -2-methoxy-5-sulfamoylbenzamide
[0556]
LC-MS (ESI) : R T = 4.23 min, mass calcd. for C 14H 12F 2N 2O 4S 342.05, m/z found 343.0 [M+H] +, 1H NMR (400MHz, DMSO-d 6) δ 10.12 (s, 1H) , 8.28 (d, J = 2.5 Hz, 1H) , 8.03 -7.93 (m, 2H) , 7.45 -7.35 (m, 4H) , 7.18 -7.10 (m, 1H) , 4.03 (s, 3H) .
[0557]
Compound 149: (S) -2-Methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) -N- (2- (trifluoromethyl) phenyl) benzamide
[0558]
LC-MS (ESI) : mass calcd. for C 19H 19F 3N 2O 5S 444.10, m/z found 445.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.24 (br. s, 1H) , 8.40 (d, J = 2.0 Hz, 1H) , 8.11 (d, J = 8.0 Hz, 1H) , 8.01 (dd, J = 8.0 Hz, J = 2.0 Hz, 2H) , 7.80 (d, J = 8.0 Hz, 1H) , 7.75 (t, J = 8.0 Hz, 1H) , 7.53 -7.40 (m, 2H) , 4.08 (s, 3H) , 3.75 -3.64 (m, 2H) , 3.63 -2.53 (m, 2H) , 3.43 -3.35 (m, 1H) , 1.94 -1.84 (m, 1H) , 1.65-1.54 (m, 1H) .
[0559]
Compound 150: (S) -2-Methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) -N- (2- (trifluoromethoxy) phenyl) benzamide
[0560]
LC-MS (ESI) : mass calcd. for C 19H 19F 3N 2O 6S 460.09, m/z found 461.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.31 (br. s, 1H) , 8.43 -8.30 (m, 2H) , 8.06 -7.96 (m, 2H) , 7.50 (d, J = 8.0 Hz, 2H) , 7.45 (d, J = 8.0 Hz, 1H) , 7.30 (t, J = 8.0 Hz, 1H) , 4.10 (s, 3H) , 3.75 -3.64 (m, 2H) , 3.63 -2.53 (m, 2H) , 3.43 -3.35 (m, 1H) , 1.94 -1.84 (m, 1H) , 1.65 -1.54 (m, 1H) .
[0561]
Compound 151: (S) -N- (2-Cyclopropylphenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0562]
LC-MS (ESI) : mass calcd. for C 21H 24N 2O 5S 416.14, m/z found 417.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.12 (s, 1H) , 8.40 (d, J = 2.5 Hz, 1H) , 8.06 (d, J = 8.0 Hz, 1H) , 8.01 -7.95 (m, 2H) , 7.47 (d, J = 9.0 Hz, 1H) , 7.28 -7.21 (m, 1H) , 7.17 -7.08 (m, 2H) , 4.08 (s, 3H) , 3.74 -3.55 (m, 4H) , 3.40 -3.37 (m, 1H) , 2.05 -1.85 (m, 2H) , 1.71 -1.57 (m, 1H) , 1.04 -0.96 (m, 2H) , 0.72 -0.62 (m, 2H) .
[0563]
Compound 152: N- (4-Fluorophenyl) -5- (N- ( (trans) -3-hydroxycyclobutyl) sulfamoyl) -2- methoxybenzamide
[0564]
LC-MS (ESI) : mass calcd. for C 18H 19FN 2O 5S 394.10, m/z found 395.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.29 (br. s, 1H) , 7.95 (d, J = 2.0 Hz, 1H) , 7.91 -7.82 (m, 2H) , 7.78 -7.70 (m, 2H) , 7.36 (d, J = 8.8 Hz, 1H) , 7.20 (t, J = 8.8 Hz, 2H) , 4.95 (d, J = 5.2 Hz, 1H) , 4.17 -4.09 (m, 1H) , 3.96 (s, 3H) , 3.74 -3.66 (m, 1H) , 2.02 -1.84 (m, 4H) .
[0565]
Compound 153: N- (4-Fluorophenyl) -5- (N- ( (cis) -3-hydroxycyclobutyl) sulfamoyl) -2-methoxy benzamide
[0566]
LC-MS (ESI) : mass calcd. for C 18H 19FN 2O 5S 394.10, m/z found 395.1 [M+H] +. 1H NMR (400MHz, DMSO-d6) δ 10.29 (br. s, 1H) , 7.97 (d, J = 2.4 Hz, 1H) , 7.91 -7.81 (m, 2H) , 7.78 -7.71 (m, 2H) , 7.36 (d, J = 9.2 Hz, 1H) , 7.20 (t, J = 8.8 Hz, 2H) , 5.03 (d, J = 5.6 Hz, 1H) , , 3.97 (s, 3H) , 3.70 -3.61 (m, 1H) , 3.14 -3.04 (m, 1H) , 2.28 -2.18 (m, 2H) , 1.63 -1.52 (m, 2H) .
[0567]
Compound 154: N- (2-Chlorophenyl) -5- (N- ( (trans) -3-hydroxycyclobutyl) sulfamoyl) -2-methoxy benzamide
[0568]
LC-MS (ESI) : mass calcd. for C 18H 19ClN 2O 5S 410.07, m/z found 411.0 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.49 (br. s, 1H) , 8.43 (d, J = 2.0 Hz, 1H) , 8.39 (d, J = 8.4 Hz, 1H) , 8.00 -7.93 (m, 2H) , 7.60 (dd, J = 8.0 Hz, J = 1.6 Hz, 1H) , 7.50 (d, J = 9.2 Hz, 1H) , 7.42 (t, J = 7.6 Hz, 1H) , 7.25 -7.19 (m, 1H) , 4.96 (d, J = 5.2 Hz, 1H) , 4.16 (s, 3H) , 4.14 -4.09 (m, 1H) , 3.78 -3.69 (m, 1H) , 2.01 –1.93 (m, 2H) , 1.93 –1.85 (m, 2H) .
[0569]
Compound 155: N- (2-Chlorophenyl) -5- (N- ( (cis) -3-hydroxycyclobutyl) sulfamoyl) -2-methoxy benzamide
[0570]
LC-MS (ESI) : mass calcd. for C 18H 19ClN 2O 5S 410.07, m/z found 411.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.49 (br. s, 1H) , 8.45 (d, J = 2.4 Hz, 1H) , 8.40 (d, J = 8.0 Hz, 1H) , 8.01-7.90 (m, 2H) , 7.60 (dd, J = 8.0 Hz, J = 1.2 Hz, 1H) , 7.49 (d, J = 9.2 Hz, 1H) , 7.42 (t, J = 7.6 Hz, 1H) , 7.25 -7.19 (m, 1H) , 5.02 (d, J = 5.2 Hz, 1H) , 4.16 (s, 3H) , 3.72 -3.61 (m, 1H) , 3.19 -3.03 (m, 1H) , 2.29 -2.19 (m, 2H) , 1.64 -1.52 (m, 2H) .
[0571]
Compound 156: N- (5-Fluoropyridin-2-yl) -5- (N- ( (trans) -3-hydroxycyclobutyl) sulfamoyl) -2- methoxybenzamide
[0572]
LC-MS (ESI) : mass calcd. for C 17H18FN 3O 5S 395.10, m/z found 396.1 [M+H] +, 1H NMR (400MHz, DMSO-d 6) δ 10.68 (br. s, 1H) , 8.39 (d, J = 2.8 Hz, 1H) , 8.32 -8.24 (m, 1H) , 8.13 (d, J = 2.4 Hz, 1H) , 7.93 -7.87 (m, 2H) , 7.86 -7.80 (m, 1H) , 7.41 (d, J = 8.8 Hz, 1H) , 4.95 (d, J = 4.8 Hz, 1H) , 4.16 -4.09 (m, 1H) , 4.02 (s, 3H) , 3.75 -3.67 (m, 1H) , 2.01 –1.93 (m, 2H) , 1.92 -1.85 (m, 2H) .
[0573]
Compound 157: N- (5-Fluoropyridin-2-yl) -5- (N- ( (cis) -3-hydroxycyclobutyl) sulfamoyl) -2- methoxybenzamide
[0574]
LC-MS (ESI) : mass calcd. for C 17H18FN 3O 5S 395.10, m/z found 396.1 [M+H] +, 1H NMR (400MHz, DMSO-d 6) δ 10.68 (br. s, 1H) , 8.39 (d, J = 2.8 Hz, 1H) , 8.32 -8.25 (m, 1H) , 8.15 (d, J = 2.4 Hz, 1H) , 7.95 -7.79 (m, 3H) , 7.40 (d, J = 8.8 Hz, 1H) , 5.02 (d, J = 5.6 Hz, 1H) , 4.03 (s, 3H) , 3.71 -3.59 (m, 1H) , 3.15 -3.04 (m, 1H) , 2.28 -2.18 (m, 2H) , 1.63 -1.52 (m, 2H) .
[0575]
Compound 158: (S) -N- (4-Fluorophenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0576]
LC-MS (ESI) : mass calcd. for C 18H 19FN 2O 5S 394.10, m/z found 395.1 [M+H] +, 1H NMR (400MHz, DMSO-d 6) δ 10.30 (br. s, 1H) , 8.00 (d, J = 2.5 Hz, 1H) , 7.96 -7.84 (m, 2H) , 7.80 -7.70 (m, 2H) , 7.38 (d, J = 8.8 Hz, 1H) , 7.20 (t, J = 9.0 Hz, 2H) , 3.97 (s, 3H) , 3.74 -3.65 (m, 2H) , 3.64-3.55 (m, 2H) , 3.39 -3.37 (m, 1H) , 1.96 -1.85 (m, 1H) , 1.68 -1.57 (m, 1H) .
[0577]
Compound 159: (S) -2-Methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) -N- (m-tolyl) benzamide
[0578]
LC-MS (ESI) : mass calcd. for C 19H 22N 2O 5S 390.12, m/z found 391.1 [M+H] +, 1H NMR (400MHz, DMSO-d 6) δ 10.17 (br. s, 1H) , 8.00 (d, J = 2.3 Hz, 1H) , 7.95-7.88 (m, 2H) , 7.55-7.53 (m, 2H) , 7.38 (d, J = 8.8 Hz, 1H) , 7.23 (t, J = 7.8 Hz, 1H) , 6.94 (d, J =7.5 Hz, 1H) , 3.97 (s, 3H) , 3.74-3.66 (m, 2H) , 3.65-3.56 (m, 2H) , 3.40-3.35 (m, 1H) , 2.31 (s, 3H) , 1.97-1.83 (m, 1H) , 1.72-1.54 (m, 1H) .
[0579]
Compound 160: (S) -N- (4-Fluoro-3- (trifluoromethyl) phenyl) -2-methoxy-5- (N- (tetrahydrofuran- 3-yl) sulfamoyl) benzamide
[0580]
LC-MS (ESI) : mass calcd. for C 19H 18F 4N 2O 5S 462.09, m/z found 463.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.60 (br. s, 1H) , 8.26-8.20 (m, 1H) , 8.04-7.90 (m, 4H) , 7.54 (t, J = 9.8 Hz, 1H) , 7.40 (d, J = 8.8 Hz, 1H) , 3.97 (s, 3H) , 3.74 -3.66 (m, 2H) , 3.65 -3.55 (m, 2H) , 3.39 -3.36 (m, 1H) , 1.96 -1.85 (m, 1H) , 1.69 -1.57 (m, 1H) .
[0581]
Compound 161 (S) -N- (5-Fluoro-4-methylpyridin-2-yl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0582]
LC-MS (ESI) : mass calcd. for C 18H 20FN 3O 5S 409.11, m/z found 410.1 [M+H] +, 1H NMR (400MHz, DMSO-d 6) δ 10.60 (br. s, 1H) , 8.27 (s, 1H) , 8.19 (d, J = 4.8 Hz, 1H) , 8.15 (d, J = 2.0 Hz, 1H) , 7.96 (d, J = 2.0 Hz, 1H) , 7.94 (d, J = 2.4 Hz, 1H) , 7.42 (d, J = 8.4 Hz, 1H) , 4.02 (s, 3H) , 3.73 -3.64 (m, 2H) , 3.64 -3.55 (m, 2H) , 3.39 -3.38 (m, 1H) , 2.34 (s, 3H) , 1.96 -1.85 (m, 1H) , 1.67 -1.59 (m, 1H) .
[0583]
Compound 162: (S) -N- (6-Cyclopropyl-5-fluoropyridin-2-yl) -2-methoxy-5- (N- (tetrahydrofuran- 3-yl) sulfamoyl) benzamide
[0584]
LC-MS (ESI) : mass calcd. for C 20H 22FN 3O 5S 435.13, m/z found 436.0 [M+H] +, 1H NMR (400MHz, DMSO-d 6) δ 10.50 (br. s, 1H) , 8.11 (s, 1H) , 8.02-7.87 (m, 3H) , 7.68 (t, J = 9.2 Hz, 1H) , 7.40 (d, J = 8.8 Hz, 1H) , 4.00 (s, 3H) , 3.73 -3.64 (m, 2H) , 3.64 -3.54 (m, 2H) , 3.42 -3.38 (m, 1H) , 2.25 –2.23 (m, 1H) , 1.96 -1.83 (m, 1H) , 1.67 -1.55 (m, 1H) , 1.07 -0.97 (m, 4H) .
[0585]
Compound 163: (S) -2-Methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) -N- (o-tolyl) benzamide
[0586]
LC-MS (ESI) : mass calcd. for C 19H 22N 2O 5S 390.12, m/z found 391.1 [M+H] +, 1H NMR (400MHz, DMSO-d 6) δ 9.87 (br. s, 1H) , 8.29 (s, 1H) , 8.02 -7.92 (m , 2H) , 7.84 (d, J = 7.6 Hz, 1H) , 7.46 (d, J = 8.8 Hz, 1H) , 7.33 -7.21 (m, 2H) , 7.14 (t, J = 7.2 Hz, 1H) , 4.09 (s, 3H) , 3.75 -3.55 (m, 4H) , 3.38 -3.30 (m, 1H) , 2.33 (s, 3H) , 1.97 -1.85 (m, 1H) , 1.69 -1.59 (m, 1H) .
[0587]
Compound 164: (S) -N- (2-Cyanophenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0588]
LC-MS (ESI) : mass calcd. for C 19H 19N 3O 5S 401.10, m/z found 402.1 [M+H] +, 1H NMR (400MHz, DMSO-d 6) δ 10.61 (br. s, 1H) , 8.37 (br. s, 1H) , 8.21 (d, J = 8.4 Hz, 1H) , 8.06 -7.97 (m, 2H) , 7.89 (d, J = 7.2 Hz, 1H) , 7.77 (t, J = 7.6 Hz, 1H) , 7.49 (d, J = 8.8 Hz, 1H) , 7.38 (t, J = 7.6 Hz, 1H) , 4.12 (s, 3H) , 3.74 -3.56 (m, 4H) , 3.39 -3.35 (m, 1H) , 1.95 -1.85 (m, 1H) , 1.68 -1.58 (m, 1H) .
[0589]
Compound 165: (S) -2-Methoxy-N- (pyrimidin-4-yl) -5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0590]
LC-MS (ESI) : mass calcd. for C 16H 18N 4O 5S 378.10, m/z found 379.1 [M+H] +, 1H NMR (400MHz, DMSO-d 6) δ 10.97 (br. s, 1H) , 8.94 (br. s, 1H) , 8.75 (d, J = 5.6 Hz, 1H) , 8.21 (d, J = 5.6 Hz, 1H) , 8.10 (d, J = 1.6 Hz, 1H) , 8.01 -7.91 (m, 2H) , 7.42 (d, J = 8.8 Hz, 1H) , 4.01 (s, 3H) , 3.74 -3.66 (m, 2H) , 3.65 -3.56 (m, 2H) , 3.39 -3.36 (m, 1H) , 1.97 -1.85 (m, 1H) , 1.69 -1.57 (m, 1H) .
[0591]
Compound 166: (S) -2-Methoxy-N- (2-methoxyphenyl) -5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0592]
LC-MS (ESI) : mass calcd. for C 19H 22N 2O 6S 406.12, m/z found 407.1 [M+H] +, 1H NMR (400MHz, DMSO-d 6) δ 10.58 (br. s, 1H) , 8.52 (d, J = 2.4 Hz, 1H) , 8.44 (d, J = 8.0 Hz, 1H) , 8.04 -7.96 (m, 2H) , 7.50 (d, J = 8.8 Hz, 1H) , 7.12 (d, J = 3.6 Hz, 2H) , 7.03 -6.96 (m, 1H) , 4.18 (s, 3H) , 3.97 (s, 3H) , 3.73 -3.65 (m, 2H) , 3.64 -3.54 (m, 2H) , 3.38 -3.35 (m, 1H) , 1.94 -1.84 (m, 1H) , 1.66 -1.57 (m, 1H) .
[0593]
Compound 167: (S) -N- (3- (Difluoromethyl) -4-fluorophenyl) -2-methoxy-5- (N- (tetrahydrofuran- 3-yl) sulfamoyl) benzamide
[0594]
LC-MS (ESI) : mass calcd. for C 19H 19F 3N 2O 5S 444.10, m/z found 445.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.48 (br. s, 1H) , 8.07 (d, J = 2.0 Hz, 1H) , 8.03 -7.97 (m, 1H) , 7.96 -7.88 (m, 2H) , 7.86 -7.82 (m, 1H) , 7.43 -7.35 (m, 2H) , 7.40 -7.07 (m, 1H) , 3.97 (s, 3H) , 3.75 -3.65 (m, 2H) , 3.65 -3.55 (m, 2H) , 3.40 -3.35 (m, 1H) , 1.95 -1.85 (m, 1H) , 1.70 -1.55 (m, 1H) .
[0595]
Compound 168: N- (5-fluoro-6-methylpyridin-2-yl) -2-methoxy-5- (N- (1- (trifluoromethyl) cyclopropyl) sulfamoyl) benzamide
[0596]
[0597]
3- ( (5-fluoro-6-methylpyridin-2-yl) carbamoyl) -4-methoxybenzene-1-sulfonyl chloride (200 mg, 0.557 mmol) was added to a solution consisting of 1- (trifluoromethyl) cyclopropan-1-amine and pyridine (2 mL) at 0 ℃. The mixture was stirred overnight at 20 ℃. The mixture was concentrated to dryness to give a residue which was purified by flash column chromatography over silica gel (eluent: petroleum ether: ethyl acetate from 100: 0 to 50: 50) to give the title compound (100 mg, purity 99.99%, 40%yield) . LC-MS (ESI) : RT = 4.89 min, mass calcd. for C 18H 17F 4N 3O 4S 447.09, m/z found 448.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.60 (s, 1H) , 9.14 (br. s., 1H) , 8.18 -8.03 (m, 2H) , 7.90 (dd, J = 2.0, 8.5 Hz, 1H) , 7.72 (t, J = 9.0 Hz, 1H) , 7.40 (d, J = 9.0 Hz, 1H) , 4.02 (s, 3H) , 2.41 (d, J = 2.0 Hz, 3H) , 1.21 -1.12 (m, 2H) , 1.07 -0.96 (m, 2H) .
[0598]
Synthetic routes for compound 168-170
[0599]
[0600]
Intermediate 169.2: (tert) -Butyl 3- (3- ( (5-fluoro-6-methylpyridin-2-yl) carbamoyl) -4-methoxy phenylsulfonamido) azetidine-1-carboxylate
[0601]
3- ( (5-Fluoro-6-methylpyridin-2-yl) carbamoyl) -4-methoxybenzene-1-sulfonyl chloride (600 mg, 1.34 mmol, purity 80%) was dissolved in dry DCM (5 mL) . tert-Butyl 3-aminoazetidine-1-carboxylate (461 mg, 2.68 mmol) and TEA (406 mg, 4.01 mmol) were added to the above mixture at 20 ℃. The mixture was stirred at 20 ℃ for 1 h. The resultant mixture was extracted with ethyl acetate (5 mL x 3) . The combined organic layers were concentrated to dryness. The residue was purified by flash column chromatography over silica gel (eluent: petroleum ether: ethyl acetate from 100: 0 to 0: 100) to afford the title compound (500 mg, 64%yield, purity 85%) . LC-MS (ESI) : RT = 0.78 min, mass calcd. for C 22H 27FN 4O 6S 494.16, m/z found 495.0 [M+H] +.
[0602]
Compound 169: 5- (N- (Azetidin-3-yl) sulfamoyl) -N- (5-fluoro-6-methylpyridin-2-yl) -2-Methoxy benzamide
[0603]
tert-Butyl-3- (3- ( (5-fluoro-6-methylpyridin-2-yl) carbamoyl) -4-methoxyphenylsulfonamido) azetidine-1-carboxylate was dissolved in HCl/dioxane (4N, 10 mL) . The reaction was stirred at 20 ℃ for 12 h before concentrating it to dryness. The mixture was adjusted to pH 7~8 with saturated aq. Na 2CO 3. Water (10 mL) was added. The precipitate was collected, dried and then recrystallized from DMF (20 mL) to afford the title compound (300 mg, 85%yield) .
[0604]
LC-MS (ESI) : RT = 4.05 min, mass calcd. for C 17H 19FN 4O 4S 394.11, m/z found 395.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.63 (s, 1H) , 9.38 (br. s., 1H) , 8.87 (br. s., 1H) , 8.12 -8.05 (m, 2H) , 7.94 (dd, J = 2.5, 8.8 Hz, 1H) , 7.71 (t, J = 9.0 Hz, 1H) , 7.41 (d, J = 8.8 Hz, 1H) , 4.13 (d, J = 7.0 Hz, 1H) , 4.00 (s, 3H) , 3.88 -3.81 (m, 2H) , 3.79 -3.71 (m, 2H) , 2.40 (d, J = 2.8 Hz, 3H) .
[0605]
Compound 170: N- (5-Fluoro-6-methylpyridin-2-yl) -2-methoxy-5- (N- (1-methylazetidin-3-yl) sulfamoyl) benzamide
[0606]
5- (N- (Azetidin-3-yl) sulfamoyl) -N- (5-fluoro-6-methylpyridin-2-yl) -2-methoxybenzamide (120 mg, 0.304 mmol) was dissolved in methanol (2 mL) in a 50 mL round-bottomed flask and then treated with formaldehyde (49.3 mg, 0.608 mmol, w/w 37%) . The mixture was stirred at 20 ℃ for 30 minutes before NaBH 3CN (57.3 mg, 0.912 mmol) was added. The reaction mixture was stirred at room temperature for 1 h and then concentrated to dryness under reduced pressure. Ethyl acetate (20mL) was added. The resultant mixture was washed with water (20mL) , brine (20mL) , dried over Na 2SO 4 and filtered. The filtrate was concentrated to dryness to give a residue which was further purified by prep. HPLC (Waters Xbridge Prep OBD C18 150mm*30mm, 5um (eluent: CH 3CN/H 2O (10mM NH 4HCO 3-ACN) from 25%to 55%, flow rate: 30 ml/min) to afford the title compound (14.2 mg, 11%yield) .
[0607]
LC-MS (ESI) : RT = 3.89 min, mass calcd. for C 18H 21FN 4O 4S 408.13, m/z found 409.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.61 (s, 1H) , 8.18 (br. s., 1H) , 8.09 (d, J = 2.3 Hz, 2H) , 7.90 (dd, J = 2.5, 8.8 Hz, 1H) , 7.72 (t, J = 9.0 Hz, 1H) , 7.38 (d, J = 9.0 Hz, 1H) , 4.01 (s, 3H) , 3.69 (br. s., 1H) , 3.33 -3.30 (m, 2H) , 2.65 (t, J = 7.5 Hz, 2H) , 2.41 (d, J = 2.8 Hz, 3H) , 2.13 (s, 3H) .
[0608]
Compound 171: (S) -N- (4-chloro-5-fluoro-6-methylpyrimidin-2-yl) -2-methoxy-5- (N- (tetrahydro furan-3-yl) sulfamoyl) benzamide
[0609]
[0610]
(S) -Methyl 2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzoate (300 mg, 0.95 mmol) and 4-chloro-5-fluoro-6-methylpyrimidin-2-amine (207 mg, 1.05 mmol) were dissolved in dry THF (5 mL) followed by the addition of trimethylaluminum (1.90 mL) drop-wise at 0 ℃. The reaction mixture was stirred at room temperature for 30 min and then quenched with saturated NH 4Cl (5 mL) . The organic phase was separated, dried over Na 2SO 4 and filtered. The filtrate was concentrated under reduced pressure to give a residue which was purified by prep. TLC to give the title compound (39.10 mg, yield: 9.25%) as a pale-yellow solid.
[0611]
LC-MS (ESI) : R T = 4.18 min, mass calcd. for C 17H 18ClFN 4O 5S 444.07, m/z found 445.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 11.15 (br. s, 1H) , 8.07 -7.73 (m, 3H) , 7.32 (d, J = 7.2 Hz, 1H) , 3.88 (s, 3H) , 3.75 -3.64 (m, 2H) , 3.63 -2.53 (m, 2H) , 3.40 -3.35 (m, 1H) , 2.46 -2.36 (m, 3H) , 1.94 -1.84 (m, 1H) , 1.65 -1.54 (m, 1H) .
[0612]
Compound 172: (S) -N- (5-fluoro-4-methylpyrimidin-2-yl) -2-methoxy-5- (N- (tetrahydrofuran-3 -yl) sulfamoyl) benzamide:
[0613]
[0614]
(S) -N- (4-chloro-5-fluoro-6-methylpyrimidin-2-yl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide (300 mg, 0.67 mmol) and TEA (1 mL) were dissolved in MeOH (5 mL) followed by the addition of Pd/C (50 mg, 10%w/w) . The reaction mixture was stirred at room temperature for 16 hours under H 2 (30 psi) and then filtered. The filtrate was concentrated under reduced pressure to give a residue which was triturated with DCM (2~3 mL) . The solid was filtered and then dried in vacuum to give the title compound (47.50 mg, yield: 17.06%) as a brown solid.
[0615]
LC-MS (ESI) : R T = 3.67 min, mass calcd. for C 17H 19FN 4O 5S 410.11, m/z found 411.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.92 (br. s, 1H) , 8.59 (br. s, 1H) , 7.95 (d, J = 2.0 Hz, 1H) , 7.91 (dd, J = 8.8 Hz, J = 2.4 Hz, 2H) , 7.32 (d, J = 8.8 Hz, 1H) , 3.88 (s, 3H) , 3.75 -3.64 (m, 2H) , 3.63 -2.53 (m, 2H) , 3.40 -3.35 (m, 1H) , 2.46 -2.36 (m, 3H) , 1.94 -1.84 (m, 1H) , 1.65 -1.54 (m, 1H) .
[0616]
Compound 173: N- (2, 4-Difluoro-3-methylphenyl) -5- (N- ( (cis) -3-hydroxycyclobutyl) sulfamoyl) -2-methoxybenzamide
[0617]
[0618]
To a solution consisting of 2, 4-difluoro-3-methylaniline (95 mg, 0.664 mmol) , triethylamine (0.14 mL, 1.00 mmol) , HATU (252 mg, 0.664 mmol) and DCM (2 mL) was added 5- (N- ( (cis) -3-hydroxycyclobutyl) sulfamoyl) -2-methoxybenzoic acid (106 mg, 0.332 mmol) under 0 ℃. The reaction mixture was stirred at 25 ℃ for 3 h. The resulting mixture was concentrated. The residue was purified by prep. HPLC (eluent: CH 3CN/H 2O (0.05%HCl) from 37%to 77%, v/v) . The pure fractions were collected and the solvent was evaporated under vacuum. The aqueous layer was lyophilized to dryness to give title compound as a white powder (15.60 mg, 97.62%purity, 10.84%yield) .
[0619]
LC-MS (ESI) : R T = 4.84 min, mass calcd. for C 19H 20F 2N 2O 5S 426.1, m/z found 427.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.10 (s, 1H) , 8.23 (d, J = 2.0 Hz, 1H) , 7.98 -7.79 (m, 3H) , 7.42 (d, J = 9.0 Hz, 1H) , 7.10 (t, J = 9.3 Hz, 1H) , 5.03 (d, J = 5.5 Hz, 1H) , 4.05 (s, 3H) , 3.72 - 3.59 (m, 1H) , 3.16 -3.03 (m, 1H) , 2.28 -2.16 (m, 5H) , 1.65 -1.49 (m, 2H) .
[0620]
Compound 174a-174b
[0621]
[0622]
Intermediate 174.2: 6-Chloro-2- (difluoromethyl) -3-fluoropyridine
[0623]
To a solution consisting of 6-chloro-3-fluoropicolinaldehyde (1.0 g, 6.27 mmol) and DCM (20 mL) was added DAST (1.5 g, 9.32 mmol) at 0 ℃. The reaction was stirred at room temperature overnight. The reaction mixture was diluted with DCM (20 mL) and then quenched with sat. NaHCO 3 (20 mL) . The organic layer was separated, washed with brine (20 mL) , dried over Na 2SO 4 and filtered. The filtrate was concentrated to dryness to give compound the title compound (1 g, 88%yield) . 1H NMR (400MHz, CDCl 3) δ 7.56 -7.46 (m, 2H) , 6.71 (t, J = 53.2 Hz, 1H) .
[0624]
Intermediate 174.3: 6- (Difluoromethyl) -N- (diphenylmethylene) -5-fluoropyridin-2-amine
[0625]
6-Chloro-2- (difluoromethyl) -3-fluoropyridine (700 mg, 3.86 mmol) , diphenylmethanimine (1.40 g, 7.73 mmol) , Cs 2CO 3 (2.51 g, 7.70 mmol) , Pd (OAc) 2 (86 mg, 0.38 mmol) and BINAP (240 mg, 0.38 mmol) was suspended in dry dioxane (15 mL) . The resultant reaction mixture was stirred at 100 ℃ overnight under N 2. The mixture was then concentrated in vacuum. The residue was diluted with DCM (40 mL) and then filtered. The filtrate was concentrated to give the title compound (2.5 g, crude) as brown oil, which was used directly for next step.
[0626]
Preparation of Compound 174.4: 6- (Difluoromethyl) -5-fluoropyridin-2-amine
[0627]
HCl (1 M, 20 mL, 20 mmol) was added to a solution consisting of 6- (difluoromethyl) -N-(diphenylmethylene) -5-fluoropyridin-2-amine (2.5 g, crude) and THF (20 mL) . The mixture was stirred at 25 ℃ for 1 h before concentrating it to dryness. The residue was purified by prep-HPLC to give the title compound (600 mg) as a light yellow solid.
[0628]
Compoud 174a: N- (6- (Difluoromethyl) -5-fluoropyridin-2-yl) -5- (N- ( (trans) -3-hydroxycyclo butyl) sulfamoyl) -2-methoxybenzamide:
[0629]
Compoud 174b: N- (6- (Difluoromethyl) -5-fluoropyridin-2-yl) -5- (N- ( (cis) -3-hydroxycyclobutyl) sulfamoyl) -2-methoxybenzamide:
[0630]
To a solution consisting of methyl 5- (N- (3-hydroxycyclobutyl) sulfamoyl) -2-methoxybenzoate (200 mg, 0.634 mmol) , 6- (difluoromethyl) -5-fluoropyridin-2-amine (525 mg, 1.901 mmol) and dry dioxane (6 mL) was added Me 3Al (2 M solution, 1.9 mL, 3.8 mmol) drop-wise at 25 ℃. The mixture was stirred at 50 ℃ for 2 hrs. After cooling to room temperature, the mixture was quenched with water (0.5 mL) , then diluted with MeOH (20 mL) and filtered. The filtrate was concentrated to dryness. The residue was purified by prep-HPLC (NH 3. H 2O as additive) to give the racemic mixture as a white solid. The racemic mixture was separated by SFC (separation condition: Column: ChiralPak AD, Daicel Chemical Industries, Ltd, 250h 30mm I.D., 10-m; Mobile phase: A: Supercritical CO 2, B: ethanol (0.1%NH 3. H 2O) , A: B =75: 25 at 80mL/min; Column Temp: 38℃; Nozzle Pressure: 100Bar; Nozzle Temp: 60℃; Evaporator Temp: 20℃; Trimmer Temp: 25℃; Wavelength: 220nm) to give 174a (16.20 mg purity 96.8%, yield: 5.52%) and 174b (77.10 mg purity 99.9%, yield: 27.29%) .
[0631]
Analytic data of 174a: LC-MS (ESI) : R T = 4.33 min, mass calcd. for C 18H 18F 3N 3O 5S 445.09, m/z found 446.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.95 (br. s, 1H) , 8.47 -8.40 (m, 1H) , 8.08 -8.00 (m, 2H) , 7.90 -7.85 (m, 2H) , 7.38 (d, J = 8.8 Hz, 1H) , 7.11 (t, J = 52.8 Hz, 1H) , 4.95 (d, J = 5.2 Hz, 1H) , 4.16 -4.08 (m, 1H) , 3.99 (s, 3H) , 3.75 -3.65 (m, 1H) , 2.02 -1.85 (m, 4H) ;
[0632]
Analytic data of 174b: LC-MS (ESI) : R T = 4.54 min, mass calcd. for C 18H 18F 3N 3O 5S 445.09, m/z found 446.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.95 (br. s, 1H) , 8.47 -8.40 (m, 1H) , 8.08 -8.00 (m, 2H) , 7.93 -7.82 (m, 2H) , 7.38 (d, J = 8.8 Hz, 1H) , 7.11 (t, J = 53.2 Hz, 1H) , 5.02 (d, J = 5.6 Hz, 1H) , 3.99 (s, 3H) , 3.70 -3.60 (m, 1H) , 3.16 -3.04 (m, 1H) , 2.30 -2.20 (m, 2H) , 1.64 -1.52 (m, 2H) .
[0633]
Compound 175
[0634]
[0635]
Intermediate 175.2: (S) -tert-Butyl 3- (3- ( (5-fluoro-6-methylpyridin-2-yl) carbamoyl) -4- methoxyphenylsulfonamido) pyrrolidine-1-carboxylate
[0636]
3- ( (5-Fluoro-6-methylpyridin-2-yl) carbamoyl) -4-methoxybenzene-1-sulfonyl chloride (1.0 g, 2.23 mmol) was dissolved in dry DCM (10 mL) . (S) -tert-Butyl 3-aminopyrrolidine-1-carboxylate (498 mg, 2.68 mmol) and TEA (677 mg, 6.69 mmol) were added to the above mixture at 0 ℃. The mixture was stirred at 20 ℃ for 4 h. The mixture was washed with H 2O (20 mL) , dried over sodium sulfate, filtered and concentrated. The residue was purified by flash column over silica gel (gradient eluent: petroleum ether: ethyl acetate from 100: 0 to 0: 100) . The residue was crystallized from ethyl acetate to afford the title compound (600 mg, 50%yield) . LC-MS (ESI) : RT = 0.76 min, mass calcd. for C 23H 29FN 4O 6S 508.2, m/z found 509.2 [M+H] +.
[0637]
Compound 175: (S) -N- (5-Fluoro-6-methylpyridin-2-yl) -2-methoxy-5- (N- (pyrrolidin-3-yl) sulfamoyl) benzamide
[0638]
(S) -tert-Butyl-3- (3- ( (5-fluoro-6-methylpyridin-2-yl) carbamoyl) -4-methoxyphenylsulfonamido) pyrrolidine-1-carboxylate was dissloved in HCl/dioxane (10 mL) . The reaction was stirred at 20 ℃ for 4 h, the solvent was concentrated in vacuum. The residue was dissolved in DMSO (10 mL) . Aqueous Na 2CO 3 (1N) was added drop-wise with stirring till PH = 7 at 20 ℃. Then a white precipitate formed. The precipitate was filtered off and dried to afford the title compound (400 mg, 85%yield) .
[0639]
LC-MS (ESI) : RT = 3.60 min, mass calcd. for C 18H 21FN 4O 4S 408.1, m/z found 409.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.60 (s, 1H) , 8.16 -8.07 (m, 2H) , 7.93 (dd, J = 2.5, 8.8 Hz, 1H) , 7.72 (t, J = 9.0 Hz, 1H) , 7.40 (d, J = 9.0 Hz, 1H) , 4.02 (s, 3H) , 3.50 -3.42 (m, 1H) , 2.76 -2.66 (m, 2H) , 2.64 -2.55 (m, 2H) , 2.41 (d, J = 2.8 Hz, 3H) , 2.39 -2.31 (m, 2H) , 1.74 -1.64 (m, 1H) , 1.42 -1.34 (m, 1H) .
[0640]
Compound 176: (S) -N- (5-Fluoro-6-methylpyridin-2-yl) -2-methoxy-5- (N- (1-methylpyrrolidin -3-yl) sulfamoyl) benzamide
[0641]
[0642]
(S) -N- (5-Fluoro-6-methylpyridin-2-yl) -2-methoxy-5- (N- (pyrrolidin-3-yl) sulfamoyl) benzamide (150 mg, 0.367 mmol) was dissolved in methanol (5 mL) in a 50 mL round-bottomed flask and then treated with formaldehyde (59.6 mg, 0.74 mmol, purity 37%) . The mixture was stirred at 20 ℃ for 30 minutes. Sodium cyanotrihydroborate (34.6 mg, 0.55 mmol) was added to the mixture. The reaction mixture was stirred at room temperature for 1 h and concentrated to dryness under reduced pressure. The crude was crystallized from a mixture of DMSO: water =1: 2. The residue was purified by prep. HPLC (column: Synergi Max-RP 200mm*25mm, 4μm; mobile phase: CH 3CN in water (0.075%TFA water) from 18%to 48%, flow rate: 30 ml/min) . The pure fractions were collected and the volatiles were removed under vacuum. The aqueous phase was basified with 1M aqueous Na 2CO 3 till pH = 7. Ethyl acetate (50 mL) was added. The organic layer was separate and filtered. The filtrate was evaporated to dryness under vacuum to afford the title compound (79.8 mg, 52%yield) .
[0643]
LC-MS (ESI) : RT = 3.65 min, mass calcd. for C 19H 23FN 4O 4S 422.1, m/z found 423.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.56 (s, 1H) , 8.14 -8.02 (m, 2H) , 7.94 -7.82 (m, 2H) , 7.68 (t, J = 8.9 Hz, 1H) , 7.37 (d, J = 8.8 Hz, 1H) , 3.98 (s, 3H) , 3.65 -3.56 (m, 1H) , 2.68 -2.59 (m, 1H) , 2.54 -2.49 (m, 1H) , 2.45 -2.40 (m, 1H) , 2.37 (d, J = 2.4 Hz, 3H) , 2.33 -2.26 (m, 1H) , 2.22 (s, 3H) , 1.94 -1.83 (m, 1H) , 1.53 -1.42 (m, 1H) .
[0644]
Compound 177 to 181 were synthesized as similar procedure to compound 175
[0645]
Compound 177: (R) -N- (5-Fluoro-6-methylpyridin-2-yl) -2-methoxy-5- (N- (pyrrolidin-3-yl) sulfamoyl) benzamide
[0646]
LC-MS (ESI) : mass calcd. for C 18H 21FN 4O 4S 408.13, m/z found 409.1 [M+H] +; 1H NMR (400MHz, DMSO-d 6) δ 10.61 (s, 1H) , 8.14 (d, J = 2.5 Hz, 1H) , 8.09 (d, J = 8.3 Hz, 1H) , 7.96 (dd, J = 2.5, 8.8 Hz, 1H) , 7.72 (t, J = 9.0 Hz, 1H) , 7.43 (d, J = 9.0 Hz, 1H) , 4.02 (s, 3H) , 3.73 -3.65 (m, 2H) , 3.13 -3.02 (m, 4H) , 2.91 -2.84 (m, 1H) , 2.41 (d, J = 2.8 Hz, 3H) , 1.95 -1.84 (m, 1H) , 1.74 -1.64 (m, 1H) .
[0647]
Compound 178: (S) -N- (4-Fluorophenyl) -2-methoxy-5- (N- (pyrrolidin-3-yl) sulfamoyl) benzamide
[0648]
LC-MS (ESI) : mass calcd. for C 18H 20FN 3O 4S 393.12, m/z found 394.1 [M+H] +; 1H NMR (400MHz, DMSO-d 6) δ 10.30 (s, 1H) , 7.99 (s, 1H) , 7.91 (d, J = 8.8 Hz, 1H) , 7.74 (dd, J = 5.3, 8.5 Hz, 2H) , 7.37 (d, J = 8.8 Hz, 1H) , 7.20 (t, J = 8.8 Hz, 2H) , 3.96 (s, 3H) , 2.79 -2.70 (m, 2H) , 2.69 -2.59 (m, 1H) , 2.47 -2.37 (m, 2H) , 1.76 -1.65 (m, 1H) , 1.48 -1.35 (m, 1H) .
[0649]
Compound 179: (S) -N- (2-Chlorophenyl) -2-methoxy-5- (N- (pyrrolidin-3-yl) sulfamoyl) benzamide
[0650]
LC-MS (ESI) : mass calcd. for C 18H 20ClN 3O 4S 409.09, m/z found 410.1 [M+H] +; 1H NMR (400MHz, DMSO-d 6) δ 10.48 (s, 1H) , 8.45 (br. s., 1H) , 8.38 (d, J = 7.8 Hz, 1H) , 8.00 (d, J = 8.3 Hz, 1H) , 7.59 (d, J = 8.0 Hz, 1H) , 7.50 (d, J = 8.5 Hz, 1H) , 7.41 (t, J = 7.7 Hz, 1H) , 7.21 (t, J = 7.7 Hz, 1H) , 4.15 (s, 3H) , 3.55 -3.47 (m, 2H) , 2.82 -2.72 (m, 2H) , 2.70 -2.65 (m, 1H) , 1.78 -1.64 (m, 1H) , 1.47 -1.37 (m, 1H) .
[0651]
Compound 180: (R) -N- (4-Fluorophenyl) -2-methoxy-5- (N- (pyrrolidin-3-yl) sulfamoyl) benzamide
[0652]
LC-MS (ESI) : mass calcd. for C 18H 20FN 3O 4S 393.12, m/z found 394.1 [M+H] +; 1H NMR (400MHz, DMSO-d 6) δ 10.39 (s, 1H) , 8.06 (d, J = 1.8 Hz, 1H) , 7.99 (d, J = 8.8 Hz, 1H) , 7.81 (dd, J = 5.0, 8.8 Hz, 2H) , 7.44 (d, J = 8.8 Hz, 1H) , 7.26 (t, J = 8.8 Hz, 2H) , 4.03 (s, 3H) , 3.66 -3.58 (m, 1H) , 2.97 -2.86 (m, 2H) , 2.86 -2.77 (m, 1H) , 2.66 -2.57 (m, 1H) , 1.89 -1.78 (m, 1H) , 1.61 -1.51 (m, 1H) .
[0653]
Compound 181: (R) -N- (3- (Difluoromethyl) -4-fluorophenyl) -2-methoxy-5- (N- (pyrrolidin-3-yl) sulfamoyl) benzamide:
[0654]
LC-MS (ESI) : mass calcd. for C 19H 20F 3N 3O 4S 443.11, m/z found 444.11 [M+H] +; 1H NMR (400MHz, DMSO-d 6) δ 10.48 (s, 1H) , 8.11 -8.05 (m, 1H) , 8.03 -7.98 (m, 1H) , 7.97 -7.82 (m, 2H) , 7.43 -7.33 (m, 1) , 7.10 (s, 1H) , 3.97 (s, 3H) , 3.56 -3.49 (m, 3H) , 2.84 -2.75 (m, 2H) , 2.73 -2.65 (m, 1H) , 1.80 -1.65 (m, 1H) , 1.51 -1.39 (m, 1H) .
[0655]
Compound 182-188
[0656]
[0657]
Intermediate 182.2: (S) -tert-butyl 3- (4-methoxy-3- (methoxycarbonyl) phenylsulfonamido) pyrrolidine-1-carboxylate
[0658]
To a solution consisting of (S) -tert-butyl 3-aminopyrrolidine-1-carboxylate (10.0 g, 53.7 mmol) , TEA (22.5 mL, 161 mmol) and DCM (100 mL) was added methyl 5- (chlorosulfonyl) -2-methoxybenzoate (14.2 g, 53.7 mmol) at 0 ℃. The mixture was stirred at room temperature for 12 hours. Water (60 mL) was added. The aqueous layer was extracted with dichloromethane (80 mL*2) . The combined organic layers were washed with brine, dried over Na 2SO 4 and filtered. The filtrate was concentrated under reduced pressure to give a residue which was purified by silica gel chromatography (elute: petroleum ether: ethyl acetate = 3: 1) to give title compound (14.5 g, 58.6%yield) .
[0659]
Intermediate 182.3: (S) -tert-butyl 3- (3- ( (2, 4-difluorophenyl) carbamoyl) -4-methoxyphenyl sulfonamido) pyrrolidine-1-carboxylate
[0660]
To a solution consisting of (S) -tert-butyl 3- (4-methoxy-3- (methoxycarbonyl) phenylsulfonamido) pyrrolidine-1-carboxylate (200 mg, 0.483 mmol) ) , 2, 4-difluoroaniline (74.9 mg, 0.580 mmol) and THF (3 mL) was added LiHMDS (2.42 mL, 2.42 mmol) . The mixture was stirred at room temperature for 12 hours and then quenched with saturated ammonium chloride. The organic layer was separated and dried over Na 2SO 4 and filtered. The filtrate was concentrated under reduced pressure to give the title compound (250 mg, 78.1%yield) .
[0661]
Compound 182: (S) -N- (2, 4-difluorophenyl) -2-methoxy-5- (N- (pyrrolidin-3-yl) sulfamoyl) benzamide
[0662]
To a solution consisting of (S) -tert-butyl 3- (3- ( (2, 4-difluorophenyl) carbamoyl) -4-methoxyphenylsulfonamido) pyrrolidine-1-carboxylate (250 mg, 0.489 mmol) and ethyl acetate (3 mL) was added HCl/ethyl acetate (3 mL, 4N) . . The mixture was stirred at room temperature for 12 hours and then adjusted to pH 7 with saturated sodium bicarbonate. The aqueous layer was extracted with ethyl acetate (30 mL*2) . The combined organic layers were washed with brine, dried over Na 2SO 4 and filtered. The filtrate was concentrated under reduced pressure to give a residue which was purified by prep. HPLC (Column: Phenomenex Gemini C18 200*25mm*10um, Flow rate: 25 ml/min, Mobile Phase A: Base water (containing 0.05%NH 3. H 2O) , Mobile Phase B: Acetonitrile. ) . The desired fraction was collected and the volatile was removed under reduced pressure. The water phase was lyophilized to give the title compound (26.10 mg, 12.3 %yield) .
[0663]
LC-MS (ESI) : R T = 4.74 min, mass calcd. for C 18H 19F 2N 3O 4S 411.42, m/z found 412.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.12 (br. s, 1H) , 8.23 (d, J = 2.0 Hz, 1H) , 7.94-8.02 (m, 2H) , 7.37-7.45 (m, 2H) , 7.14 (t, J = 8.0 Hz, 1H) , 4.04 (s, 3H) , 2.61-2.77 (m, 4H) , 2.38-2.43 (m, 1H) , 1.65-1.74 (m, 1H) , 1.35-1.43 (m, 1H) .
[0664]
Compound 183 -188 were synthesized as similar procedure to compound 182
[0665]
Compound 183: (S) -N- (3- (difluoromethyl) -4-fluorophenyl) -2-methoxy-5- (N- (pyrrolidin-3-yl) sulfamoyl) benzamide
[0666]
LC-MS (ESI) : mass calcd. for C 19H 20F 3N 3O 4S 443.44, m/z found 444.0 [M+H] +, 1H NMR (400MHz, DMSO-d 6) δ 10.51 (br. s, 2H) , 8.06-8.10 (m, 1H) , 8.00 (d, J = 2.0 Hz, 1H) , 7.94 (dd, J = 8.8 Hz, J = 2.4 Hz, 1H) , 7.84-7.90 (m, 1H) , 7.36-7.42 (m, 2H) , 7.24-7.21 (m, 1 H) , 3.97 (s, 3H) , 2.74-2.94 (m, 4H) , 2.57-2.63 (m, 1H) , 1.74-1.83 (m, 1H) , 1.48-1.56 (m, 1H) .
[0667]
Compound 184: (S) -2-methoxy-N- (2-methoxyphenyl) -5- (N- (pyrrolidin-3-yl) sulfamoyl) benzamide
[0668]
LC-MS (ESI) : mass calcd. for C 19H 23N 3O 5S 405.47, m/z found 406.2 [M+H] +, 1H NMR (400MHz, DMSO-d 6) δ 10.59 (br. s, 2H) , 8.52 (s, 1H) , 8.43 (d, J = 8.0 Hz, 1H) , 7.95-8.02 (m, 1H) , 7.50 (d, J = 8.8 Hz, 1H) , 7.13 (d, J = 3.6 Hz, 2H) , 6.96-7.03 (m, 1H) , 4.17 (s, 3H) , 3.97 (s, 3H) , 2.57-2.80 (m, 4H) , 2.38-2.44 (m, 1H) , 1.65-1.76 (m, 1H) , 1.34-1.44 (m, 1H) .
[0669]
Compound 185: (S) -N- (4-chloro-2-fluorophenyl) -2-methoxy-5- (N- (pyrrolidin-3-yl) sulfamoyl) benzamide
[0670]
LC-MS (ESI) : mass calcd. for C 18H 19ClFN 3O 4S 427.88, m/z found 428.1 [M+H] +, 1H NMR (400MHz, DMSO-d 6) δ 10.24 (br. s, 2H) , 8.24 (s, 1H) , 8.11 (t, J = 8.4 Hz, 1H) , 7.94-7.99 (m, 1H) , 7.57 (d, J = 10.4 Hz , 1H) , 7.44 (d, J = 8.8 Hz , 1H) , 7.34 (d, J = 8.8 Hz , 1H) , 4.05 (s, 3H) , 2.58-2.78 (m, 4H) , 2.38-2.42 (m, 1H) , 1.64-1.73 (m, 1H) , 1.32-1.43 (m, 1H) .
[0671]
Compound 186: (S) -N- (2-chloro-5-fluorophenyl) -2-methoxy-5- (N- (pyrrolidin-3-yl) sulfamoyl) benzamide
[0672]
LC-MS (ESI) : mass calcd. for C 18H 19ClFN 3O 4S 427.88, m/z found 428.1 [M+H] +, 1H NMR (400MHz, DMSO-d 6) δ 10.63 (br. s, 2H) , 8.47 (s, 1H) , 8.32 (d, J = 10.4 Hz , 1H) , 8.02 (d, J = 10.8 Hz , 1H) , 7.61-7.67 (m, 1H) , 7.51 (d, J = 8.8 Hz , 1H) , 7.13 (t, J = 6.4 Hz , 1H) , 4.16 (s, 3H) , 2.60-2.89 (m, 4H) , 1.65-1.85 (m, 2H) .
[0673]
Compound 187: (S) -N- (4-fluoro-3-methylphenyl) -2-methoxy-5- (N- (pyrrolidin-3-yl) sulfamoyl) benzamide
[0674]
LC-MS (ESI) : mass calcd. for C 19H 22FN 3O 4S 407.46, m/z found 408.1 M+H] +, 1H NMR (400MHz, DMSO-d 6) δ 10.23 (br. s, 1H) , 7.97-8.02 (m, 1H) , 7.87-7.95 (m, 1H) , 7.61-7.65 (m, 1H) , 7.52-7.58 (m, 1H) , 7.34-7.41 (m, 1H) , 7.13 (t, J = 9.2 Hz , 1H) , 3.97 (s, 3H) , 2.58-2.80 (m, 4H) , 2.39-2.45 (m, 1H) , 2.24 (s, 3H) , 1.66-1.75 (m, 1H) , 1.36-1.45 (m, 1H) .
[0675]
Compound 188: (R) -N- (2, 4-difluorophenyl) -2-methoxy-5- (N- (pyrrolidin-3-yl) sulfamoyl) benzamide
[0676]
LC-MS (ESI) : mass calcd. for C 18H 19F 2N 3O 4S 411.11, m/z found 412.1 [M+H] +, 1H NMR (400MHz, DMSO-d 6) δ 10.12 (br. s., 1H) , 8.24 (d, J = 2.0 Hz, 1H) , 8.05 -7.90 (m, 2H) , 7.49 -7.30 (m, 2H) , 7.14 (t, J = 7.8 Hz, 1H) , 4.04 (s, 3H) , 2.82 -2.71 (m, 2H) , 2.70 -2.61 (m, 2H) , 2.44 (m, 1H) , 1.78 -1.65 (m, 1H) , 1.41 (m, J = 5.8, 13.2 Hz, 1H) .
[0677]
Compound 189:
[0678]
[0679]
Intermediate 189.2: (S) -Methyl 2-methoxy-5- (N-methyl-N- (tetrahydrofuran-3-yl) sulfamoyl) benzoate
[0680]
(S) -Methyl 2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzoate (1.00 g, 3.17 mmol) and potassium carbonate (893 mg, 6.46 mmol) were dissolved in DMF (5 mL) at 0 ℃. Then iodomethane (539 mg, 3.80 mmol) was added into the mixture and the mixture was stirred at room temperature for 2 hours. The mixture was poured into ice water and precipitation formed. The precipitation was collected. The crude product (1.00 g crude) was used directly for next step without further purification.
[0681]
Intermediate 189.3: (S) -2-Methoxy-5- (N-methyl-N- (tetrahydrofuran-3-yl) sulfamoyl) benzoic acid
[0682]
To a solution consisting of (S) -methyl 2-methoxy-5- (N-methyl-N- (tetrahydrofuran-3-yl) sulfamoyl) benzoate (1.00 g, 3.04 mmol) in THF (4 mL) and H 2O (1 mL) was added lithium hydroxide hydrate (151 mg, 3.60 mmol) . The mixture was stirred at room temperature for 2 hours and the resultant solution was concentrated under reduced pressure. The residue was adjusted to pH = 5~6 (1 N HCl) and precipitation formed. The precipitation was collected. The crude product (800 mg crude) was used directly for next step without further purification.
[0683]
Intermediate 189.4: (S) -2-Methoxy-5- (N-methyl-N- (tetrahydrofuran-3-yl) sulfamoyl) benzoyl chloride
[0684]
To a solution of ( S) -2-methoxy-5- (N-methyl-N- (tetrahydrofuran-3-yl) sulfamoyl) benzoic acid (300 mg, 0.95 mmol) in DCM (3 mL) was added oxalyl dichloride (150 mg, 1.18 mmol) . The mixture was stirred at room temperature for 2 hours and the resultant solution was concentrated under reduced pressure. The crude product (310 mg crude) was used directly for next step without further purification.
[0685]
Compound 189: (S) -N- (5-fluoro-6-methylpyridin-2-yl) -2-methoxy-5- (N-methyl-N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0686]
(S) -2-Methoxy-5- (N-methyl-N- (tetrahydrofuran-3-yl) sulfamoyl) benzoyl chloride (310 mg, 0.93 mmol) was added into a solution consisting of 5-fluoro-6-methylpyridin-2-amine (117 mg, 0.93 mmol) , triethylamine (202 mg, 2.00 mmol) and DCM (3 mL) . The reaction was stirred at 25 ℃ for 2 hours. The mixture was concentrated under reduced pressure. The residue was purified by prep. TLC to give the title compound as a pale-yellow solid (154.80 mg, 37.4%yield, purity: 95.0%) .
[0687]
LC-MS (ESI) : R T = 4.71 min, mass calcd. for C 19H 22FN 3O 5S 423.5, m/z found 424.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.65 (br. s, 1H) , 8.06 (d, J = 6.4 Hz, 1H) , 7.97 (s, 1H) , 7.90 (dd, J = 8.8 Hz, J = 2.4 Hz, 1H) , 7.69 (t, J = 8.8 Hz, 1H) , 7.36 (d, J = 4.8 Hz, 1H) , 4.59 -4.49 (m, 2H) , 3.98 (s, 3H) , 3.81 -3.69 (m, 2H) , 3.55 -3.45 (m, 1H) , 2.62 (s, 3H) , 2.42 -2.32 (m, 3H) , 1.94 -1.84 (m, 1H) , 1.56 -1.45 (m, 1H) .
[0688]
Compund 190-196
[0689]
[0690]
Intermediate 190.2: 4- (Methoxy-d3) -3- (methoxycarbonyl) benzenesulfonic acid
[0691]
Chlorosulfonic acid (20 mL) was added to methyl 2- (methoxy-d3) benzoate (3.00 g, 17.7 mmol) drop-wise at room temperature. The mixture was stirred at that temperature for 2 hours and then concentrated under reduced pressure to give the crude product (2.20 g) . The residue was used for next step without further purification.
[0692]
Intermediate 190.3: Methyl 5- (chlorosulfonyl) -2- (methoxy-d3) benzoate
[0693]
Sulfurous dichloride (10 mL) was added to 4- (methoxy-d3) -3- (methoxycarbonyl) benzenesulfonic acid (2.20 g, 8.83 mmol) drop-wise at room temperature. The mixture was stirred at that temperature for 2 hours and then concentrated under reduced pressure to give the crude product (2.00 g) . The residue was used for next step without further purification.
[0694]
Intermediate 190.4: (S) -Methyl 2- (methoxy-d3) -5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzoate
[0695]
To a solution consisting of (S) -3-aminotetrahydrofuran hydrochloride (1.01 g, 8.17 mmol, Shanghai Nuohey Chemical Technology CO., LTD. ) , TEA (2.23 g, 22.04 mmol) and DCM (20 mL) was added methyl 5- (chlorosulfonyl) -2- (methoxy-d3) benzoate (2.00 g, 7.47 mmol) . The mixture was stirred at room temperature for 2 hours and the resultant solution was concentrated under reduced pressure. Water and ethyl acetate were added. The organic layer was separated and the water phase was extracted twice with ethyl acetate. The combined organic layers were washed with brine, dried over Na 2SO 4 and filtered. The filtrate was concentrated under reduced pressure to give the title compound (2.00 g, 84.09%yield) .
[0696]
Intermediate 190.5: (S) -2- (methoxy-d3) -5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzoic acid Lithium hydroxide (158 mg, 3.77 mmol) was added into a solution consisting of (S) -methyl 2-(methoxy-d3) -5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzoate (2.00 g, 6.28 mmol) , THF (4 mL) and H 2O (1 mL) . The reaction mixture was stirred at room temperature for 2 hours before concentrating it under reduced pressure to remove volatiles. The resultant aqueous phase was adjusted to pH = 5-6 with aq. HCl solution and the precipitation was collected and dried to give the product (1.40 g, 73.22%yield) .
[0697]
Intermediate 190.6: (S) -2- (methoxy-d3) -5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzoyl chloride
[0698]
Oxalyl dichloride (876 mg, 6.90 mmol) was added into a solution consisting of (S) -2- (methoxy-d3)-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzoic acid (1.40 g, 4.60 mmol) and DCM (20 mL) . The reaction was stirred at room temperature for 2 hours. The resultant mixture was concentrated under reduced pressure to give the title compound (1.50 g crude) , which was used for the next step directly.
[0699]
Compound 190: (S) -N- (4-fluorophenyl) -2- (methoxy-d3) -5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0700]
(S) -2- (Methoxy-d3) -5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzoylchloride (200 mg, 0.62 mmol) was dissolved in dry DCM (2 mL) and the resultant solution was added drop-wise to a well stirred solution consisting of 4-fluoroaniline (76.0 mg, 0.68 mmol) , TEA (182 mg, 1.80 mmol) and DCM (3 mL) at room temperature. The reaction mixture was stirred at room temperature for 2 hours and then diluted with DCM (5 mL) . Water (5 mL) was added. The organic phase was separated, dried over Na 2SO 4 and filtered. The filtrate was concentrated under reduced pressure to give a residue which was purified by prep-TLC.
[0701]
LC-MS (ESI) : R T = 4.21 min, mass calcd. for C 18H 16D 3FN 2O 5S 397.44, m/z found 398.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.30 (br. s, 1H) , 8.00 (d, J = 4.0 Hz, 1H) , 7.98 -7.86 (m, 2H) , 7.81 -7.68 (m, 2H) , 7.38 (d, J = 8.8 Hz, 1H) , 7.20 (t, J = 8.8 Hz, 2H) , 3.74 -3.54 (m, 4H) , 3.30 -3.20 (m, 1H) , 1.96 -1.85 (m, 1H) , 1.68 -1.58 (m, 1H) .
[0702]
Compound 191 -196 were synthesized as similar procedure to compound 190
[0703]
Compound 191: (S) -N- (4-fluoro-3-methylphenyl) -2- (methoxy-d3) -5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0704]
LC-MS (ESI) : mass calcd. for C 19H 18D 3FN 2O 5S 411.46, m/z found 412.1 [M+H] +. 1H NMR (400 MHz, DMSO-d 6) δ 10.23 (br. s, 1H) , 8.00 (d, J = 4.0 Hz, 1H) , 7.98 -7.86 (m, 2H) , 7.68 -7.51 (m, 2H) , 7.38 (d, J = 8.8 Hz, 1H) , 7.13 (t, J = 8.8 Hz, 1H) , 3.74 -3.54 (m, 4H) , 3.30 -3.20 (m, 1H) , 2.24 (s, 3H) , 1.96 -1.85 (m, 1H) , 1.68 -1.58 (m, 1H) .
[0705]
Compound 192: (S) -N- (3- (Difluoromethyl) -4-fluorophenyl) -2- (methoxy-d3) -5- (N- (tetrahydro furan-3-yl) sulfamoyl) benzamide
[0706]
LC-MS (ESI) : mass calcd. for C 19H 16D 3F 3N 2O 5S 447.44, m/z found 448.1 [M+H] +. 1H NMR (400 MHz, DMSO-d 6) δ 10.50 (br. s, 1H) , 8.15 -7.77 (m, 5H) , 7.47 -7.32 (m, 2H) , 7.25 (t, J = 56.0 Hz, 1H) , 3.74 -3.54 (m, 4H) , 3.30 -3.20 (m, 1H) , 1.96 -1.85 (m, 1H) , 1.68 -1.58 (m, 1H) .
[0707]
Compound 193: (S) -N- (5-fluoropyridin-2-yl) -2- (methoxy-d3) -5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0708]
LC-MS (ESI) : mass calcd. for C 17H 15D 3FN 3O 5S 398.42, m/z found 399.1 [M+H] +. 1H NMR (400 MHz, DMSO-d 6) δ 10.69 (br. s, 1H) , 8.44 -8.10 (m, 3H) , 8.03 -7.76 (m, 3H) , 7.42 (d, J = 8.8 Hz, 1H) , 3.74 -3.54 (m, 4H) , 3.30 -3.20 (m, 1H) , 1.96 -1.85 (m, 1H) , 1.68 -1.58 (m, 1H) .
[0709]
Compound 194: (S) -N- (5-fluoro-6-methylpyridin-2-yl) -2- (methoxy-d3) -5- (N- (tetrahydrofuran-3 -yl) sulfamoyl) benzamide
[0710]
LC-MS (ESI) : mass calcd. for C 18H 17D 3FN 3O 5S 412.45, m/z found 413.1 [M+H] +. 1H NMR (400 MHz, DMSO-d 6) δ 10.61 (br. s, 1H) , 8.14 (d, J = 4.0 Hz, 1H) , 8.10 (d, J = 8.8 Hz, 1H) , 7.94 (dd, J = 8.8 Hz, J = 4.0 Hz, 2H) , 7.72 (t, J = 8.8 Hz, 1H) , 7.40 (d, J = 8.8 Hz, 1H) , 3.74 -3.54 (m, 4H) , 3.30 -3.20 (m, 1H) , 2.47 -2.24 (m, 3H) , 1.96 -1.85 (m, 1H) , 1.68 -1.58 (m, 1H) .
[0711]
Compound 195: (S) -N- (6-cyclopropyl-5-fluoropyridin-2-yl) -2- (methoxy-d3) -5- (N- (tetrahydro furan-3-yl) sulfamoyl) benzamide
[0712]
LC-MS (ESI) : mass calcd. for C 20H 19D 3FN 3O 5S 438.49, m/z found 439.2 [M+H] +. 1H NMR (400 MHz, DMSO-d 6) δ 10.47 (br. s, 1H) , 8.10 (s, 1H) , 7.93 (d, J = 8.8 Hz, 2H) , 7.66 (t, J = 9.2 Hz, 1H) , 7.37 (d, J = 8.4 Hz, 1H) , 3.74 -3.54 (m, 4H) , 3.30 -3.20 (m, 1H) , 2.32 -2.18 (m, 1H) , 1.96 -1.85 (m, 1H) , 1.68 -1.58 (m, 1H) , 1.17 -0.76 (m, 4H) .
[0713]
Compound 196: (S) -N- (3, 5-difluoropyridin-2-yl) -2- (methoxy-d3) -5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0714]
LC-MS (ESI) : mass calcd. for C 17H 14D 3F 2N 3O 5S 416.41, m/z found 417.1 [M+H] +. 1H NMR (400 MHz, DMSO-d 6) δ 10.49 (br. s, 1H) , 8.40 (s, 1H) , 8.16 -8.04 (m, 2H) , 8.02 -7.92 (m, 1H) , 7.39 (d, J = 8.8 Hz, 1H) , 3.75 -3.53 (m, 4H) , 3.40 -3.35 (m, 1H) , 1.96 -1.85 (m, 1H) , 1.68 -1.58 (m, 1H) .
[0715]
Compound 197
[0716]
[0717]
Intermediate 197.2: Methyl 2-isopropoxybenzoate
[0718]
To a solution consisting of methyl 2-hydroxybenzoate (2.00 g, 13.1 mmol) , K 2CO 3 (5.45 g, 39.4 mmol) and DMF (20 mL) was added 2-iodopropane (4.47 g, 26.3 mmol) . The mixture was stirred at room temperature for 12 hours. Water (20 mL) was added into the mixture. The aqueous layer was extracted with ethyl acetate (40 mL x 2) . The combined organic layers were washed with brine (20 mL x 2) and dried over Na 2SO 4. The organic layer was filtered and concentrated under reduced pressure to give the title compound. (2.00 g, 78.3%yield) .
[0719]
Intermediate 197.3: Methyl 5- (chlorosulfonyl) -2-hydroxybenzoate
[0720]
To a solution consisting of methyl 2-isopropoxybenzoate (1.00 g, 5.15 mmol) and sulfurous dichloride (8 mL) was added sulfurochloridic acid (0.847 mL, 12.9 mmol) at 0 ℃. The mixture was stirred at room temperature for 12 hours. The reaction mixture was poured into ice water. The title compound was precipitated and filtered. (1.00 g, 77.5%yield) 1H NMR (400MHz, DMSO-d 6) δ 8.02 (d, J = 2.4 Hz, 1H) , 7.70 (dd, J = 2.4, 8.8 Hz, 1H) , 6.94 (d, J = 8.4 Hz, 1H) , 3.89 (s, 3H) .
[0721]
Intermediate 197.4: (S) -Methyl 2-hydroxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzoate
[0722]
To a solution consisting of (S) -3-aminotetrahydrofuran hydrochloride (172 mg, 1.40 mmol, Shanghai Nuohey Chemical Technology CO., LTD. ) , TEA (0.584 mL, 4.19 mmol) and DCM (5 mL) was added methyl 5- (chlorosulfonyl) -2-hydroxybenzoate (350 mg, 1.40 mmol) . The mixture was stirred at room temperature for 2 hours and the resultant solution was concentrated under reduced pressure. Water and ethyl acetate were added. The organic layer was separated and the water phase was extracted with ethyl acetate (20 mL x 2) . The combined organic layers were washed with brine, dried over Na 2SO 4 and filtered. The filtrate was concentrated under reduced pressure to give the title compound (250 mg, 59.5%yield) .
[0723]
Intermediate 197.5: (S) -Methyl 2-isopropoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzoate
[0724]
To a solution consisting of (S) -methyl 2-hydroxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzoate (250 mg, 0.830 mmol) , K 2CO 3 (344 mg, 2.49 mmol) and DMF (4 mL) was added 2-iodopropane (169 mg, 0.996 mmol) . The mixture was stirred at 50 ℃ for 12 hours. Water (20 mL) was added into the mixture. The aqueous layer was extracted with ethyl acetate (40 mL x 2) . The combined organic layers were washed with brine (20 mL x 2) and dried over Na 2SO 4. The organic layer was filtered and concentrated under reduced pressure to give the title compound (200 mg, 70.1%yield) .
[0725]
Compound 197: (S) -N- (5-fluoro-6-methylpyridin-2-yl) -2-isopropoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0726]
To a solution consisting of (S) -methyl 2-isopropoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzoate (200 mg, 0.582 mmol) ) , 5-fluoro-6-methylpyridin-2-amine (87.8 mg, 0.696 mmol) and THF (4 mL) was added LiHMDS (2.91 mL, 2.91 mmol) . The mixture was stirred at room temperature for 1 hour. The mixture was quenched with saturated ammonium chloride. The organic layer was separated, dried over Na 2SO 4 and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by prep. HPLC (Column: Phenomenex Gemini 150*25mm*5um, Flow rate: 25 ml/min, Mobile Phase A: Base water (containing 0.05%NH 3. H 2O) , Mobile Phase B: Acetonitrile. ) to give the title compuond (17.20 mg, 6.70%yield) .
[0727]
LC-MS (ESI) : R T = 5.38 min, mass calcd. for C 20H 24FN 3O 5S 437.14, m/z found 438.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.74 (br. s, 1H) , 8.33 (s, 1H) , 8.11 (d, J = 6.4 Hz, 1H) , 7.90-7.99 (m, 2H) , 7.72 (t, J = 9.2 Hz, 1H) , 7.47 (d, J = 8.8 Hz, 1H) , 4.97-5.04 (m, 1H) , 3.66-3.73 (m, 2H) , 3.56-3.64 (m, 2H) , 2.41 (s, 3H) , 1.85-1.95 (m, 1H) , 1.58-1.67 (m, 1H) , 1.45 (d, J = 6.0 Hz, 6H) .
[0728]
Compound 198
[0729]
[0730]
Intermediate 198.2: Methyl 2-ethoxybenzoate
[0731]
To a solution consisting of methyl 2-hydroxybenzoate (2.00 g, 13.1 mmol) , K 2CO 3 (5.45 g, 39.4 mmol) and DMF (20 mL) was added iodoethane (4.10 g, 26.3 mmol) . The mixture was stirred at room temperature for 12 hours. Water (20 mL) was added into the mixture. The aqueous layer was extracted with ethyl acetate (40 mL x 2) . The combined organic layers were washed with brine (20 mL x 2) and dried over Na 2SO 4. The organic layer was filtered and concentrated under reduced pressure to give the title compound (2.00 g, 84.4%yield) .
[0732]
Intermediate 198.3: Methyl 5- (chlorosulfonyl) -2-ethoxybenzoate
[0733]
To a solution consisting of methyl 2-ethoxybenzoate (1.00 g, 5.55 mmol) and sulfurous dichloride (8 mL) was added sulfurochloridic acid (0.913 mL, 13.9 mmol) at 0 ℃. The mixture was stirred at room temperature for 12 hours. The reaction mixture was poured into ice water. Title compound was precipitated and filtered (500 mg, 32.3%yield) . 1H NMR (400MHz, DMSO-d 6) δ 7.87 (d, J = 1.6 Hz, 1H) , 7.71 -7.68 (m, 1H) , 7.08 (d, J = 8.8 Hz, 1H) , 4.08 (q, J = 6.8 Hz, 2H) , 3.77 (s, 3H) , 1.30 (t, J = 7.2 Hz, 3H) .
[0734]
Intermediate 198.4: (S) -methyl 2-ethoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzoate
[0735]
To a solution consisting of (S) -3-aminotetrahydrofuran hydrochloride (155 mg, 1.26 mmol, Shanghai Nuohey Chemical Technology CO., LTD. ) , TEA (0.527 mL, 3.78 mmol) and DCM (5 mL) was added methyl 5- (chlorosulfonyl) -2-ethoxybenzoate (350 mg, 1.26 mmol) . The mixture was stirred at room temperature for 2 hours and the resultant solution was concentrated under reduced pressure. Water and ethyl acetate were added. The organic layer was separated and the water phase was extracted with ethyl acetate (20 mL x 2) . The combined organic layers were washed with brine, dried over Na 2SO 4 and filtered. The filtrate was concentrated under reduced pressure to give the title compound (300 mg, 72.5%yield) .
[0736]
Compound 198: (S) -2-ethoxy-N- (5-fluoro-6-methylpyridin-2-yl) -5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0737]
To a solution consisting of (S) -methyl 2-ethoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzoate (300 mg, 0.911 mmol) ) , 5-fluoro-6-methylpyridin-2-amine (138 mg, 1.09 mmol) and THF (4 mL) was added LiHMDS (4.56 mL, 4.56 mmol) . The mixture was stirred at room temperature for 12 hours. The mixture was quenched with saturated ammonium chloride. The organic layer was separated, dried over Na 2SO 4 and filtered. The filtered was concentrated under reduced pressure. The residue was purified by prep. HPLC (Column: Xtimate C18 150*25mm*5um, Flow rate: 25 ml/min, Mobile Phase A: Base water (containing 0.05%NH 3. H 2O) , Mobile Phase B: Acetonitrile. ) to give the title compound (138.30 mg, 35.89%yield) .
[0738]
LC-MS (ESI) : R T = 5.11 min, mass calcd. for C 19H 22FN 3O 5S 423.13, m/z found 424.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.69 (br. s, 1H) , 8.25 (d, J = 1.6 Hz , 1H) , 8.11 (d, J = 6.4 Hz, 1H) , 7.91-7.97 (m, 2H) , 7.72 (t, J = 9.2 Hz, 1H) , 7.41 (d, J = 8.8 Hz, 1H) , 4.34 (q, J = 6.8 Hz, 2H) , 3.66-3.73 (m, 2H) , 3.55-3.64 (m, 2H) , 3.34-3.37 (m, 1H) , 2.40 (d, J = 2.4 Hz, 3H) , 1.85-1.95 (m, 1H) , 1.57-1.67 (m, 1H) 1.48 (t, J = 6.8 Hz, 3H) .
[0739]
Compound 199
[0740]
[0741]
Intermediate 199.2: Methyl 2-propoxybenzoate
[0742]
To a solution consisting of methyl 2-hydroxybenzoate (2.00 g, 13.1 mmol) , K 2CO 3 (5.45 g, 39.4 mmol) and DMF (20 mL) was added 1-iodopropane (4.47 g, 26.3 mmol) . The mixture was stirred at room temperature for 12 hours. Water (20 mL) was added into the mixture. The aqueous layer was extracted with ethyl acetate (40 mL x 2) . The combined organic layers were washed with brine (20 mL x 2) and dried over Na 2SO 4. The organic layer was filtered and concentrated under reduced pressure to give the title compound (2.00 g, 78.33%yield) .
[0743]
Intermediate 199.3: Methyl 5- (chlorosulfonyl) -2-propoxybenzoate
[0744]
To a solution consisting of methyl 2-propoxybenzoate (1.00 g, 5.15 mmol) and sulfurous dichloride (8 mL) was added sulfurochloridic acid (0.847 mL, 12.9 mmol) at 0 ℃. The mixture was stirred at room temperature for 12 hours. The reaction mixture was poured into ice water. The aqueous layer was extracted with ethyl acetate (20 mL x 2) . The combined organic layers were washed with brine (15 mL x 2) and dried over Na 2SO 4. The organic layer was filtered and concentrated under reduced pressure. The crude product was purified by silica gel chromatography (eluent: petroleum ether: ethyl acetate = 10: 1) to give the title compound (350 mg, 23.2%yield) .
[0745]
1H NMR (400MHz, DMSO-d 6) δ 7.89 (d, J = 2.0 Hz, 1H) , 7.71 (dd, J = 1.6, 8.4 Hz, 1H) , 7.09 (d, J = 8.4 Hz, 1H) , 4.01 (t, J = 6.4 Hz, 2H) , 3.79 (s, 3H) , 1.75 -1.70 (m, 2H) , 0.99 (t, J = 7.6 Hz, 3H) .
[0746]
Intermediate 199.4: (S) -methyl 2-propoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzoate
[0747]
To a solution consisting of (S) -3-aminotetrahydrofuran hydrochloride (148 mg, 1.20 mmol, Shanghai Nuohey Chemical Technology CO., LTD. ) , TEA (0.500 mL, 3.59 mmol) and DCM (5 mL) was added methyl 5- (chlorosulfonyl) -2-propoxybenzoate (350 mg, 1.20 mmol) . The mixture was stirred at room temperature for 2 hours and the resultant solution was concentrated under reduced pressure. Water and ethyl acetate were added. The organic layer was separated and the water phase was extracted with ethyl acetate (20 mL x 2) . The combined organic layers were washed with brine, dried over Na 2SO 4 and filtered. The filtrate was concentrated under reduced pressure to give the title compound (300 mg, 73.1%yield) .
[0748]
Compound 199: (S) -N- (5-fluoro-6-methylpyridin-2-yl) -2-propoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0749]
To a solution consisting of (S) -methyl 2-propoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzoate (300 mg, 0.874 mmol) ) , 5-fluoro-6-methylpyridin-2-amine (132 mg, 1.05 mmol) and THF (3 mL) was added LiHMDS (4.37 mL, 4.37 mmol) . The mixture was stirred at room temperature for 12 hours. The mixture was quenched with saturated ammonium chloride. The organic layer was separated, dried over Na 2SO 4 and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography to give the title compound (187.80 mg, 47.60%yield) .
[0750]
LC-MS (ESI) : R T = 5.48 min, mass calcd. for C 20H 24FN 3O 5S 437.14, m/z found 438.1 [M+H] +. Total run time was 9.5 minutes. 1H NMR (400MHz, DMSO-d 6) δ 10.67 (br. s, 1H) , 8.28 (s, 1H) , 8.11 (d, J = 6.4 Hz, 1H) , 7.91-7.98 (m, 2H) , 7.72 (t, J = 9.2 Hz, 1H) , 7.42 (d, J = 8.8 Hz, 1H) , 4.25 (t, J = 6.0 Hz, 2H) , 3.66-3.73 (m, 2H) , 3.56-3.64 (m, 2H) , 2.40 (d, J = 1.2 Hz, 3H) , 1.85-1.94 (m, 3H) , 1.58-1.66 (m, 1H) 1.10 (t, J = 7.2 Hz, 3H) .
[0751]
Compound 200
[0752]
[0753]
Intermediate 200.2: 5- (Chlorosulfonyl) -3-fluoro-2-methoxybenzoic acid
[0754]
Sulfurochloridic acid (0.484 mL, 7.35 mmol) was added into a solution consisting of 3-fluoro-2-methoxybenzoic acid (500 mg, 2.94 mmol) and sulfurous dichloride (5 mL) at 0 ℃. The mixture was stirred at room temperature for 2 hours. The mixture was poured into ice water. The aqueous layer was extracted with ethyl acetate (50 mL x 2) . The combined organic layers were washed with brine and dried over Na 2SO 4. The organic layer was filtered and concentrated under reduced pressure. The crude product was purified by silica gel chromatography (eluent: petroleum ether: ethyl acetate=10: 1) to give title compound (200 mg, 23%yield) . 1H NMR (400 MHz, DMSO-d 6) δ 7.67 (s, 1H) , 7.48 (d, J = 10.8 Hz, 2H) , 3.82 (s, 3H) .
[0755]
Intermediate 200.3: 5- (Chlorosulfonyl) -3-fluoro-2-methoxybenzoyl chloride
[0756]
Oxalyl dichloride (0.315 mL, 3.72 mmol) was added into a solution consisting of 5-(chlorosulfonyl) -3-fluoro-2-methoxybenzoic acid (200 mg, 0.744 mmol) and DCM (4 mL) at 0 ℃. The reaction was stirred at room temperature for 1 hour. The mixture reaction was concentrated under reduced pressure to give the crude product (200 mg, 75%yield) .
[0757]
Intermediate 200.4: 3-Fluoro-5- ( (4-fluoro-3-methylphenyl) carbamoyl) -4-methoxybenzene-1- sulfonyl chloride
[0758]
4-Fluoro-3-methylaniline (87.2 mg, 0.697 mmol) was added into a solution consisting of 5- (chlorosulfonyl) -3-fluoro-2-methoxybenzoyl chloride (200 mg, 0.697 mmol) and toluene (5 mL) . The reaction was refluxed for 1 hour. The mixture reaction was concentrated under reduced pressure to give the crude product (250 mg, 76%yield) .
[0759]
Compound 200: (S) -3-fluoro-N- (4-fluoro-3-methylphenyl) -2-methoxy-5- (N- (tetrahydrofuran-3- yl) sulfamoyl) benzamide
[0760]
3-Fluoro-5- ( (4-fluoro-3-methylphenyl) carbamoyl) -4-methoxybenzene-1-sulfonyl chloride (250 mg, 0.665 mmol) was added into a solution consisting of (S) -3-aminotetrahydrofuran hydrochloride (82.2 mg, 0.665 mmol, Shanghai Nuohey Chemical Technology CO., LTD. ) , TEA (0.278 mL, 2.00 mmol) and DCM (5 mL) . The reaction was stirred at room temperature for 2 hours. The mixture reaction was concentrated under reduced pressure. The residue was purified by prep. HPLC: (Column: Phenomenex Gemini C18 200 x 25 mm x 10 μm, Flow rate: 25mL/min, Mobile Phase A: Base water (containing 0.05%NH 3. H 2O) , Mobile Phase B: Acetonitrile. ) . The desired fraction was collected and evaporated to remove off CH 3CN in vacuum. The residue was lyophilized to dryness to give the title compound (102.90 mg, 36%yield, purity 99.99%) .
[0761]
LC-MS (ESI) : R T = 4.68 min, mass calcd. for C 19H 20F 2N 2O 5S 426.43, m/z found 427.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.45 (br. s, 1H) , 8.08 (s, 1H) , 7.83 (dd, J = 11.2 Hz, J = 2.0 Hz, 1H) , 7.76 (s, 1H) , 7.63 (dd, J = 7.2 Hz, J = 2.0 Hz, 1H) , 7.47-7.55 (m, 1H) , , 7.14 (t, J = 9.6 Hz, 1H) , 4.02 (d, J = 2.0 Hz, 3H) , 3.57-3.80 (m, 4H) , 3.37-3.42 (m, 1H) , 2.25 (s, 3H) , 1.90-2.01 (m, 1H) , 1.60-1.70 (m, 1H) .
[0762]
Compound 201
[0763]
[0764]
Intermediate 201.2: 5- (Chlorosulfonyl) -4-fluoro-2-methoxybenzoic acid
[0765]
Sulfurochloridic acid (0.894 mL, 13.6 mmol) was added into a solution consisting of 4-fluoro-2-methoxybenzoic acid (1.00 g, 5.43 mmol) and sulfurous dichloride (4 mL) at 0 ℃. The mixture was stirred at room temperature for 4 hours. The mixture was stirred at 80 ℃ for 4 hours. The mixture was poured into ice water. The aqueous layer was extracted with ethyl acetate (80 mL x 2) . The combined organic layers were washed with brine and dried over Na 2SO 4. The organic layer was filtered and concentrated under reduced pressure. The crude product was purified by silica gel chromatography (eluent: petroleum ether: ethyl acetate=1: 1) to give the title compound (600 mg, 37%yield) . 1H NMR (400 MHz, DMSO-d 6) δ 8.00 (d, J = 8.8 Hz, 1H) , 6.93 (d, J = 12.4 Hz, 2H) , 3.78 (s, 3H) .
[0766]
Intermediate 201.3: 5- (Chlorosulfonyl) -4-fluoro-2-methoxybenzoyl chloride
[0767]
Oxalyl dichloride (0.473 mL, 5.59 mmol) was added into a solution consisting of 5- (chlorosulfonyl) -4-fluoro-2-methoxybenzoic acid (300 mg, 1.12 mmol) and DCM (4 mL) at 0 ℃. The reaction was stirred at room temperature for 1 hour. The mixture reaction was concentrated under reduced pressure to give the crude product (320 mg, 90%yield) .
[0768]
Intermediate 201.4: 4-Fluoro-5- ( (4-fluoro-3-methylphenyl) carbamoyl) -4-methoxybenzene-1- sulfonyl chloride
[0769]
4-Fluoro-3-methylaniline (126 mg, 1.00 mmol) was added into a solution consisting of 5- (chlorosulfonyl) -4-fluoro-2-methoxybenzoyl chloride (320 mg, 1.12 mmol) and toluene (5 mL) . The reaction was refluxed for 1 hour. The mixture reaction was concentrated under reduced pressure to give the crude product (419 mg, 80%yield) .
[0770]
Compound 201: (S) -4-fluoro-N- (4-fluoro-3-methylphenyl) -2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) benzamide
[0771]
4-Fluoro-5- ( (4-fluoro-3-methylphenyl) carbamoyl) -4-methoxybenzene-1-sulfonyl chloride (400 mg, 1.06 mmol) was added into a solution consisting of (S) -3-aminotetrahydrofuran hydrochloride (131 mg, 1.06 mmol, Shanghai Nuohey Chemical Technology CO., LTD. ) , TEA (0.445 mL, 3.19 mmol) and DCM (5 mL) . The reaction was stirred at room temperature for 2 hours. The mixture reaction was concentrated under reduced pressure. The residue was purified by high performance liquid chromatography. HPLC condition : (Column: Phenomenex Gemini C18 200 x 25mm x 10 μm, Flow rate: 25mL/min, Mobile Phase A: Base water (containing 0.05%NH 3. H 2O) , Mobile Phase B: Acetonitrile. ) . The desired fraction was collected and evaporated to remove off CH 3CN in vacuum. The residue was lyophilized to dryness to give the title compound (33.80 mg, 7.33%yield, purity 99.01%) .
[0772]
LC-MS (ESI) : R T = 4.60 min, mass calcd. for C 19H 20F 2N 2O 5S 426.43, m/z found 427.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.65 (br. s, 1H) , 8.22 (s, 1H) , 7.85 (t, J = 8.8 Hz, 1H) , 7.61 (dd, J = 6.8 Hz, J = 2.4 Hz, 1H) , 7.45-7.50 (m, 1H) , 7.10-7.17 (m, 2H) , 3.91 (s, 3H) , 3.58-3.77 (m, 4H) , 3.40-3.41 (m, 1H) , 2.24 (s, 3H) , 1.93-2.00 (m, 1H) , 1.68-1.75 (m, 1H) .
[0773]
Compound 202a-202b
[0774]
[0775]
Intermediate 202.2: N- (4-Fluoro-3-methylphenyl) -2-methoxy-5-nitrobenzamide
[0776]
2-Methoxy-5-nitrobenzoic acid (2.0 g, 10 mmol) was dissolved in dry DMF (20 mL) . 4-Fluoro-3-methylaniline (1.9 g, 15 mmol) , HATU (5.7 g, 15 mmol) and DIEA (3.9 g, 30 mmol) were added to the above mixture. The mixture was stirred at 25 ℃ for 3 h. The mixture was poured into water (100 mL) and extracted with DCM (100 mL x 3) . The combined organic extracts were washed with saturated aq. NaHCO 3 (50 mL) , brine (50 mL) , dried over Na 2SO 4 and filtered. The filtrate was concentrated under reduced pressure to give a residue which was purified by column chromatography over silica gel (petroleum ether: ethyl acetate = 5: 1) to afford the title compound (3 g, 97.2%yield) .
[0777]
Intermediate 202.3: 5-Amino-N- (4-fluoro-3-methylphenyl) -2-methoxybenzamide
[0778]
N- (4-Fluoro-3-methylphenyl) -2-methoxy-5-nitrobenzamide (2.8 g, 9.2 mmol) was dissolved in dry MeOH (50 mL) . Pd/C (280 mg, 10%) was added to the above mixture. The mixture was stirred at 25 ℃ under H 2 (50 psi) for 5 h. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure to afford the title compound (2.5 g, 99%yield) .
[0779]
Compound 202a
[0780]
(S*) N-4-fluoro-3-methylphenyl) -2-methoxy-5- (tetrahydrofuran-3-sulfonamido) benzamide Compound 202b
[0781]
(R*) N-4-fluoro-3-methylphenyl) -2-methoxy-5- (tetrahydrofuran-3-sulfonamido) benzamide
[0782]
To a solution consisting of 5-amino-N- (4-fluoro-3-methylphenyl) -2-methoxybenzamide (300 mg, 1.09 mmol) , DBU (500 mg, 3.28 mmol) and THF (6 mL) were added tetrahydrofuran-3-sulfonyl chloride (373 mg, 2.19 mmol) . The reaction mixture was refluxed for 12 hours. Water (10 mL) was added into the mixture. The resultant mixture was extracted with ethyl acetate (20 mL x 2) . The combined organic extracts were washed with brine, dried over Na 2SO 4 and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by prep. HPLC (Column: OJ (250 x 30 mm 5 μm) , Flow rate: 25ml/min, Mobile Phase A: 40%MeOH + NH 3H 2O 50 mL/min 220 nm water, Mobile Phase B: Acetonitrile) to give the crude compound which was further purified by prep. SFC (separation condition: Column: ChiralPak OJ-H, Daicel Chemical Industries, Ltd, 250 × 30 mm I.D., 5μm; Mobile phase: A: Supercritical CO 2, B: Methanol (0.1%NH 3. H 2O) , A: B = 65: 35 at 60mL/min; Column Temp: 38 ℃; Nozzle Pressure: 100Bar; Nozzle Temp: 60 ℃; Evaporator Temp: 20 ℃; Trimmer Temp: 25 ℃; Wavelength: 220 nm) to afford Compound 202a (58.5 mg, 13.08%yield, purity 100%) and Compound 202b (55.8 mg, 12.53%yield, purity 100%) . Compound 202a:
[0783]
LC-MS (ESI) : R T = 4.65 min, mass calcd. for C 19H 21FN 2O 5S 408.12, m/z found 409.0 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.10 (br. s, 1H) , 7.63 (dd, J = 6.8 Hz, J = 2.4 Hz 1H) , 7.52 -7.58 (m, 1H) , 7.49 (d, J = 2.8 Hz, 1H) , 7.35 (dd, J = 8.8 Hz, J = 2.8 Hz 1H) , 7.07 -7.20 (m, 2H) , 3.91 -3.97 (m, 1H) , 3.88 (s, 3H) , 3.77 -3.85 (m, 3H) , 3.60 -3.67 (m, 1H) , 2.23 (d, J = 1.6 Hz, 3H) , 2.10-2.16 (m, 2H) . Compound 202b: LC-MS (ESI) : R T = 4.65 min, mass calcd. for C 19H 21FN 2O 5S 408.12, m/z found 409.0 [M+H] +. 1H NMR (400MHz, DMSO-d 6) δ 10.10 (br. s, 1H) , 7.63 (dd, J = 6.8 Hz, J = 2.4 Hz 1H) , 7.52 -7.58 (m, 1H) , 7.49 (d, J = 2.8 Hz, 1H) , 7.35 (dd, J = 8.8 Hz, J = 2.8 Hz 1H) , 7.07 -7.20 (m, 2H) , 3.91 -3.97 (m, 1H) , 3.88 (s, 3H) , 3.76 -3.85 (m, 3H) , 3.60 -3.67 (m, 1H) , 2.23 (d, J = 1.6 Hz, 3H) , 2.10 -2.16 (m, 2H) .
[0784]
Compound 203
[0785]
[0786]
Intermediate 203.2: 4-Methoxy-3-nitrobenzene-1-sulfonyl chloride
[0787]
1-Methoxy-2-nitrobenzene (3.00 g, 19.6 mmol) was dissolved in sulfurochloridic acid (30.0 g, 257 mmol) at 0 ℃ and then stirred at room temperature for 1 h. The mixture was poured into ice water. The title compound was precipitated and filtered. (4.15 g, 75.76%yield) . 1H NMR (400MHz, DMSO-d 6) δ 7.94 (s, 1H) , 7.80 (d, J = 8.4 Hz, 1 H) , 7.29 (d, J = 8.4 Hz, 1H) , 3.89 (s, 3H) .
[0788]
Intermediate 203.3: (S) -4-Methoxy-3-nitro-N- (tetrahydrofuran-3-yl) benzenesulfonamide
[0789]
To a solution consisting of (S) -3-aminotetrahydrofuran hydrochloride (589 mg, 4.77 mmol) , TEA (1.66 mL, 11.9 mmol) and DCM (10 mL) was added 4-methoxy-3-nitrobenzene-1-sulfonyl chloride (1.00 g, 3.97 mmol) at 0 ℃. The mixture was stirred at room temperature for 4 h. The resultant solution was concentrated under reduced pressure to give the title compound (1.00 g, 67%yield) .
[0790]
Intermediate 203.4: (S) -3-Amino-4-methoxy-N- (tetrahydrofuran-3-yl) benzenesulfonamide
[0791]
To a solution consisting of (S) -4-Methoxy-3-nitro-N- (tetrahydrofuran-3-yl) benzenesulfonamide (1 g, 3.31 mmol) and methanol (30 mL) was added Pd (OH) 2/C (20%w/w, 100 mg) . The mixture was hydrogenated at room temperature (30 psi) for 2 hrs. The catalyst was filtered off and the filtrate was concentrated to dryness to give the title compound (800 mg, 67%yield) .
[0792]
Compound 203: (S) -4-Fluoro-N- (2-methoxy-5- (N- (tetrahydrofuran-3-yl) sulfamoyl) phenyl) -3 -methylbenzamide
[0793]
To a solution consisting of 4-fluoro-3-methylbenzoic acid (226 mg, 1.47 mmol) , (S) -3-amino-4-methoxy-N- (tetrahydrofuran-3-yl) benzenesulfonamide (400 mg, 1.47 mmol) , TEA (0.614 mL, 4.41 mmol) and DMF (5 mL) was added HATU (670 mg, 1.76 mmol) . The reaction mixture was stirred at room temperature for 12 hrs. Water was added into the mixture. The aqueous layer was extracted with ethyl acetate (25 mL x 2) . The organic layers were combined, washed with brine, dried over Na 2SO 4 and filtered. The filtrate was concentrated to dryness under reduced pressure. The residue was purified by prep. HPLC (Column: YMC-Actus. Triart C18 150 x 30 x 5um, Flow rate: 30mL/min, Mobile Phase A: Base water (containing 0.05%NH 3. H 2O) , Mobile Phase B: Acetonitrile, Gradient: 25-55% (%B) ) to give the title compound (191.00 mg, purity 99.99%, 31.86%yield) . LC-MS (ESI) : R T = 4.63 min, mass calcd. for C 19H 21FN 2O 5S 408.12, m/z found 409.1 [M+H] +, 1H NMR (400MHz, DMSO-d 6) δ 9.63 (br. s, 1H) , 8.25 (d, J = 2.5 Hz, 1H) , 7.94 (dd, J = 1.9, 7.4 Hz, 1H) , 7.89 -7.83 (m, 1H) , 7.65 (dd, J = 2.3, 8.8 Hz, 1H) , 7.33 -7.28 (m, 2H) , 3.93 (s, 3H) 3.73 -3.54 (m, 4H) , 3.38-3.36 (m, 1H) , 2.32 (d, J = 1.8 Hz, 3H) , 1.97-1.86 (m, 1H) , 1.69-1.58 (m, 1H) .
[0794]
Compound 204a-204b
[0795]
[0796]
Intermediate 204.2: N- (4-Fluoro-3-methylphenyl) -2-methoxy-5- (tetrahydrofuran-3-sulfonamido) benzamide
[0797]
5-Amino-N- (4-fluoro-3-methylphenyl) -2-methoxybenzamide (300 mg, 1.094 mmol) and DBU (426 mg, 2.798 mmol) were dissolved in THF (10 mL) followed by the addition of tetrahydrofuran-3-sulfonyl chloride (313 mg, 1.835 mmol) . The mixture was stirred at 90 ℃ for 16 hours before concentrating it to dryness. The residue was purified by prep. TLC (petroleum ether: ethyl acetate = 3: 1) and prep. HPLC (formic acid as additive) to give the title compound (80 mg, 17.92%yield) .
[0798]
Compound 204a: (R*) -N- (4-Fluoro-3-methylphenyl) -2-methoxy-5- (N-methyltetrahydrofuran-3 -sulfonamido) benzamide
[0799]
Compound 204b: (S*) -N- (4-Fluoro-3-methylphenyl) -2-methoxy-5- (N-methyltetrahydrofuran-3 -sulfonamido) benzamide
[0800]
[0801]
N- (4-Fluoro-3-methylphenyl) -2-methoxy-5- (tetrahydrofuran-3-sulfonamido) benzamide (80 mg, 0.196 mmol) and K 2CO 3 (59 mg, 0.427 mmol) were dissolved in DMF (3 mL) followed by the addition of iodomethane (34 mg, 0.24 mmol) . The mixture was stirred at 90 ℃ for 16 hours before concentrating it to dryness. The residue was purified by prep. TLC (petroleum ether: ethyl acetate = 3: 1) , prep-HPLC (RP-18 (NH 4HCO 3 as additive) and SFC to obtain the title two compounds. Compound 204a (9.11 mg, 11.22%yield) .
[0802]
LC-MS (ESI) : mass calcd. for C 20H 23FN 2O 5S 422.13, m/z found 423.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) 10.14 (br. s, 1H) , 7.69 -7.60 (m, 2H) , 7.59 -7.50 (m, 2H) , 7.20 (d, J = 8.0 Hz, 1H) , 7.11 (t, J = 8.0 Hz, 1H) , 4.18 -4.08 (m, 1H) , 3.95 -3.91 (m, 1H) , 3.90 (s, 3H) , 3.79 -3.72 (m, 2H) , 3.66 -3.59 (m, 1H) , 3.27 (s, 3H) , 2.23 (s, 3H) , 2.21 -2.15 (m, 1H) , 2.04 -1.95 (m, 1H) . Compound 204b (24.60 mg, 29.59%yield) . LC-MS (ESI) : mass calcd. for C 20H 23FN 2O 5S 422.13, m/z found 423.1 [M+H] +. 1H NMR (400MHz, DMSO-d 6) 10.14 (br. s, 1H) , 7.69 -7.60 (m, 2H) , 7.59 -7.50 (m, 2H) , 7.20 (d, J = 8.0 Hz, 1H) , 7.11 (t, J = 8.0 Hz, 1H) , 4.18 -4.08 (m, 1H) , 3.95 -3.91 (m, 1H) , 3.90 (s, 3H) , 3.79 -3.72 (m, 2H) , 3.66 -3.59 (m, 1H) , 3.27 (s, 3H) , 2.23 (s, 3H) , 2.21 -2.15 (m, 1H) , 2.04 -1.95 (m, 1H) .
[0803]
Biological examples –5HTR2b antagonist activity of compounds
[0804]
The 5HTR2B antagonist activity was measured using human Maverick/293 cells in a calcium mobilization assay. The measurement starting with plating human Maverick/293 cells (log phase) onto 96-well black and incubate at 37℃ overnight, Followed by starving cells for 2 h by changing complete medium to DMEM without FBS, removing the medium from the 96-well plate. Loading staining calcium buffer into each well and incubated the plate at 37℃ for 50 min. After removal of staining calcium buffer, diluted antagonist were added into the well, incubate 15 to 30 minutes. Dispense serotonin as the 5HTR2B agonists into each well. Intracellular calcium concentration is recorded for 80 seconds by monitoring an emission at a wavelength of 525 nm with an excitation wavelength of 485 nm. Inhibition efficiency of the cell line was determined following the equation: %Inhibition= 100%- (D-B) / (S-B) *100%. (S: The peak value in the presence of agonist serotonin; D: The peak value in the presence of different dilution compound or serotonin; B: The peak value in the presence of calcium HBSS buffer only) . Finally the data was displayed graphically using GraphPad Prism 5.0. A dose response curve was fitted using nonlinear regression model with a sigmoidal dose response. The IC50 was automatically produced by GraphPad Prism 5.0. Results are displayed in Table 3.
[0805]
Table 3
[0806]
[0807]

Claims

[Claim 1]
A compound of Formula (I) or a stereoisomer or tautomeric form thereof, wherein: Ar represents a monocyclic or bicyclic aromatic ring, optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such aromatic ring optionally being substituted with one or more substituents each independently selected from the group consisting of halogen, -CN, -OR 6, C 1-C 3 alkyl, C 3-C 7cycloalkyl, CHF 2, CH 2F and CF 3; R 1 represents a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such 3-7 membered saturated ring optionally being substituted with one or more substituents each independently selected from the group consisting of Fluor, -OH, oxo and C 1-C 3 alkyl optionally substituted with one or more Fluor and/or OH; R 6 represents hydrogen, C 1-C 3 alkyl optionally substituted with one or more Fluor, or -C 1-C 3 alkyl-O (R 5) ; R 5 represents hydrogen or C 1-C 3 alkyl; or a pharmaceutically acceptable salt or a solvate thereof.
[Claim 2]
The compound according to claim 1, wherein Ar is phenyl, pyridine or benzimidazole optionally substituted with one or more substituents each independently selected from the group consisting of -CN, halogen, C 1-C 3 alkyl, C 1-C 3cycloalkyl, CHF 2, CH 2F and CF 3.
[Claim 3]
The compound according to claim 1 or 2 wherein R 1 represents a 4-7 membered saturated ring containing carbon atoms and optionally one oxygen atom, such 4-7 membered saturated ring optionally substituted with one or more of C 1-C 3alkyl and/or OH.
[Claim 4]
The compound according to anyone of the previous claims wherein R 1 represents a 5 membered saturated ring containing carbon atoms and one oxygen atom.
[Claim 5]
A compound according to anyone of the previous claims, wherein Ar is phenyl or pyridine, optionally substituted with one or more substituents each independently selected from halogen, -OH, C 1-C 3 alkyl, C 1-C 3cycloalkyl, CHF 2, CH 2F and CF 3.
[Claim 6]
Use of a compound according to Formula A or a stereoisomer or tautomeric form, and/or a salt or solvate thereof, in the manufacture of a medicament for the prevention or treatment of fibrosis and/or cirrhosis in a mammal, wherein Ar represents a monocyclic or bicyclic aromatic ring, optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, such aromatic ring optionally being substituted with one or more substituents each independently selected from the group consisting of hydrogen, halogen, -CN, -OH, C 1-C 3 alkyl, C 3-C 7cycloalkyl, -O (R 6) , CHF 2, CH 2F and CF 3; R 1 represents hydrogen, a 3-7 membered saturated ring optionally containing one or more heteroatoms each independently selected from the group consisting of O, S and N, or C 1-C 6 alkyl, such 3-7 membered saturated ring or C 1-C 6alkyl optionally being substituted with one or more substituents each independently selected from the group consisting of C 1-C 3 alkyl, halogen, CHF 2, CH 2F and CF 3, -CN, -C (=O) R 5, oxo-C (=O) N (R 6) 2, -N (R 6) 2 and -OR 6; R 2 represents hydrogen, or C 1-C 3 alkyl; R 3 represents Fluor or -OC 1-C 3 alkyl optionally substituted with one or more Fluor; R 4 represents hydrogen, Fluor or -OC 1-C 3 alkyl; R 6 represents hydrogen, C 1-C 3 alkyl optionally substituted with one or more Fluor, or -C 1-C 3 alkyl-O (R 5) ; R 5 represents hydrogen or C 1-C 3 alkyl.
[Claim 7]
The use according to claim 6, wherein R 3 represents Fluor or -OC 1-C 3 alkyl and R 2 and R 4 represent hydrogen.
[Claim 8]
The use according to claim 6 or 7, wherein Ar is phenyl, pyridine or benzimidazole optionally substituted with one or more substituents each independently selected from the group consisting of halogen, C 1-C 3 alkyl, C 1-C 3cycloalkyl, CHF 2, CH 2F and CF 3.
[Claim 9]
The use according to claim anyone of claims 6 to 8, wherein R 1 represents a 5 membered saturated ring containing carbon atoms and one oxygen atom.
[Claim 10]
The use according to anyone of claims 6 to 9, wherein Ar is phenyl optionally substituted with one or more substituents each independently selected from -CN, C 1-C 3 alkyl, C 1-C 3cycloalkyl, CHF 2, CH 2F and CF 3.
[Claim 11]
A pharmaceutical composition comprising a compound according to any of claims 1 to 5, and a pharmaceutically acceptable carrier.
[Claim 12]
A product containing (a) a compound of formula (I) as defined in any one of claims 1 to 5, and (b) another fibrosis and/or cirrhosis inhibitor, as a combined preparation for simultaneous, separate or sequential use in the treatment of fibrosis and/or cirrhosis.